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ABSTRACT 
The Role of Leptin in Body Weight Regulation 
Alicja Skowronski 
 
Leptin is an adipocyte-derived hormone which circulates in concentrations that are closely 
correlated with amounts of body fat. It provides a chronic signal to the central nervous system 
(CNS) regarding quantity of stored body fat and as such it is involved in the regulation of long 
term energy homeostasis. Leptin also declines abruptly when negative energy is imposed, 
providing a signal of incipient threats to the adequacy of fat stores. 
 Humans and mice maintain body weight (fat) at remarkably stable levels without conscious 
effort to adjust food intake or energy expenditure. Changes in body weight induced by either 
overfeeding or dietary restriction are rapidly reversed when free feeding is resumed, indicating 
that altered body weight is accompanied by physiological adjustments that oppose this change. 
The “set-point” that is being defended depends on individuals’ genetic makeup and 
developmental environment during the perinatal period. 
Several aspects of leptin physiology were investigated in the work presented in this dissertation 
including:  
 the effects of transient hyperleptinemia at specific developmental periods on subsequent 
body weight set point in mice;  
 regulation of body weight in the absence of leptin in mice;  
 genetic contributors to circulating leptin concentrations in human and mice, and;  
 the efficacy of an MC4R agonist – a downstream target of leptin – on maintenance of 
reduced body weight in mice. 
Chapter 2 and 3. The effects of transient hyperleptinemia at specific developmental periods 
on subsequent body weight set point in mice 
To assess whether leptin per se influences the body weight set point and whether there is a 
critical time window for such effects, we generated a transgenic mouse in which non-invasive 
induction of transient hyperleptinemia is dissociated from adiposity. This transgenic mouse uses 
a TET-ON system in which transgenic (CMV-driven) leptin expression is regulated by exposure 
to doxycycline (dox) in a dose-responsive manner that can be rapidly turned on and off. 
Circulating leptin concentrations can be elevated to those in a high fat-fed obese mouse within 
one day and either sustained indefinitely or restored to baseline concentrations within 24 hours. 
Acute overexpression of leptin in the adult transgenic mice reduces food intake and causes 
transient weight loss – confirming that the transgenic leptin is bioactive and capable of triggering 
anticipated physiological responses. This leptin transgenic mouse enables reversible increases in 
circulating leptin to virtually any level at any point in development.  
Using this system we investigated the physiological consequences of developmentally timed 
transient hyperleptinemia on subsequent apparent set point for adiposity. Specifically, we 
evaluated the physiological effects of elevated leptin during adulthood, “adolescence” and the 
immediate postnatal period on the defense of body weight (adiposity) later in life and on the 
susceptibility to gain weight when offered a highly palatable diet ad libitum. We showed that 
inducing chronic hyperleptinemia in adult or “adolescent” mice does not increase the set point of 
defended body weight when excess leptin is removed; however, transient elevation of circulating 
leptin in the immediate postnatal period increases the hyperphagic response of the offspring to a 
highly palatable diet 7 weeks later, and renders animals more susceptible to obesity as adults. We 
demonstrated that leptin per se is capable of influencing the susceptibility of mice to gain weight 
on high fat diet; however, these effects are restricted to a critical time window which we 
identified to be the immediate postnatal period.  
Chapter 4. Regulation of body weight in the absence of leptin in mice 
Leptin-deficient Lepob/ob mice show metabolic compensation for lost weight and they appear to 
defend body fat by leptin-independent mechanisms. We attempted to identify mechanisms 
involved in leptin-independent regulation of body weight. Lepob/ob mice were either fed ad 
libitum or calorie restricted to lose 20% of body weight. Calorie-restricted mice reduced energy 
expenditure and, when released to ad libitum feeding, regained fat and lean mass (to the levels of 
ad libitum controls) within 5 weeks. Calorie-restricted mice did so while their ad libitum caloric 
intake was equal to that of the control animals. These results confirm that, in congenitally leptin 
deficient animals, leptin is not required for compensatory reduction in energy expenditure 
accompanying weight loss, but suggest that the hyperphagia of the weight-reduced state is leptin-
dependent. 
Chapter 5. Genetic contributors to circulating leptin concentrations in human and mice 
While circulating leptin concentrations correlate closely with body fat, at any given level of 
adiposity, there is substantial variation in circulating leptin. We collaborated with Dr. Ruth Loos 
– professor of Environmental Medicine & Public Health at Icahn School of Medicine at Mount 
Sinai – and her associates who carried out a genome-wide association study of circulating leptin 
concentrations adjusted for body mass and composition, and identified five loci associated with 
reduced circulating leptin concentrations [1]. The aim of the study was to identify and 
functionally assess potentially causal gene(s) within each implicated region. Our aim was to 
identify genes that modify leptin production/release in a manner that might account for reduced 
circulating leptin concentrations and hence predisposition to obesity. We developed an assay to 
directly measure effects of the candidate genes in ex vivo adipose tissue explants on production 
and secretion of leptin. Using siRNAs, we knocked down expression of these genes in 
perigonadal adipose tissue explants from mice fed high fat diet and demonstrated that Adig, 
located in the SLC32A1 locus, modulates leptin production and secretion [1]. These studies 
provide a prototype for the functional deconvolution of groups of genes identified by genome-
wide association studies in which a specific cell type can be implicated. 
Chapter 6. The efficacy of an MC4R agonist – a downstream target of leptin – on 
maintenance of reduced body weight in mice 
Finally, we investigated the efficacy of an MC4R agonist in maintenance of reduced body weight 
in mice [2]. Weight loss is difficult to maintain due to physiological adaptations in energy 
expenditure and drive to eat that accompany this state. Exogenous leptin sufficient to restore 
circulating levels to those preceding weight (fat) loss reverses many of the relevant phenotypes. 
MC4R is a downstream target of leptin signaling and is central in energy homeostasis. In 
collaboration with scientists at AstraZeneca, we studied the effectiveness of a novel peptide 
MC4R agonist in maintenance of reduced body weight compared to its use in inducing weight 
loss. In the weight reduced state, 5x lower doses of the same molecule were comparably 
efficacious to a higher dose in the ad libitum state [2]. This protocol provides a model for 
evaluating the mechanisms and quantitative efficacy of weight-maintenance strategies and 
agents. These data support the concept that the pharmacology of the weight reduced state may be 
more tractable than that designed to induce weight loss. 
Overall, the major conclusions from these studies are that:  
 transient hyperleptinemia during the postnatal period can influence the susceptibility of 
mice to diet-induced obesity in adulthood; 
 factors other than leptin contribute to body weight regulation in leptin deficient mice;  
 functional, biological assays can be used to identify causal genes in genome-wide 
association study identified loci, and;  
 pharmacological agents to maintain reduced weight may be a tractable target for 
treatment of obesity.  
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Chapter 1   
 
“Introduction”    
 
Obesity and Energy Homeostasis 
Obesity is a major public concern in the United States and in other parts of the world [3]. More 
than sixty percent of US adults are overweight or obese [4], increasing the risk for a number of 
medical and psychiatric disorders including type II diabetes mellitus, hypertension, stroke, 
coronary heart disease, and certain types of cancer [5, 6]. Transient obesity is not without risk; 
midlife obesity is associated with increased risk of dementia and Alzheimer's disease in later life 
[7], even if obesity is later rectified [8]. Additionally, obesity puts a substantial economic burden 
on society [9]; it is estimated that over $190 billion is spent annually on health care costs of 
obesity and related diseases [10], hence the need for effective prevention and treatment.  
Since 1988, the most dramatic increases in obesity rates have occurred in adolescents and 
children. In the United States, obesity increased among adolescents aged 12 to 19 from 11% in 
1988-1994 to 21% in 2013-2014. Extreme obesity in the same age group had a more dramatic 
increase, from 3% in 1988-1994 to 9% in 2013-2014 [11]. 
Childhood obesity is associated with both short term [12] and long term health effects [13]. In 
humans, adiposity decreases from the first year of life till its nadir at the age of 6–8 years, and 
then begins to increase again [14]. Several potential mechanisms have been suggested to explain 
how childhood obesity may predispose or cause adult disease. Total body fat and body fat 
distribution contribute to morbidity risk [15, 16]. Obesity lessens life expectancy markedly, 
especially among younger adults [17]. A 20-year-old white male with a body mass index (BMI) 
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greater than 45 is estimated to have 13 years of life lost due to obesity [17], shortening his life 
expectancy from 78 to 65, representing a 22% reduction in the remaining years of life [17]. 
Obesity is a result of chronic imbalances of food intake (FI) and energy expenditure (EE) leading 
to storage of excess energy as adipose tissue. The idea of total body fat regulation was first 
proposed by Kennedy in 1953 in his “lipostatic theory” where he suggested the existence of a 
signal from adipose tissue reporting fat mass to the hypothalamus [18]. Later, Coleman’s 
parabiosis experiments in mice segregating for ob and db mutations with wild-type (WT) mice 
detected an apparent satiety factor in WT mice that was capable of reducing the body weight of 
ob mice but not of db mice, suggesting that the ob mutation encoded a ligand for which the db 
mutation was a receptor [19]. Two decades later, those genes were isolated by positional cloning 
and identified as leptin and leptin receptor, respectively [20-22], consistent with the lipostatic 
theory. Leptin is an adipokine which – in weight stable animals – circulates in direct proportion 
to fat stores, and informs the central nervous system (CNS) about the status of fat stores [20]. 
Changes in circulating leptin concentrations affect pathways that mediate energy homeostasis 
(intake, expenditure and partitioning of ingested calories) as well as thermoregulation and 
fertility [20, 23]. Circulating leptin exerts its effects on energy homeostasis through binding to its 
receptors that are expressed in many tissues, but predominantly in the brain [21].  
 
Leptin 
Leptin – a 167 amino acid hormone encoded by the LEP gene located on human chromosome 7 
– is primarily produced by adipose tissue [20]. Low levels of leptin expression are detected in 
brown adipose tissue [24], stomach [25], placenta [26], mammary tissue [27] and ovaries [28]. In 
weight-stable mice and humans, circulating leptin concentrations are highly correlated with fat 
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mass. Plasma leptin follows a circadian rhythm (increases during dark cycle) [29] and responds 
to nutritional state. Fasting acutely decreases circulating leptin [30], while feeding increases 
leptin synthesis which is mediated, at least in part, by elevated circulating insulin during feeding 
[31]. Plasma leptin also depends on gender [32], fat distribution [33, 34], and the size of 
adipocytes [34, 35]. Several factors have been identified as regulators of leptin expression and 
secretion including inflammatory cytokines, glucocorticoids and insulin [36]. However, the 
molecular mechanism(s) of this regulation is not well understood. 
While leptin concentrations at usual body weight are proportionate to the amount of stored fat, at 
any given level of adiposity there is some degree of discordance. In collaboration with Ruth Loos 
(professor of Environmental Medicine & Public Health at Icahn School of Medicine at Mount 
Sinai), we used this variability in circulating leptin to identify genetic loci that are associated 
with greater or lesser leptin production per unit of fat mass using a genome-wide association 
study (GWAS) approach [1]. We then developed a functional assay to analyze candidate causal 
genes that contribute to differences in circulating leptin. The details of these experiments are 
found in Chapter 5. 
  
Leptin signaling 
Early evidence confirming the importance of the hypothalamus in the regulation of body weight 
came from ablation of specific hypothalamic regions. The most pronounced phenotypes were 
seen when hypothalamic ventromedial nucleus (VMH) and lateral hypothalamic area (LHA) 
were lesioned, with the former leading to extreme obesity in rats and the latter resulting in 
anorexia and weight loss [37, 38]. Leptin is one of the major signals responsible for 
communication between fat stores and the CNS. In mice, there are six isoforms of leptin receptor 
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(LepRa-LepRf) all products of the Lepr gene, resulting from either alternative splicing of 
transcripts or posttranslational modifications and they all contain the extracellular domain [39, 
40]. So-called “short forms” of LepR (LepRa, LepRc, LepRd, and LepRf) contain extracellular, 
transmembrane, and truncated intracellular domains. All isoforms except LepRe include the 
intracellular ‘Box 1’ motif and the Janus kinase (Jak) 2 tyrosine kinase binding domain [41]; 
however, only the LepRb isoform contains the ‘Box 2’motif, required for efficient Janus 
kinase/signal transducers and activators of transcription (Jak/STAT) pathway activation [42]. 
Soluble leptin receptor, LepRe, lacks both transmembrane and intracellular domains and acts as a 
major leptin-binding protein in the circulation [43, 44]. Leptin’s action on energy intake and 
expenditure is primarily via LepRb signaling expressed in the central nervous system [45]; 
however other cell types outside of the CNS express LepRb including T-cells [46], the pancreatic 
β-cells [47], and epithelial cells lining the colon crypts [48]. 
LepRb is a type I cytokine receptor belonging to the IL-6 receptor family [49]. Leptin binds to 
the extracellular domain of LepRb, activating Jak2 which stimulates the phosphorylation of 
Tyr985, Tyr1077, and Tyr1138 residues in the intracellular portion of LepRb [50]. The most 
critical signaling pathway for leptin’s action in energy homeostasis is the phosphorylation of 
Tyr1138 which recruits the STAT3 transcription factor [51]; phosphorylation of STAT3 
promotes its translocation into the nucleus where it mediates expression of target genes, 
including Socs3 (a feedback inhibitor of LepRb signaling) [42, 52]. Phosphorylation of Tyr985 
recruits PTPN1, which initiates the ERK signaling cascade; Tyr 1077 phosphorylation induces 
STAT5 phosphorylation affecting transcription of target genes in the nucleus. LepRb signaling 
induction has feedback inhibition loops; these include suppressor of cytokine signaling 3 (SOC3) 
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which dephosphorylates Tyr985 [53] and protein-tyrosine phosphatase 1B (PTP1B) which 
dephosphorylates Jak2 and STAT3 [54]; both of these pathways act to inhibit LepRb action.  
LepRb is widely expressed in the mediobasal hypothalamus [55, 56]. Martin Myers’ group 
confirmed the expression of the LepRb isoform in the brain using a leptin receptor reporter 
mouse [57]. They, and others, found many brain regions that express LepRb but the highest 
expression was found in the hypothalamic nuclei, including the arcuate (ARH), dorsomedial 
hypothalamus (DMH), VMH, LHA, and ventral premammillary nuclei (PMv) [57-59]. Other 
areas with high LepRb expression are the ventral tegmental area (VTA) involved in the reward 
system [60] and the brainstem (specifically nucleus of the solitary tract) which plays a role in 
modulating satiety [61]. 
 
Leptin signaling in the arcuate nucleus of the hypothalamus  
Leptin signaling via the Jak2/STAT3 pathway in pro-opiomelanocortin (POMC)- and Agouti 
related protein (AgRP)/ Neuropeptide Y (NPY)-expressing neurons, first order neurons located 
in the ARH, influences the neuroendocrine systems related to energy homeostasis [62]. 
Activation of the Jak2/STAT3 pathway by leptin signaling inhibits orexigenic pathways 
(decreases expression of Npy and Agrp) [63] and activates the anorectic pathways (increases 
Pomc and Cart) [64]. POMC is posttranslationally cleaved by proconvertases (PC1 and PC2) and 
other peptidases to multiple smaller peptides including β-endorphin and α-melanocyte 
stimulating hormone (α-MSH) [65]. α-MSH inhibits energy intake and stimulates energy 
expenditure via melanocortin 4 receptors (MC4R) and, to a lesser degree, melanocortin 3 
receptors (MC3R) located on second order neurons (neurons that receive inputs directly from 
first order neurons) located in specific nuclei, including the PVH [66]. In contrast, AgRP is a 
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functional antagonist (inverse agonist) of the MC3R and MC4R receptors [67] opposing the 
effects of POMC. AgRP levels increase with fasting and decline following food intake or leptin 
administration [68, 69]. NPY stimulates appetite independently of MC4R; it is an agonist of 
NPY receptors with expression also controlled by nutritional status [62, 68]. The importance of 
POMC and AgRP neurons in the control of energy balance is supported by mutations in the 
POMC gene that lead to severe human obesity [70] and rodent knockouts are obese and 
insensitive to leptin [71]. Ablation of NPY/AgRP neurons in adult brains induces severe anorexia 
leading to death [72, 73]; however, ablating these neurons during development does not cause 
anorexia and subsequent death suggesting that compensatory signals can be established early.   
In humans, mutations in the MC4R gene account for about 3% of severe, early-onset obesity and 
represent the most common cause of monogenic human obesity [74]. Similarly, Mc4r null mice 
are obese both due to increased energy intake and, to a lesser degree, by decreased energy 
expenditure. Conversely, intracerebroventricular (ICV) administration of MC3/4R agonist, MTII, 
to diet induced obese (DIO) mice inhibits food intake, induces weight loss and elevates energy 
expenditure [75] further supporting the role of melanocortin pathway in energy regulation. 
 MC4 receptor is expressed broadly across the rodent CNS [76, 77]; however, the paraventricular 
nucleus of the hypothalamus (PVH) contains MC4R-expressing neurons that regulate appetite 
[78, 79] whereas cholinergic MC4R neurons in the dorsal motor nucleus of the vagus (DMV, 
within the brainstem) and spinal cord mediate energy expenditure and glucose homeostasis [80].  
 
Leptin signaling in other brain regions  
In addition to the classic leptin signaling pathways in the ARH involved in weight-homeostatic 
neurocircuits, other brain regions (within and outside of the hypothalamus) express LepRb and 
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mediate leptin effects on energy homeostasis. LepRb expressing neurons in the DMH are 
important in regulation of energy expenditure via sympathetic activation of brown adipose tissue 
(BAT) thermogenesis [81]. Neurons expressing steroidogenic factor 1 (SF-1) are restricted to the 
VMH. A subset of these SF-1 neurons co-express LepRb; deletion of LepRb specifically in these 
SF-1 neurons results in both increased body weight and susceptibility to DIO via effects on body 
food intake and energy expenditure. This indicates a leptin VMH connection in regulating energy 
balance [82].  
Brainstem regions – including the nucleus tractus solitarius (NTS) and the area postrema (AP) – 
are involved in feeding behavior [83, 84]. The brainstem is a critical area for the integration of 
gastrointestinal signals including vagal afferents and gut peptides such as glucagon-like peptide-
1 (GLP-1) and cholecystokinin (CCK) [84]. LepRb is expressed in the NTS and AP; 
administration of leptin directly to the NTS suppresses food intake. Additionally, leptin acts 
synergistically with GLP-1 and CCK, released during feeding, to induce satiety after a meal [85, 
86].  
Leptin plays a role in hedonic circuits through its action on the mesolimbic dopamine system – 
one of the most critical brain reward pathways – to influence food reward and the motivation to 
eat. The anatomic core of this system is located in a subset of dopaminergic neurons in the 
VTA/substantia nigra (SN) which project to the striatum [nucleus accumbens (NAc), 
caudate/putamen], amygdala, and prefrontal cortex [87]. Leptin receptors (LepRb) are expressed 
in the VTA and the SN [88]; leptin inhibits LepRb neurons within the VTA and decreases food 
intake by decreasing food reward [60, 89]. A subset of GABAergic/inhibitory neurons within the 
LHA also express LepRb and innervate the VTA [90]. Direct LHA leptin injection confirms 
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leptin action on LHA LepRb neurons by decreasing food intake and body weight over a period of 
24 hours [90].  
 
Congenital Leptin-deficient mice and humans 
Congenital leptin (Lepob/ob) or leptin receptor (Leprdb/db) deficiency renders mice morbidly obese 
due to both increased hyperphagia and decreased EE. Gross differences in body weight are 
detectable as early as 2 weeks of age. Lepob/ob and Leprdb/db become hyperglycemic and 
hyperinsulinemic, they have defects in thermoregulation – apparent by decreased body 
temperature and a reduced thermogenic response to cold [91], and upon fasting or caloric 
restriction they become torpid [92]. Deficiency in leptin signaling causes hypogonadotropic 
hypogonadism resulting in infertility of both males and females [93]. Additionally, Lepob/ob have 
impaired immunity [94]. Administration of exogenous leptin largely rescues the obesity and 
related phenotypes in Lepob/ob mice. The wide range of phenotypes associated with congenital 
leptin deficiency highlights the physiological importance of leptin in regulating not only energy 
homeostasis but also multiple other systems.  
The first two humans with homozygous frame shift mutations of LEP were identified in 1997 by 
O’Rahilly and colleagues; they were leptin-deficient, severely hyperphagic, and morbidly obese 
[95]. Mice lacking leptin reduce energy expenditure [91] but leptin deficient humans have no 
detectable changes in resting or free-living energy expenditure [96]. While inactivating leptin 
mutations are exceedingly rare, recombinant human leptin therapy is available and results in 
remarkable benefits for these patients including normalization of body weight and many of the 
associated comorbid phenotypes [97].  
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I investigated whether Lepob/ob mice are capable of regulating body weight in the absence of 
leptin signaling (Chapter 4).  
 
Leptin and metabolic adaptations (weight-reduced state) 
Humans and rodents regulate and defend set-points (threshold levels below which metabolic-
behavioral defense of body weight is invoked) of body fat without conscious effort to adjust food 
intake or energy expenditure [98]. In rodents and humans, changes in body weight imposed by 
either overfeeding or dietary restriction are rapidly reversed when free feeding is resumed [99-
101]. Following a ten percent reduction in body weight, energy expenditure is approximately 
20% lower than what would be estimated from changes in body mass and composition [99]. The 
magnitude of this response is comparable in obese and lean subjects indicating that the same 
metabolic adaptations are present regardless of the baseline (usual) body weight and adiposity. In 
addition to decreased EE, weight-reduced humans display other physiological adaptations that 
promote body weight regain including increased hunger, decreased circulating leptin and 
bioactive thyroid hormones, decreased sympathetic nervous system (SNS) tone, and increased 
parasympathetic nervous system (PNS) tone [99, 102, 103]. The difference in EE is accounted 
for primarily by decreased nonresting energy expenditure (NREE). Reduction in NREE is a 
result of increased skeletal muscle contractile efficiency during low intensity physical activity 
rather than increased physical activity [104]. Muscle biopsies from weight-reduced individuals 
have decreased activity of a glycolytic enzyme, phosphofructokinase (PFK) [105], increased 
expression of more efficient myosin heavy chain isoform (MHC I), and 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2, which contributes to muscle 
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efficiency independently of MHC I) [106]. These biochemical changes in muscle during 
maintenance of reduced weight are consistent with the decline in NREE reported in vivo.  
fMRI studies show that humans in a weight-reduced state presented with food items display 
increased neural activity in brain areas associated with reward valuation and processing of visual 
food cues and reduced activity in areas involved in restraint compared to themselves at their 
usual weight [107]. 
These studies suggest that the weight-reduced state can be perceived as one of relative leptin 
insufficiency due to reduced body fat. Exogenous leptin is ineffective at weight loss induction in 
humans [108, 109], however, Leibel, Rosenbaum, and colleagues demonstrated that majority of 
phenotypes associated with the weight-reduced state – including EE reduction, increased hunger, 
decreased circulating thyroid hormones, decreased SNS tone, and brain fMRI patterns – are 
reversed with replacement doses of exogenous leptin sufficient to restore circulating 
concentrations of leptin to those present prior to weight loss [107, 110].  
The phenotype of the weight-reduced state in mice is similar to that described in humans. Mice 
maintaining a reduced body weight show decreased EE, increased hunger, and increased food 
seeking behavior leading to greater ad libitum food intake. Weight-reduced mice have decreased 
excitatory synapses onto ARH POMC neurons [111], similar to changes seen in leptin deficient, 
Lepob/ob mice [106, 112].  
 
Leptin as a signal for sufficiency of body fat stores 
Administration of supraphysiological doses (~10 fold above physiological concentrations) of 
leptin to lean or obese humans has limited capacity to induce weight loss [108] but 
supplementation of exogenous leptin in individuals in a weight-reduced state (a state of relative 
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leptin insufficiency) is effective in partially reversing the physiological adaptations [110] 
suggesting that the primary role of leptin is to defend fat stores, not to protect against fat gain. 
Leibel and associates proposed that the central nervous system responds in a threshold-like 
manner in response to alterations in circulating leptin concentrations [98]. Each individual has a 
different leptin threshold; genetic differences as well as developmental processes can affect both 
gene expression and neuroanatomical structure of circuits involved in setting the leptin threshold 
[98]. The extent to which the functionality of these molecules, cells and circuits can be 
influenced by “environmental” factors and the mechanisms by which these effects are conveyed 
remain unclear. Understanding the physiological and molecular mechanisms underlying these 
effects is important to the prevention and treatment of obesity. 
 
Physiological and CNS changes due to elevation of body weight 
In contrast to the physiological responses triggered during weight loss, gradually increasing body 
weight does not seem to invoke strong counter-regulatory mechanisms. DIO mice maintained at 
elevated adiposity for prolonged periods of time appear to defend a higher body weight (fat) 
when weight is reduced by hypocaloric feeding [111]. The threshold for minimum adiposity can 
be elevated; however the mechanisms driving this upward re-setting are unknown. Body weight 
(and fat) elevation is associated with many physiological changes such as increased free fatty 
acids, glucose, insulin, and proinflammatory cytokines; insulin resistance and decreased 
adiponectin and ghrelin. Additionally, increased adiposity results in fat-appropriate elevations in 
circulating leptin as well as decreased hypothalamic leptin signaling which has been suggested as 
a pathophysiological mechanism in the development of obesity [113].  
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Several mechanisms have been implicated in obesity-attenuated responsiveness to leptin 
including reduced leptin transport across the blood-brain barrier (BBB) [114, 115] and processes 
that can reduce LepRb cellular signaling including increased hypothalamic free fatty acids (FFA) 
[116, 117], endoplasmic reticulum (ER) stress [118, 119], inflammation [119, 120], feedback 
inhibition [121], and, more likely, the interplay among these processes.  
The ratio of cerebrospinal fluid (CSF) to serum leptin concentration in lean humans is about 4 
fold greater than that of obese individuals [122]. DIO rodents respond to centrally administered 
leptin (ICV injections), but not to peripherally administered leptin (subcutaneous pumps or 
intraperitoneal injections) [123, 124]. Recent studies have indicated that leptin enters 
hypothalamic neurons via tanycytes – specialized hypothalamic glial cells – located in the 
median eminence (ME) that extend from the surface of the 3rd ventricle to the fenestrated 
capillaries [115]. The ME is a circumventricular organ located at the base of the hypothalamus, 
which serves as an interface between the portal blood and the hypothalamus and allows 
circulating factors to enter the CSF and mediobasal hypothalamic (MBH) neurons [125]. Balland 
et al. demonstrated that blood-borne leptin first enters tanycytes through LepR (tanycytes 
express all isoforms of LepR) but its entrance is not dependent on LepRb signaling cascade 
[115]. Leptin is then released from tanycytes to the CSF by a process requiring activation of 
ERK pathway and can then reach MBH neurons [115]. In mice lacking the long form of LepR, 
Lepdb/db, and in HFD-fed mice, leptin accumulates in tanycytes in the ME but fails to appear in 
the neurons of the MBH [115]. Additionally, activating ERK signaling cascade in tanycytes 
rescues leptin’s release into the CSF and results in activation of the MBH neurons [115]. These 
findings suggest that leptin signaling in the hypothalamus may be diminished due to disruption 
of leptin transport to the CNS due to HFD feeding.  
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Leptin signaling is negatively regulated by SOCS3 [121] which belongs to a family of cytokine-
inducible inhibitors of signaling and binds directly to the Tyr985 amino acid of LepRb, 
inhibiting leptin-induced STAT3 signaling; it has therefore been implicated in cellular leptin 
resistance. In DIO rodents, Socs3 expression is increased specifically in the hypothalamus when 
the animals are initially exposed to HFD [126]. Mice with POMC-specific Socs3 overexpression 
are fatter than WT mice when on a chow diet [127]; neuronal deletion of SOCS3 results in 
decreased weight gain on HFD [128].  
Providing a link between calorically dense foods (such as HFD) and disruption of energy 
balance, De Souza and colleagues showed that HFD feeding promotes hypothalamic 
inflammation in rodents [120]. Earlier reports established that HFD feeding leads to chronic low-
grade inflammation in peripheral tissues including adipose tissue [129, 130] and liver [131, 132] 
which then contributes to insulin resistance and glucose intolerance [133]. Preceding any large 
changes in body weight or reduced leptin signaling, hypothalamic inflammation develops within 
the first few days of HFD feeding [134]. HFD feeding induces hypothalamic inflammation by 
activating the proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), Interleukin 1 
beta (IL-1β), and Interleukin 6 (IL-6), and inflammatory signaling pathways including IκB 
kinase/ nuclear factor kappa-light-chain-enhancer of activated β cells (IKKβ/NF-κB) and Toll-
like receptor 4/ myeloid differentiation primary response gene 88 (TLR4/MyD88) in the 
hypothalamus [119, 120]. Saturated fatty acids (SFA) can directly induce inflammatory response 
via the TLR4/MyD88 pathway; disruption of this pathway protects mice against DIO and 
cellular leptin resistance [116, 117]. TLR4/MyD88 further signals via the IKKβ/NF-κB which 
induces a proinflammatory program in the hypothalamus. Specifically activating IKKβ in the 
brain leads to increased food intake and weight gain due to attenuated leptin signaling [119]. 
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Endoplasmic reticulum (ER) stress was implicated as a downstream target of SFA-induced TLR4 
signaling, ultimately leading to hypothalamic inflammatory activation [117]. Ozcan et al. 
demonstrated that increased circulating cytokines and free fatty acids as a result of exposure to 
HFD contributes to the induction of ER stress in the hypothalamus of DIO mice and 
subsequently decreases leptin signaling [118]. Inflammatory and ER stress pathways are 
involved directly with leptin signaling; activation of NF-κB and elevated ER stress upregulates 
the previously mentioned inhibitor of LepRb, Socs3 [119]. The interplay of these various cellular 
pathways are complex and it remains unclear which factors are the primary drivers as opposed to 
secondary responders in triggering attenuation of cellular leptin signaling in the hypothalamus.  
Further support for the pathogenic role of HFD feeding in promoting hypothalamic inflammation 
is provided by studies demonstrating accumulation of activated glial cells in the hypothalamus of 
DIO rodents [134]. Glial cells include astrocytes, microglia, tanycytes, polydendrocytes, and 
oligodendrocytes and are the most abundant cell type in the CNS [135]. They are involved in 
various processes in the CNS critical during development, health and disease [136]. Microglia 
are tissue-resident macrophages in the CNS which play a role in synaptic pruning, cellular debris 
phagocytosis, immune surveillance and inflammation. Astrocytes contribute to nutrient support, 
neurotransmitter reuptake, neurovascular coupling and gliotransmitter (chemical transmitter 
released from glial cells) production [136]. Glial activation – also known as gliosis – refers to 
morphological (amoeboid form) and gene expression changes in microlia and astrocytes. In an 
activated state, microglia express major histocompatability complex proteins and inducible nitric 
oxide [137], whereas astrocytes induce expression of specific structural proteins such as glial 
fibrillary acidic protein (GFAP) and vimentin [138]. Within the first week of HFD consumption, 
hypothalamic inflammation is induced [120] and, over the same time period, mice accumulate 
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activated microglia and astrocytes in the MBH [134] circumstantially suggesting that gliosis 
mediates the inflammatory response. Indeed, expression of proinflammatory genes in microglia 
is elevated in the hypothalami of HFD-fed mice and ablation of microglia normalizes 
hypothalamic inflammation and neuronal stress [139, 140]. Astrocytes, when activated by CNS 
insults such as brain injury or ischemia, also produce proinflammatory cytokines (TNF-α, IL-1β, 
and IL-6) [141, 142]. Some in vitro studies suggest that SFA can activate proinflammatory 
signals in cultured astrocytes [143]. However, it is unclear whether this response occurs in vivo 
with astrocyte activation resulting from HFD feeding. Activation of microglia and astrocytes 
usually occurs together and there is certainly crosstalk between them; proinflammatory factors 
secreted from microglia can signal to astrocytes and astrocytes can communicate with microglia 
via factors that they release such as colony stimulating factor-1 (CSF-1) and ATP [136]. 
Surprisingly, C57Bl6 female mice do not exhibit central inflammatory and gliosis response when 
exposed to HFD [144]. While female mice gain weight on HFD, they do so to a lesser extent 
compared to male mice [145]. Recently, Dorfman et al. demonstrated that females on HFD do 
not show a decrease in CX3CL1, a chemokine secreted by neurons to maintain microglial 
quiescence, as occurs in male mice on HFD. When exposed to HFD, CX3CL1-deficient females 
show activation of microglia and weight gain comparable to that observed in male mice [146] 
indicating that decreased gliosis and weight gain on HFD in female mice may be mediated, at 
least in part, via the CX3CL1-CX3CR1 pathway.       
In rodents, during postnatal weeks 2 and 3, glia cell number markedly increases [147] coinciding 
with the leptin surge [148]. Astrocytes express LepRb [149, 150]. Exogenous leptin 
administration between P8-P12 increases proliferation of astrocytes in the hypothalamus and 
astrocyte-specific deletion of LepRb results in decreased astrogenesis [151]. Conditional deletion 
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of LepRb in adult mouse astrocytes leads to morphological changes in astrocytes and increases 
synaptic inputs onto hypothalamic POMC and AgRP neurons [149]. Additionally, these mice 
display a decrease in leptin-induced suppression of food intake [149]. These results suggest a 
direct impact of leptin on astrocyte development and function in adult mice. 
Lepob/ob (leptin deficient) mice become severely obese on chow diets, and have reduced activated 
microglia compared to WT mice on chow or on HFD [152]. Exposing Lepob/ob mice to HFD 
increases microglial markers to a lesser degree than HFD feeding in WT mice [152]. These 
findings suggest that leptin, HFD, or the interaction of both is required for HFD-induced gliosis. 
Astrocyte activation was not evaluated in this study. Martin Myers and colleagues showed that 
10-days of continuous systemic leptin infusion in WT mice fed a chow diet was sufficient to 
induce microglial and astrocyte activation in the hypothalamus (personal communication). This 
finding implicates a direct role of leptin in gliosis, suggesting that elevated leptin per se (which 
is physiologically increased by obesity) may contribute to hypothalamic inflammation and 
subsequently to attenuated leptin signaling.  
It remains unclear whether CNS changes associated with HFD feeding and/or obesity described 
above are secondary to increased adiposity or if they are contributing factors to the development 
and/or perpetuation of obesity. Determining causality is challenging due to the interrelated nature 
of obesity, physiologic, neuronal, and structural changes but the disentanglement of these factors 
is critical in understanding the pathophysiology of obesity in an environment characterized by 
calorically dense and highly palatable diet.  
Part of my PhD research, focused on the investigation of hyperleptinemia per se as a contributing 
factor to the elevation of body weight threshold. This work is described in more detail in Chapter 




Developmental influence on body weight 
Investigation of the pathways linking perinatal environments and future health outcomes can be 
helpful in prevention of obesity and obesity-related diseases. Adverse or suboptimal environment 
during fetal/early development leads to increased risk of disease in adult life. In 1990, based on 
historical cohort studies, David Barker noted that infants who are small at birth are at higher risk 
for increased blood pressure and other adverse cardiovascular endpoints in adulthood [153]. The 
Dutch Hunger Winter of 1944-45 provides a unique opportunity to investigate how gestational 
undernutrition impacts the risk of disease later in life. The data collected from the offspring of 
women exposed to famine at different stages of gestation demonstrates that the timing of 
undernutrition in the programming of adult disease is critical. Only those fetuses exposed to 
famine during early gestation had a higher prevalence of obesity and cardiovascular disease 
[154]. Undernutrition during late gestation resulted in smaller birth weight and that cohort 
continued to be smaller as adults with lower rates of obesity [154, 155]. 
In the current environment, nutritional excess, rather than scarcity is prevalent. Epidemiological 
studies indicate that maternal obesity (even accounting for shared genotype) predisposes 
offspring to obesity and metabolic disease [156-158]. The underlying cellular and molecular 
mechanism(s) for these effects of maternal programming of adult disease are unclear. Rodent 
studies have indicated that maternal HFD feeding and/or obesity during critical developmental 
periods leads to obesity and metabolic disease including insulin resistance and hepatic steatosis 
in the offspring later in life [159-163]. As discussed in the previous section, many physiological 
and molecular alterations occur as a result of obesity and HFD feeding and these changes may 
have profound effects on the offspring during gestation and in the postnatal period. The 
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developing hypothalamus may be especially influenced by the hormonal milieu; suboptimal 
concentrations of various hormones may affect neurogenesis (alter the number of neurons born 
during gestation that are involved in feeding behavior), axonal outgrowth of neurons 
participating in feeding circuits during early postnatal period, or epigenetic modifications to 
genes important in body weight regulation [164]. The pathways predicted to be primarily 
affected by such perinatal programming are those critical in energy homeostasis; such as those 
involving leptin- and insulin-responsive POMC and AgRP neurons [64, 72]. 
The first critical period of hypothalamic development is in-utero when hypothalamic 
neurogenesis occurs and neuronal cell numbers are determined. In mice, most of hypothalamic 
neurogenesis for neurons involved in energy balance happens mid-gestation, between embryonic 
days 12 and 14 [165]. These neurons do not send their axonal projections to their target sites 
until the postnatal period, marking the second critical period during development of the 
hypothalamus [166, 167]. Simerly and colleagues demonstrated that at birth, the ARH 
projections are immature and these projections develop mostly during the second postnatal week 
of life [167]. The mature innervation from the ARH to the DMH and PVH is achieved by P6 and 
P12, respectively, whereas projections from ARH to LHA begin at P12 [167].  
Leptin is an essential factor in the process of projection formation in the feeding circuits. Lepob/ob 
mice have a severe reduction in the density of axons from ARH neurons to PVH, DMH, and 
LHA and this decrease persists through adulthood [166]. The phenotype of diminished ARH 
projections in Lepob/ob mice can be rescued with exogenous leptin, however, the time window for 
this effect is restricted to the postnatal period (P4-P12). Specifically, Bouyer and Simerly defined 
that early exposure of Lepob/ob mice to exogenous leptin rescues AgRP inputs to preautonomic 
but not the neuroendocrine neurons within the PVH indicating that in addition to its role in 
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formation of hypothalamic projections, leptin is also important in targeting of axons originating 
from the ARH to specific cell-types within the hypothalamic nuclei [168]. Administration of 
leptin to adult Lepob/ob mice does not restore hypothalamic projection densities. The offspring of 
dams exposed to HFD during gestation and lactation [169] or during lactation only [170] gain 
more weight than controls. The density of AgRP immunoreactive fibers in the PVH are 
decreased in the offspring of HFD dams compared to chow fed dams [169]. Vogt et al. reported 
reduced fiber densities of AgRP and α-MSH projections from the ARH to three downstream 
hypothalamic areas: PVH, DMH and LHA in the offspring of dams fed HFD during lactation 
[170]. These data suggest that ambient leptin is critical in the development of hypothalamic 
feeding circuits. 
Metabolic signals other than leptin (such as insulin and ghrelin) may also act as neurotrophic 
factors during early development. A single injection of insulin directly into the hypothalamus of 
P8 rats results in decreased neuronal density in the VMH of P15 pups and increased body weight 
gain as adults [171]. Carmody et al. demonstrated that HFD feeding, in addition to maternal 
insulin resistance (dams were heterozygous for a null allele of the insulin receptor), increases the 
number of POMC-expressing cells in the ARH of P9 offspring [172]. This suggests that insulin 
can influence the specification of POMC neurons in response to maternal HFD feeding [172]. 
Vogt et al. showed that elevated insulin resulting from maternal HFD exposure disrupts POMC 
neuron innervation to the preautonomic compartment of the PVH. Blocking insulin signaling 
specifically in POMC neurons, under conditions of maternal HFD feeding, rescues the 
projections in this circuit and corrects glucose intolerance [170], implicating the role of insulin in 
the development of hypothalamic circuits involved in glucose homeostasis.  
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Ghrelin’s role has also been studied during mouse postnatal development. Ghrelin – an appetite 
stimulating circulating factor – is primarily produced in the stomach and signals through the 
growth hormone secretagogue receptor (GHSR) [173, 174]. GHSR is expressed most densely in 
the hypothalamus; administration of ghrelin activates neurons in brain areas known to control 
feeding (such as ARH, VMH, and PVH) [175]. Steculorum et al. reported that in WT mice 
circulating ghrelin levels during postnatal period start rising from P6 and reach adult 
concentrations by P14 [176]. They evaluated the physiological and neurobiological roles of 
ghrelin during postnatal development by either blocking ghrelin signaling from P4 to P22 or 
elevating circulating ghrelin concentrations from P4 to P12. Blocking ghrelin action resulted in 
enhanced overall fiber density in the PVH, including AgRP and αMSH immunoreactive fibers; 
administration of ghrelin had the opposite effects – innervation in the PVH was reduced. 
Surprisingly, both interventions resulted in increased body weight, fat, and blood glucose. While 
the overall density of AgRP and αMSH fibers in the PVH are affected in an opposite way by 
ghrelin and anti-ghrelin treatment, the ratio of orexigenic AgRP to anorexigenic αMSH is 
increased in both conditions which could explain the increased body weight in both 
manipulations [177]. These data emphasize that appropriate timing and magnitude of ghrelin’s 
action is important in proper formation of hypothalamic neurocircuits and in control of body 
weight in adulthood [176].  
The studies described above indicate that suboptimal concentrations of metabolic hormones 
including leptin, insulin, and ghrelin during the immediate postnatal period – a critical window 
for development of feeding circuits– are capable of permanently altering the neuroanatomical 
organization of the hypothalamic circuits essential in the control of body weight and glucose 
homeostasis. Whether hyperleptinemia per se can influence the formation of these circuits has 
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not been evaluated but is of obvious relevance. Investigating the role of these hormones during 
other developmental periods such as gestation and adolescence requires further investigation. To 
this end, during my doctoral training, I have made a transgenic mouse with the capability to 
precisely and temporally restrict hyperleptinemia completely dissociated from diet or obesity and 
its metabolic consequences and used it to address some of the questions raised in this section. 
These studies are described in the 2nd and 3rd chapter.  
 
Pharmacology 
Obesity is a chronic disease with serious health consequences. Modest weight loss of only 5-10% 
of body weight in obese patients has substantial health benefits including improvements in blood 
glucose, prevention of type 2 diabetes, reduction of blood pressure and triglycerides, and 
increasing HDL cholesterol [178, 179]. While temporary weight loss in humans is achievable 
with lifestyle interventions such as diet and exercise [180], the recidivism rates are very high 
indicating that maintenance of a reduced body weight is the major challenge in obesity treatment 
[181]. The inability to maintain weight loss is a result of physiological and molecular changes 
that accompany the weight reduced state (described in an earlier section) which ultimately 
promote weight regain [99, 102, 103].  
These physiological responses during maintenance of reduced body weight are similar but not 
identical to those seen during dynamic weight loss [182]. Current efforts in obesity treatment are 
primarily focused on the induction of weight loss, yet the therapies available are less than 
satisfactory [183]. As discussed earlier, exogenous leptin has limited efficacy in induction of 
weight loss in lean or obese subjects [108]; however, it is much more effective during the 
maintenance of reduced weight when given in small doses [110]. This observation suggests that 
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pharmacological strategies for relieving the physiological adaptations to the weight reduced state 
could have important applications in the treatment of obesity. The physiology of the weight- 
reduced state suggests that pharmacologic agents affecting energy homeostasis would have 
greater efficacy in individuals maintaining weight loss. In the Chapter 6 of this thesis we 
compare the effects of a novel MC4R agonist on inducing vs. maintaining weight loss to in mice.  
 
Summary 
This thesis includes 5 manuscripts investigating aspects of leptin physiology in regulation of 
body weight. Chapter 2 describes the creation of a transgenic mouse that overexpresses leptin 
independent of adiposity. Leptin expression can be transiently turned on or off at any age. These 
mice provide a model to investigate whether hyperleptinemia per se drives conditions associated 
with obesity without the other, related, confounds such as diet, circulating lipids, glucose, 
insulin, ghrelin, etc. Moreover, this mouse model allows for precise temporal control of 
hyperleptinemia.  
We have used this leptin transgenic mouse to evaluate the physiological effects of elevated leptin 
during distinct developmental periods on the defense of body weight later in life (Chapter 3). We 
have shown that exposing adult or “adolescent” mice to chronic hyperleptinemia (via transient 
dox exposure) does not alter either body composition or weight; however, inducing 
hyperleptinemia during the nursing period (P0-P22) results in increased body weight gain in 
these mice when exposed to high fat (60% kcals from fat) diet later in life.  
Chapter four investigates energy homeostasis of leptin deficient mice. Mice that lack leptin are 
still capable of regulating body weight and energy expenditure. This work attempts to determine 
a signal, independent of leptin, that is produced by adipose tissue and alters energy expenditure 
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when the mouse’s food intake is restricted in. It does not appear that this signal alters food 
intake, since, when leptin deficient mice are released from restriction, they do not overeat 
relative to never restricted mice. This is in contrast to leptin competent mice that transiently 
overeat for several days post-release. 
In humans and mice, leptin circulates in proportion to fat mass. However, there is variation 
among humans in this relationship, with some displaying levels of plasma leptin well below 
those predicted by fat mass. Dr. Ruth Loos and colleagues at Icahn School of Medicine at Mount 
Sinai carried out a GWAS on circulating leptin and found associations – controlled for adiposity 
– in 4 genomic regions. To identify the causal genes in implicated loci, we developed a 
functional assay to systematically knock down (using siRNA) candidate genes in explanted 
mouse adipose tissue and measured both leptin expression and secretion in media. With this 
approach we attempted to find the genes that influence circulating leptin in humans independent 
of fat mass and demonstrated a technique to determine the genetic signal that was revealed by the 
GWAS [1]. 
The final chapter describes experiments which investigate the efficacy of an MC4R agonist, in 
maintaining reduced body weight in mice. As described in earlier sections, weight loss leads to 
physiological adjustments that work coordinately to promote weight regain. MC4R is a 
downstream target of leptin that is central to energy homeostasis. The MC4R agonist was 
effective at a significantly lower dose when used to maintain reduced body weight than to induce 
weight loss in ad libitum fed mice, supporting the idea that targeting the weight reduced state 






1. Kilpelainen, T.O., et al., Genome-wide meta-analysis uncovers novel loci influencing 
circulating leptin levels. Nat Commun, 2016. 7: p. 10494. 
2. Skowronski, A.A., et al., Effects of a novel MC4R agonist on maintenance of reduced 
body weight in diet-induced obese mice. Obesity (Silver Spring), 2014. 22(5): p. 1287-95. 
3. Kelly, T., et al., Global burden of obesity in 2005 and projections to 2030. Int J Obes 
(Lond), 2008. 32(9): p. 1431-7. 
4. Wang, Y., et al., Will all Americans become overweight or obese? estimating the 
progression and cost of the US obesity epidemic. Obesity (Silver Spring), 2008. 16(10): 
p. 2323-30. 
5. Malnick, S.D. and H. Knobler, The medical complications of obesity. QJM, 2006. 99(9): 
p. 565-79. 
6. Haslam, D.W. and W.P. James, Obesity. Lancet, 2005. 366(9492): p. 1197-209. 
7. Kivipelto, M., et al., Obesity and vascular risk factors at midlife and the risk of dementia 
and Alzheimer disease. Arch Neurol, 2005. 62(10): p. 1556-60. 
8. Whitmer, R.A., et al., Body mass index in midlife and risk of Alzheimer disease and 
vascular dementia. Curr Alzheimer Res, 2007. 4(2): p. 103-9. 
9. Thorpe, K.E., et al., The impact of obesity on rising medical spending. Health Aff 
(Millwood), 2004. Suppl Web Exclusives: p. W4-480-6. 
10. Cawley, J. and C. Meyerhoefer, The medical care costs of obesity: an instrumental 
variables approach. J Health Econ, 2012. 31(1): p. 219-30. 
11. Ogden, C.L., et al., Prevalence of Obesity Among Adults and Youth: United States, 2011-
2014. NCHS Data Brief, 2015(219): p. 1-8. 
12. Reilly, J.J., Descriptive epidemiology and health consequences of childhood obesity. Best 
Pract Res Clin Endocrinol Metab, 2005. 19(3): p. 327-41. 
13. Maffeis, C. and L. Tato, Long-term effects of childhood obesity on morbidity and 
mortality. Horm Res, 2001. 55 Suppl 1: p. 42-5. 
14. Forbes, D.C. and D.E. White, A case of marked and unresponsive obesity. Can Vet J, 
1987. 28(4): p. 187. 
15. Flegal, K.M. and B.I. Graubard, Estimates of excess deaths associated with body mass 
index and other anthropometric variables. Am J Clin Nutr, 2009. 89(4): p. 1213-9. 
16. Pischon, T., et al., General and abdominal adiposity and risk of death in Europe. N Engl 
J Med, 2008. 359(20): p. 2105-20. 
 25 
 
17. Fontaine, K.R., et al., Years of life lost due to obesity. JAMA, 2003. 289(2): p. 187-93. 
18. Kennedy, G.C., The role of depot fat in the hypothalamic control of food intake in the rat. 
Proc R Soc Lond B Biol Sci, 1953. 140(901): p. 578-96. 
19. Coleman, D.L., Effects of parabiosis of obese with diabetes and normal mice. 
Diabetologia, 1973. 9(4): p. 294-8. 
20. Zhang, Y., et al., Positional cloning of the mouse obese gene and its human homologue. 
Nature, 1994. 372(6505): p. 425-32. 
21. Tartaglia, L.A., et al., Identification and expression cloning of a leptin receptor, OB-R. 
Cell, 1995. 83(7): p. 1263-71. 
22. Chua, S.C., Jr., et al., Phenotypes of mouse diabetes and rat fatty due to mutations in the 
OB (leptin) receptor. Science, 1996. 271(5251): p. 994-6. 
23. Rosenbaum, M., et al., Effects of gender, body composition, and menopause on plasma 
concentrations of leptin. Journal of Clinical Endocrinology & Metabolism, 1996. 81(9): 
p. 3424-3427. 
24. Zhang, Y., et al., Mechanisms for LEPR-mediated regulation of leptin expression in 
brown and white adipocytes in rat pups. Physiol Genomics, 2001. 4(3): p. 189-99. 
25. Cinti, S., et al., Leptin in the human stomach. Gut, 2001. 49(1): p. 155. 
26. Masuzaki, H., et al., Nonadipose tissue production of leptin: leptin as a novel placenta-
derived hormone in humans. Nat Med, 1997. 3(9): p. 1029-33. 
27. Smith-Kirwin, S.M., et al., Leptin expression in human mammary epithelial cells and 
breast milk. J Clin Endocrinol Metab, 1998. 83(5): p. 1810-3. 
28. Ahima, R.S. and J.S. Flier, Leptin. Annu Rev Physiol, 2000. 62: p. 413-37. 
29. Sinha, M.K., et al., Nocturnal rise of leptin in lean, obese, and non-insulin-dependent 
diabetes mellitus subjects. J Clin Invest, 1996. 97(5): p. 1344-7. 
30. Ahima, R.S., et al., Role of leptin in the neuroendocrine response to fasting. Nature, 
1996. 382(6588): p. 250-2. 
31. Lee, M.J., et al., Feeding and insulin increase leptin translation. Importance of the leptin 
mRNA untranslated regions. J Biol Chem, 2007. 282(1): p. 72-80. 
32. Rosenbaum, M., et al., Sexual dimorphism in circulating leptin concentrations is not 
accounted for by differences in adipose tissue distribution. Int J Obes Relat Metab 
Disord, 2001. 25(9): p. 1365-71. 
33. Russell, C.D., et al., Regulation of the leptin content of obese human adipose tissue. Am J 
Physiol Endocrinol Metab, 2001. 280(3): p. E399-404. 
 26 
 
34. Guo, K.Y., et al., Effects of obesity on the relationship of leptin mRNA expression and 
adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr 
Comp Physiol, 2004. 287(1): p. R112-9. 
35. Zhang, Y., et al., Fat cell size and adipokine expression in relation to gender, depot, and 
metabolic risk factors in morbidly obese adolescents. Obesity (Silver Spring), 2014. 
22(3): p. 691-7. 
36. Lee, M.J. and S.K. Fried, Integration of hormonal and nutrient signals that regulate 
leptin synthesis and secretion. Am J Physiol Endocrinol Metab, 2009. 296(6): p. E1230-
8. 
37. Hetherington, A.W. and S.W. Ranson, Hypothalamic lesions and adiposity in the rat. 
Anatomical Record, 1940. 78(2): p. 149-172. 
38. Anand, B.K. and J.R. Brobeck, Hypothalamic Control of Food Intake in Rats and Cats. 
Yale Journal of Biology and Medicine, 1951. 24(2): p. 123-140. 
39. Tartaglia, L.A., The leptin receptor. J Biol Chem, 1997. 272(10): p. 6093-6. 
40. Chua, S.C., Jr., et al., Fine structure of the murine leptin receptor gene: splice site 
suppression is required to form two alternatively spliced transcripts. Genomics, 1997. 
45(2): p. 264-70. 
41. Myers, M.G., M.A. Cowley, and H. Munzberg, Mechanisms of leptin action and leptin 
resistance. Annu Rev Physiol, 2008. 70: p. 537-56. 
42. Banks, A.S., et al., Activation of downstream signals by the long form of the leptin 
receptor. J Biol Chem, 2000. 275(19): p. 14563-72. 
43. Ge, H., et al., Generation of soluble leptin receptor by ectodomain shedding of 
membrane-spanning receptors in vitro and in vivo. J Biol Chem, 2002. 277(48): p. 
45898-903. 
44. Gavrilova, O., et al., Hyperleptinemia of pregnancy associated with the appearance of a 
circulating form of the leptin receptor. J Biol Chem, 1997. 272(48): p. 30546-51. 
45. de Luca, C., et al., Complete rescue of obesity, diabetes, and infertility in db/db mice by 
neuron-specific LEPR-B transgenes. J Clin Invest, 2005. 115(12): p. 3484-93. 
46. Lord, G.M., et al., Leptin modulates the T-cell immune response and reverses starvation-
induced immunosuppression. Nature, 1998. 394(6696): p. 897-901. 
47. Covey, S.D., et al., The pancreatic beta cell is a key site for mediating the effects of leptin 
on glucose homeostasis. Cell Metab, 2006. 4(4): p. 291-302. 
 27 
 
48. Drew, J.E., et al., Insulin, leptin, and adiponectin receptors in colon: regulation relative 
to differing body adiposity independent of diet and in response to dimethylhydrazine. Am 
J Physiol Gastrointest Liver Physiol, 2007. 293(4): p. G682-91. 
49. Baumann, H., et al., The full-length leptin receptor has signaling capabilities of 
interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A, 1996. 93(16): p. 8374-8. 
50. Gong, Y., et al., The long form of the leptin receptor regulates STAT5 and ribosomal 
protein S6 via alternate mechanisms. J Biol Chem, 2007. 282(42): p. 31019-27. 
51. Darnell, J.E., Jr., I.M. Kerr, and G.R. Stark, Jak-STAT pathways and transcriptional 
activation in response to IFNs and other extracellular signaling proteins. Science, 1994. 
264(5164): p. 1415-21. 
52. Bjorbaek, C., et al., The role of SOCS-3 in leptin signaling and leptin resistance. J Biol 
Chem, 1999. 274(42): p. 30059-65. 
53. Bjorbaek, C., et al., SOCS3 mediates feedback inhibition of the leptin receptor via 
Tyr985. J Biol Chem, 2000. 275(51): p. 40649-57. 
54. Zabolotny, J.M., et al., PTP1B regulates leptin signal transduction in vivo. Dev Cell, 
2002. 2(4): p. 489-95. 
55. Mercer, J.G., et al., Localization of leptin receptor mRNA and the long form splice 
variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ 
hybridization. FEBS Lett, 1996. 387(2-3): p. 113-6. 
56. Elmquist, J.K., et al., Distributions of leptin receptor mRNA isoforms in the rat brain. J 
Comp Neurol, 1998. 395(4): p. 535-47. 
57. Leshan, R.L., et al., Leptin receptor signaling and action in the central nervous system. 
Obesity (Silver Spring), 2006. 14 Suppl 5: p. 208S-212S. 
58. Patterson, C.M., et al., Molecular mapping of mouse brain regions innervated by leptin 
receptor-expressing cells. Brain Res, 2011. 1378: p. 18-28. 
59. Scott, M.M., et al., Leptin targets in the mouse brain. J Comp Neurol, 2009. 514(5): p. 
518-32. 
60. Hommel, J.D., et al., Leptin receptor signaling in midbrain dopamine neurons regulates 
feeding. Neuron, 2006. 51(6): p. 801-10. 
61. Hayes, M.R., et al., Endogenous leptin signaling in the caudal nucleus tractus solitarius 
and area postrema is required for energy balance regulation. Cell Metab, 2010. 11(1): p. 
77-83. 
62. Schwartz, M.W., et al., Central nervous system control of food intake. Nature, 2000. 
404(6778): p. 661-71. 
 28 
 
63. Hahn, T.M., et al., Coexpression of Agrp and NPY in fasting-activated hypothalamic 
neurons. Nat Neurosci, 1998. 1(4): p. 271-2. 
64. Cowley, M.A., et al., Leptin activates anorexigenic POMC neurons through a neural 
network in the arcuate nucleus. Nature, 2001. 411(6836): p. 480-4. 
65. Benjannet, S., et al., PC1 and PC2 are proprotein convertases capable of cleaving 
proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci U S A, 1991. 
88(9): p. 3564-8. 
66. Seeley, R.J., et al., Melanocortin receptors in leptin effects. Nature, 1997. 390(6658): p. 
349. 
67. Ollmann, M.M., et al., Antagonism of central melanocortin receptors in vitro and in vivo 
by agouti-related protein. Science, 1997. 278(5335): p. 135-8. 
68. Swart, I., et al., Hypothalamic NPY, AGRP, and POMC mRNA responses to leptin and 
refeeding in mice. Am J Physiol Regul Integr Comp Physiol, 2002. 283(5): p. R1020-6. 
69. Korner, J., et al., Leptin regulation of Agrp and Npy mRNA in the rat hypothalamus. J 
Neuroendocrinol, 2001. 13(11): p. 959-66. 
70. Krude, H., et al., Severe early-onset obesity, adrenal insufficiency and red hair 
pigmentation caused by POMC mutations in humans. Nature Genetics, 1998. 19(2): p. 
155-157. 
71. Challis, B.G., et al., Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding 
but respond normally to the acute anorectic effects of peptide-YY3-36. Proceedings of the 
National Academy of Sciences of the United States of America, 2004. 101(13): p. 4695-
4700. 
72. Luquet, S., et al., NPY/AgRP neurons are essential for feeding in adult mice but can be 
ablated in neonates. Science, 2005. 310(5748): p. 683-685. 
73. Gropp, E., et al., Agouti-related peptide-expressing neurons are mandatory for feeding. 
Nature Neuroscience, 2005. 8(10): p. 1289-1291. 
74. Farooqi, I.S., et al., Clinical spectrum of obesity and mutations in the melanocortin 4 
receptor gene. N Engl J Med, 2003. 348(12): p. 1085-95. 
75. Pierroz, D.D., et al., Effects of acute and chronic administration of the melanocortin 
agonist MTII in mice with diet-induced obesity. Diabetes, 2002. 51(5): p. 1337-45. 
76. Mountjoy, K.G., et al., Localization of the melanocortin-4 receptor (MC4-R) in 
neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol, 1994. 
8(10): p. 1298-308. 
 29 
 
77. Kishi, T., et al., Expression of melanocortin 4 receptor mRNA in the central nervous 
system of the rat. J Comp Neurol, 2003. 457(3): p. 213-35. 
78. Shah, B.P., et al., MC4R-expressing glutamatergic neurons in the paraventricular 
hypothalamus regulate feeding and are synaptically connected to the parabrachial 
nucleus. Proc Natl Acad Sci U S A, 2014. 111(36): p. 13193-8. 
79. Balthasar, N., et al., Divergence of melanocortin pathways in the control of food intake 
and energy expenditure. Cell, 2005. 123(3): p. 493-505. 
80. Rossi, J., et al., Melanocortin-4 receptors expressed by cholinergic neurons regulate 
energy balance and glucose homeostasis. Cell Metab, 2011. 13(2): p. 195-204. 
81. Enriori, P.J., et al., Leptin action in the dorsomedial hypothalamus increases sympathetic 
tone to brown adipose tissue in spite of systemic leptin resistance. J Neurosci, 2011. 
31(34): p. 12189-97. 
82. Dhillon, H., et al., Leptin directly activates SF1 neurons in the VMH, and this action by 
leptin is required for normal body-weight homeostasis. Neuron, 2006. 49(2): p. 191-203. 
83. Elmquist, J.K., et al., Identifying hypothalamic pathways controlling food intake, body 
weight, and glucose homeostasis. J Comp Neurol, 2005. 493(1): p. 63-71. 
84. Grill, H.J., Distributed neural control of energy balance: contributions from hindbrain 
and hypothalamus. Obesity (Silver Spring), 2006. 14 Suppl 5: p. 216S-221S. 
85. Morton, G.J., et al., Leptin action in the forebrain regulates the hindbrain response to 
satiety signals. J Clin Invest, 2005. 115(3): p. 703-10. 
86. Huo, L., et al., Leptin and the control of food intake: neurons in the nucleus of the 
solitary tract are activated by both gastric distension and leptin. Endocrinology, 2007. 
148(5): p. 2189-97. 
87. Kelley, A.E. and K.C. Berridge, The neuroscience of natural rewards: relevance to 
addictive drugs. J Neurosci, 2002. 22(9): p. 3306-11. 
88. Figlewicz, D.P., et al., Expression of receptors for insulin and leptin in the ventral 
tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res, 2003. 964(1): p. 107-15. 
89. Davis, J.F., et al., Leptin regulates energy balance and motivation through action at 
distinct neural circuits. Biol Psychiatry, 2011. 69(7): p. 668-74. 
90. Leinninger, G.M., et al., Leptin acts via leptin receptor-expressing lateral hypothalamic 
neurons to modulate the mesolimbic dopamine system and suppress feeding. Cell Metab, 
2009. 10(2): p. 89-98. 
91. Trayhurn, P., P.L. Thurlby, and W.P. James, Thermogenic defect in pre-obese ob/ob 
mice. Nature, 1977. 266(5597): p. 60-2. 
 30 
 
92. Himms-Hagen, J., Food restriction increases torpor and improves brown adipose tissue 
thermogenesis in ob/ob mice. Am J Physiol, 1985. 248(5 Pt 1): p. E531-9. 
93. Barash, I.A., et al., Leptin is a metabolic signal to the reproductive system. 
Endocrinology, 1996. 137(7): p. 3144-7. 
94. Sheena, J. and C.J. Meade, Mice bearing the ob/ob mutation have impaired immunity. Int 
Arch Allergy Appl Immunol, 1978. 57(3): p. 263-8. 
95. Montague, C.T., et al., Congenital leptin deficiency is associated with severe early-onset 
obesity in humans. Nature, 1997. 387(6636): p. 903-8. 
96. Farooqi, I.S., et al., Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and 
neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin 
Invest, 2002. 110(8): p. 1093-103. 
97. Farooqi, I.S., et al., Effects of recombinant leptin therapy in a child with congenital leptin 
deficiency. N Engl J Med, 1999. 341(12): p. 879-84. 
98. Leibel, R.L., The role of leptin in the control of body weight. Nutr Rev, 2002. 60(10 Pt 2): 
p. S15-9; discussion S68-84, 85-7. 
99. Leibel, R.L., M. Rosenbaum, and J. Hirsch, Changes in energy expenditure resulting 
from altered body weight. N Engl J Med, 1995. 332(10): p. 621-8. 
100. Rosenbaum, M., et al., A comparative study of different means of assessing long-term 
energy expenditure in humans. Am J Physiol, 1996. 270(3 Pt 2): p. R496-504. 
101. Sims, E.A., et al., Endocrine and metabolic effects of experimental obesity in man. 
Recent Prog Horm Res, 1973. 29: p. 457-96. 
102. Rosenbaum, M., et al., Effects of changes in body weight on carbohydrate metabolism, 
catecholamine excretion, and thyroid function. Am J Clin Nutr, 2000. 71(6): p. 1421-32. 
103. Rosenbaum, M., et al., Long-term persistence of adaptive thermogenesis in subjects who 
have maintained a reduced body weight. Am J Clin Nutr, 2008. 88(4): p. 906-12. 
104. Rosenbaum, M., et al., Effects of experimental weight perturbation on skeletal muscle 
work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol, 2003. 
285(1): p. R183-92. 
105. Goldsmith, R., et al., Effects of experimental weight perturbation on skeletal muscle work 
efficiency, fuel utilization, and biochemistry in human subjects. Am J Physiol Regul 
Integr Comp Physiol, 2010. 298(1): p. R79-88. 
106. Baldwin, K.M., et al., Effects of weight loss and leptin on skeletal muscle in human 
subjects. Am J Physiol Regul Integr Comp Physiol, 2011. 301(5): p. R1259-66. 
 31 
 
107. Rosenbaum, M., et al., Leptin reverses weight loss-induced changes in regional neural 
activity responses to visual food stimuli. J Clin Invest, 2008. 118(7): p. 2583-91. 
108. Heymsfield, S.B., et al., Recombinant leptin for weight loss in obese and lean adults: a 
randomized, controlled, dose-escalation trial. JAMA, 1999. 282(16): p. 1568-75. 
109. Mackintosh, R.M. and J. Hirsch, The effects of leptin administration in non-obese human 
subjects. Obes Res, 2001. 9(8): p. 462-9. 
110. Rosenbaum, M., et al., Low-dose leptin reverses skeletal muscle, autonomic, and 
neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest, 2005. 
115(12): p. 3579-86. 
111. Ravussin, Y., et al., Effects of chronic weight perturbation on energy homeostasis and 
brain structure in mice. Am J Physiol Regul Integr Comp Physiol, 2011. 300(6): p. 
R1352-62. 
112. Pinto, S., et al., Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science, 
2004. 304(5667): p. 110-5. 
113. Mantzoros, C.S., et al., Leptin in human physiology and pathophysiology. Am J Physiol 
Endocrinol Metab, 2011. 301(4): p. E567-84. 
114. Levin, B.E., A.A. Dunn-Meynell, and W.A. Banks, Obesity-prone rats have normal 
blood-brain barrier transport but defective central leptin signaling before obesity onset. 
Am J Physiol Regul Integr Comp Physiol, 2004. 286(1): p. R143-50. 
115. Balland, E., et al., Hypothalamic tanycytes are an ERK-gated conduit for leptin into the 
brain. Cell Metab, 2014. 19(2): p. 293-301. 
116. Kleinridders, A., et al., MyD88 signaling in the CNS is required for development of fatty 
acid-induced leptin resistance and diet-induced obesity. Cell Metab, 2009. 10(4): p. 249-
59. 
117. Milanski, M., et al., Saturated fatty acids produce an inflammatory response 
predominantly through the activation of TLR4 signaling in hypothalamus: implications 
for the pathogenesis of obesity. J Neurosci, 2009. 29(2): p. 359-70. 
118. Ozcan, L., et al., Endoplasmic reticulum stress plays a central role in development of 
leptin resistance. Cell Metab, 2009. 9(1): p. 35-51. 
119. Zhang, X., et al., Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to 
energy imbalance and obesity. Cell, 2008. 135(1): p. 61-73. 
120. De Souza, C.T., et al., Consumption of a fat-rich diet activates a proinflammatory 
response and induces insulin resistance in the hypothalamus. Endocrinology, 2005. 
146(10): p. 4192-9. 
 32 
 
121. Bjorbaek, C., et al., Identification of SOCS-3 as a potential mediator of central leptin 
resistance. Mol Cell, 1998. 1(4): p. 619-25. 
122. Caro, J.F., et al., Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible 
mechanism for leptin resistance. Lancet, 1996. 348(9021): p. 159-61. 
123. Van Heek, M., et al., Diet-induced obese mice develop peripheral, but not central, 
resistance to leptin. J Clin Invest, 1997. 99(3): p. 385-90. 
124. Halaas, J.L., et al., Physiological response to long-term peripheral and central leptin 
infusion in lean and obese mice. Proc Natl Acad Sci U S A, 1997. 94(16): p. 8878-83. 
125. Ganong, W.F., Circumventricular organs: definition and role in the regulation of 
endocrine and autonomic function. Clin Exp Pharmacol Physiol, 2000. 27(5-6): p. 422-7. 
126. Munzberg, H., J.S. Flier, and C. Bjorbaek, Region-specific leptin resistance within the 
hypothalamus of diet-induced obese mice. Endocrinology, 2004. 145(11): p. 4880-9. 
127. Reed, A.S., et al., Functional role of suppressor of cytokine signaling 3 upregulation in 
hypothalamic leptin resistance and long-term energy homeostasis. Diabetes, 2010. 59(4): 
p. 894-906. 
128. Mori, H., et al., Socs3 deficiency in the brain elevates leptin sensitivity and confers 
resistance to diet-induced obesity. Nat Med, 2004. 10(7): p. 739-43. 
129. Weisberg, S.P., et al., Obesity is associated with macrophage accumulation in adipose 
tissue. J Clin Invest, 2003. 112(12): p. 1796-808. 
130. Xu, H., et al., Chronic inflammation in fat plays a crucial role in the development of 
obesity-related insulin resistance. J Clin Invest, 2003. 112(12): p. 1821-30. 
131. Boden, G., et al., Free fatty acids produce insulin resistance and activate the 
proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes, 2005. 54(12): p. 
3458-65. 
132. Park, E.J., et al., Dietary and genetic obesity promote liver inflammation and 
tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010. 140(2): p. 197-208. 
133. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature, 2006. 444(7121): p. 
860-7. 
134. Thaler, J.P., et al., Obesity is associated with hypothalamic injury in rodents and humans. 
J Clin Invest, 2012. 122(1): p. 153-62. 
135. Douglass, J.D., M.D. Dorfman, and J.P. Thaler, Glia: silent partners in energy 
homeostasis and obesity pathogenesis. Diabetologia, 2017. 60(2): p. 226-236. 
 33 
 
136. Barres, B.A., The mystery and magic of glia: a perspective on their roles in health and 
disease. Neuron, 2008. 60(3): p. 430-40. 
137. Aloisi, F., Immune function of microglia. Glia, 2001. 36(2): p. 165-79. 
138. Ridet, J.L., et al., Immunocytochemical characterization of a new marker of fibrous and 
reactive astrocytes. Cell Tissue Res, 1996. 283(1): p. 39-49. 
139. Valdearcos, M., et al., Microglia dictate the impact of saturated fat consumption on 
hypothalamic inflammation and neuronal function. Cell Rep, 2014. 9(6): p. 2124-38. 
140. Baufeld, C., et al., High-fat diet-induced brain region-specific phenotypic spectrum of 
CNS resident microglia. Acta Neuropathol, 2016. 132(3): p. 361-75. 
141. Lieberman, A.P., et al., Production of tumor necrosis factor and other cytokines by 
astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci 
U S A, 1989. 86(16): p. 6348-52. 
142. Lee, S.C., et al., Cytokine production by human fetal microglia and astrocytes. 
Differential induction by lipopolysaccharide and IL-1 beta. J Immunol, 1993. 150(7): p. 
2659-67. 
143. Gupta, S., et al., Saturated long-chain fatty acids activate inflammatory signaling in 
astrocytes. J Neurochem, 2012. 120(6): p. 1060-71. 
144. Morselli, E., et al., Hypothalamic PGC-1alpha protects against high-fat diet exposure by 
regulating ERalpha. Cell Rep, 2014. 9(2): p. 633-45. 
145. Yang, Y., et al., Variations in body weight, food intake and body composition after long-
term high-fat diet feeding in C57BL/6J mice. Obesity (Silver Spring), 2014. 22(10): p. 
2147-55. 
146. Dorfman, M.D., et al., Sex differences in microglial CX3CR1 signalling determine 
obesity susceptibility in mice. Nat Commun, 2017. 8: p. 14556. 
147. Bandeira, F., R. Lent, and S. Herculano-Houzel, Changing numbers of neuronal and non-
neuronal cells underlie postnatal brain growth in the rat. Proc Natl Acad Sci U S A, 
2009. 106(33): p. 14108-13. 
148. Ahima, R.S., D. Prabakaran, and J.S. Flier, Postnatal leptin surge and regulation of 
circadian rhythm of leptin by feeding. Implications for energy homeostasis and 
neuroendocrine function. J Clin Invest, 1998. 101(5): p. 1020-7. 
149. Kim, J.G., et al., Leptin signaling in astrocytes regulates hypothalamic neuronal circuits 
and feeding. Nat Neurosci, 2014. 17(7): p. 908-10. 
150. Pan, W., et al., Astrocyte leptin receptor (ObR) and leptin transport in adult-onset obese 
mice. Endocrinology, 2008. 149(6): p. 2798-806. 
 34 
 
151. Rottkamp, D.M., et al., Leptin potentiates astrogenesis in the developing hypothalamus. 
Mol Metab, 2015. 4(11): p. 881-9. 
152. Gao, Y., et al., Hormones and diet, but not body weight, control hypothalamic microglial 
activity. Glia, 2014. 62(1): p. 17-25. 
153. Barker, D.J., The fetal and infant origins of adult disease. BMJ, 1990. 301(6761): p. 
1111. 
154. Ravelli, G.P., Z.A. Stein, and M.W. Susser, Obesity in young men after famine exposure 
in utero and early infancy. N Engl J Med, 1976. 295(7): p. 349-53. 
155. Roseboom, T., S. de Rooij, and R. Painter, The Dutch famine and its long-term 
consequences for adult health. Early Hum Dev, 2006. 82(8): p. 485-91. 
156. Whitaker, R.C., Predicting preschooler obesity at birth: the role of maternal obesity in 
early pregnancy. Pediatrics, 2004. 114(1): p. e29-36. 
157. Nehring, I., S. Lehmann, and R. von Kries, Gestational weight gain in accordance to the 
IOM/NRC criteria and the risk for childhood overweight: a meta-analysis. Pediatr Obes, 
2013. 8(3): p. 218-24. 
158. Drake, A.J. and R.M. Reynolds, Impact of maternal obesity on offspring obesity and 
cardiometabolic disease risk. Reproduction, 2010. 140(3): p. 387-98. 
159. Bayol, S.A., S.J. Farrington, and N.C. Stickland, A maternal 'junk food' diet in pregnancy 
and lactation promotes an exacerbated taste for 'junk food' and a greater propensity for 
obesity in rat offspring. Br J Nutr, 2007. 98(4): p. 843-51. 
160. Samuelsson, A.M., et al., Diet-induced obesity in female mice leads to offspring 
hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of 
developmental programming. Hypertension, 2008. 51(2): p. 383-92. 
161. Nivoit, P., et al., Established diet-induced obesity in female rats leads to offspring 
hyperphagia, adiposity and insulin resistance. Diabetologia, 2009. 52(6): p. 1133-42. 
162. Tamashiro, K.L., et al., Prenatal stress or high-fat diet increases susceptibility to diet-
induced obesity in rat offspring. Diabetes, 2009. 58(5): p. 1116-25. 
163. Habbout, A., et al., Postnatal overfeeding in rodents by litter size reduction induces 
major short- and long-term pathophysiological consequences. J Nutr, 2013. 143(5): p. 
553-62. 
164. Belgardt, B.F. and J.C. Bruning, CNS leptin and insulin action in the control of energy 
homeostasis. Ann N Y Acad Sci, 2010. 1212: p. 97-113. 
165. Bouret, S.G., Role of early hormonal and nutritional experiences in shaping feeding 
behavior and hypothalamic development. J Nutr, 2010. 140(3): p. 653-7. 
 35 
 
166. Bouret, S.G., S.J. Draper, and R.B. Simerly, Trophic action of leptin on hypothalamic 
neurons that regulate feeding. Science, 2004. 304(5667): p. 108-10. 
167. Bouret, S.G., S.J. Draper, and R.B. Simerly, Formation of projection pathways from the 
arcuate nucleus of the hypothalamus to hypothalamic regions implicated in the neural 
control of feeding behavior in mice. J Neurosci, 2004. 24(11): p. 2797-805. 
168. Bouyer, K. and R.B. Simerly, Neonatal leptin exposure specifies innervation of 
presympathetic hypothalamic neurons and improves the metabolic status of leptin-
deficient mice. J Neurosci, 2013. 33(2): p. 840-51. 
169. Kirk, S.L., et al., Maternal obesity induced by diet in rats permanently influences central 
processes regulating food intake in offspring. PLoS One, 2009. 4(6): p. e5870. 
170. Vogt, M.C., et al., Neonatal insulin action impairs hypothalamic neurocircuit formation 
in response to maternal high-fat feeding. Cell, 2014. 156(3): p. 495-509. 
171. Plagemann, A., et al., Morphological alterations of hypothalamic nuclei due to 
intrahypothalamic hyperinsulinism in newborn rats. Int J Dev Neurosci, 1999. 17(1): p. 
37-44. 
172. Carmody, J.S., et al., Respective contributions of maternal insulin resistance and diet to 
metabolic and hypothalamic phenotypes of progeny. Obesity (Silver Spring), 2011. 19(3): 
p. 492-9. 
173. Kojima, M., et al., Ghrelin is a growth-hormone-releasing acylated peptide from 
stomach. Nature, 1999. 402(6762): p. 656-60. 
174. Asakawa, A., et al., Ghrelin is an appetite-stimulatory signal from stomach with 
structural resemblance to motilin. Gastroenterology, 2001. 120(2): p. 337-45. 
175. Williams, K.W. and J.K. Elmquist, From neuroanatomy to behavior: central integration 
of peripheral signals regulating feeding behavior. Nat Neurosci, 2012. 15(10): p. 1350-5. 
176. Steculorum, S.M., et al., Neonatal ghrelin programs development of hypothalamic 
feeding circuits. J Clin Invest, 2015. 125(2): p. 846-58. 
177. Tong, J. and D. D'Alessio, Ghrelin and hypothalamic development: too little and too 
much of a good thing. J Clin Invest, 2015. 125(2): p. 490-2. 
178. Wing, R.R., et al., Benefits of modest weight loss in improving cardiovascular risk 
factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 2011. 
34(7): p. 1481-6. 
179. Hamman, R.F., et al., Effect of weight loss with lifestyle intervention on risk of diabetes. 
Diabetes Care, 2006. 29(9): p. 2102-7. 
 36 
 
180. Carvajal, R., et al., Managing obesity in primary care practice: a narrative review. Ann 
N Y Acad Sci, 2013. 1281: p. 191-206. 
181. Atkinson, R.L., Proposed standards for judging the success of the treatment of obesity. 
Ann Intern Med, 1993. 119(7 Pt 2): p. 677-80. 
182. Rosenbaum, M. and R.L. Leibel, 20 years of leptin: role of leptin in energy homeostasis 
in humans. J Endocrinol, 2014. 223(1): p. T83-96. 
183. Yanovski, S.Z. and J.A. Yanovski, Long-term drug treatment for obesity: a systematic 




Chapter 2  
 
“Creation of a tetracycline-inducible leptin overexpressing transgenic mouse”    
 
Alicja A. Skowronski, Charles A. LeDuc, Kylie S. Foo, Dieter Egli, Rudolph L. Leibel 
 
Author contributions:  
A.A.S., C.A.L., and R.L. designed experiments. A.A.S., C.A.L., K.S.F., and D.E. performed 
experiments. A.A.S., C.A.L., and R.L. analyzed and interpreted data, and wrote the manuscript. 
 
Introduction 
Obesity has been associated with type II diabetes mellitus, hypertension, stroke, coronary heart 
disease, and certain types of cancer [1]; even moderate weight loss can improve metabolic 
function and health outcomes [2, 3]. The molecular mechanisms responsible for the adverse 
effects of obesity are generally unclear, and may vary by phenotype.  However, one consequence 
of increased adiposity is increased circulating leptin. Leptin [4] is a hormone primarily secreted 
by adipose tissue that acts through the central nervous system to regulate long term food intake 
and energy expenditure [5].  Circulating leptin concentrations are directly proportional to fat 
stores in weight stable humans [6] and rodents [7].  The hormone signals through the long form 
of the leptin receptor (LepRb) expressed in specific areas of the hypothalamus, midbrain and 
brainstem [8].  Mice or humans lacking either functional leptin [4, 9] or its receptor [10, 11] are 
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hyperphagic and hypometabolic, resulting in extreme obesity. Administration of exogenous 
leptin normalizes the physiology of leptin deficient mice and humans [12, 13]; however, obese 
humans with intact leptin signaling have increased levels of circulating leptin – proportional to 
increased adiposity – and supplementation with additional leptin conveys minimal effect on body 
weight [14-16]. In lean rodents, administration of exogenous leptin transiently reduces food 
intake and body weight [17]. Obese animals display decreased sensitivity to exogenous leptin 
[18].  Aspects of the neuroanatomic substrates for mediation of regulatory responses to leptin are 
conveyed by the hormone’s effects on the development of these circuits.  Congenital absence of 
leptin reduces brain size [19]; absence of the hormone during early postnatal periods critical to 
maturation of hypothalamic neuronal circuitry permanently impairs the development and 
function of these circuits [20-22]. 
Neurophysiological models of body weight homeostasis posit various “set point” constructs that 
include variable sensitivity to leptin’s access to and actions within the CNS as causes for the 
defense of adiposity.   Some of this variability is attributed to genetic and developmental effects 
on the molecules and pathways that comprise these complex circuits.  An unanswered question is 
the extent to which the functionality of these circuits can be influenced by “environmental” 
factors such as intrauterine events, diet, and intercurrent obesity.  Specifically, can the set point 
for adiposity be altered by pre- and/or postnatal factors.  Since dietary fat content [23], adiposity 
[23] and leptin per se [20] have been implicated in such effects, and since these elements covary 
experimentally, it has been difficult to developmentally isolate these factors.    
Transgenic mice that congenitally overexpress leptin have been created [24, 25].  These mice 
initially have reduced body weight and fat stores but, by 33 weeks, are indistinguishable from 
wild type littermates.  When exposed to high fat diet at 9 weeks of age for 20 weeks, these mice 
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are more prone to diet induced obesity [26].  While transgenic mice that constitutively 
overexpress leptin are useful in assessing life-long hyperleptinemia, congenital models are 
limited and do not allow for assessment of the effects of transient hyperleptinemia.  
We generated a transgenic mouse that permits non-invasive induction of hyperleptinemia 
completely dissociated from obesity. A TET-ON system enables transgenic leptin expression that 
is regulated by exposure to the tetracycline analog, doxycycline (dox), in a dose-responsive 
manner; the response can be rapidly turned on and off. These mice provide a model with which 
to investigate whether hyperleptinemia per se drives the conditions associated with obesity 
without the other, related, confounds such as diet. 
 
Methods 
Leptin/rtTA double transgenic mice were made using a commercially available KH2 embryonic 
stem (ES) cell line (Mirimus, Inc). KH2 ES cells contain an FRT-hygro-pA “homing” cassette in 
the ColA1 locus and a reverse tet-transactivator (rtTA) located in the Rosa26 locus (R26-rtTA; 
Figure 2.1A). The mouse leptin gene (Lep) was isolated using PCR with forward primer: 5’ 
GGCGCGAATTCATGTGCTGGAGACCCCTGTGT and reverse primer 5’ 
TCATCAAGACCATTGTCACCAGGAT (primers were designed to introduce EcoR1 sites 
flanking the gene). PCR reaction was run using cDNA from a wild type C57BL6J mouse; it was 
then cloned into the EcoRI site of pBS31tetOpgkATGfrt vector (source D. Egli, Figure 2.1A). 
pBS31tetOpgkATGfrt-Lep vector was electroporated into KH2 cells with FlpE Recombinase 
(pCAGGS-FLPe) as described earlier [27] (Figure 2.1A). KH2-Lep cells were selected with 
hygromycin (Sigma). To confirm integration, leptin transgene expression in KH2-Lep cells was 
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induced in vitro with 4 concentrations of dox: 50, 100, 200, and 400 ng/ml for 48 hours. Media 
was collected after 48 hours of dox treatment and leptin protein contents measured using leptin 
ELISA (R&D). Four clones that responded to dox treatment were selected for karyotypic 
analysis (Cell line genetics, Inc). Cytogenetic analysis was performed on 20 G-banded 
metaphase cells for each clone. Three out of four clones were karyotypically abnormal; one had 
an inverted duplication on chromosome 4 from band D1 to band C4, and two had a large 
metacentric chromosome resulting from fusion of the centromeres of chromosomes 1 and 13.  
The clone that was karyotypically normal was selected for mouse generation. Chimeric mice 
were generated by injecting ES cells into non-agouti BDF2 blastocysts followed by transferring 
embryos into day 2.5 pseudopregnant albino ICR females.  Pups were delivered by Caesarian 
section on embryonic day 19.5 and fostered to an ICR foster mother that had given birth within 
the previous 4 days. 
To secrete leptin in response to dox, mice must segregate for two transgenes (2TG): the dox-
responsive leptin transgene (tetracycline-responsive elements-CMV-Lep, TRE-Lep), and a 
reverse transactivator rtTA (rtTA is driven by the Rosa26 promoter; R26-rtTA) [28]. Mice that 
segregate for both transgenes are denominated: 2TG. Single transgenic littermates (1TG) carry 
either the dox responsive leptin transgene or the reverse transactivator rtTA and do not secrete 
leptin when exposed to dox were used as controls.  
Genotypes in 1TG and 2TG mice were confirmed with primers described by Jackson 
Laboratories for Rosa26-rtTA::Col1a1-tetO-H2B-mCherry mice which contain the same alleles 
as our mice (the same Rosa26-rtTA transgene, while H2B-mCherry transgene was generated 




Mutant Reverse  5’ GCG AAG AGT TTG TCC TCA ACC 
Common Forward 5’ AAA GTC GCT CTG AGT TGT TAT 
Wild type Reverse  5’ GGA GCG GGA GAA ATG GAT ATG 
ColA1-TRE-Lep locus: 
Mutant Forward  5’ GCA GAA GCG CGG CCG TCT GG 
Common Reverse 5’ CCC TCC ATG TGT GAC CAA GG 
Wild type Forward  5’ GCA CAG CAT TGC GGA CAT GC 
 
Animals: Throughout the study, mice were maintained at room ambient 22-24°C with a 12-h 
dark-light cycle (lights on at 0700h) in a pathogen-free barrier facility. The protocol was 
approved by the Columbia University Institutional Animal Care and Use Committee. 
Induction of leptin in transgenic mice: 36 male mice (1TG, n=18 and 2TG, n=18) at 3 weeks of 
age were exposed to 50 µg/ml of dox in drinking water for 7 days. Body composition by 
EchoMRI and concomitant blood were obtained at baseline and after 7 days of dox exposure. 
Acute induction of leptin: Five 12 week old male 2TG mice were treated with ad libitum access 
to 200 µg/ml of dox in drinking water for 24 hours to induce transgenic leptin expression.   
Blood was collected at baseline (prior to dox administration) and at 24 hours of dox exposure. 
Dox-free water was provided for the following 24 hours. This 24-hour on and off dox treatment 
 42 
 
was repeated. Blood was collected every morning to determine both how quickly leptin induction 
can be turned on and off, and to show that there is no residual alteration of endogenous leptin 
production.  
Dox gavage:  Five 8 week old male 2TG mice were gavaged with 400 µg of doxycycline 
(suspended in 400 µl of water). Blood was collected at baseline (immediately prior to gavage) 
and at 2h, 4h, 6h, 8h, 10h, 12h, 14h, and 24h using heparinized tubes. 
Leptin secretion from ex-vivo tissues:  14 2TG mice were treated with 300 µg/ml of dox in 5% 
sucrose water or with 5% sucrose water only (ad libitum access) for 48 hours to induce leptin 
expression. Mice were then sacrificed and tissues harvested for culture and RNA isolation: 
subcutaneous adipose tissue (SCAT), perigonadal adipose tissue (PGAT), brown adipose tissue 
(BAT), liver (LIV), kidney (KID), stomach (STO), duodenum (DUO), jejunum (JEJ), ileum 
(ILE), spleen (SPL), lung, hypothalamus (HYPO). Approximately 100 mg of each tissue (except 
for HYPO which was ~20 mg) was minced into 4-5 pieces and cultured for 4 h in 0.5 ml of 
M199 media with 7 nM insulin and 25 nM dexamethasone [30].  Leptin secreted into the media 
was normalized by tissue mass. After 4 h in culture, media were collected for determination of 
leptin concentration.  
RNA extraction, cDNA, qPCR: Total RNA was isolated using TRIzol reagent (Invitrogen). One 
µg of RNA was reverse transcribed using Transcriptor First Strand cDNA Synthesis Kit (Roche) 
using both OligoDT and random hexamer primers. Lightcycler 480 SYBR Green I Master was 
used for quantitative PCR assays (Roche). Relative gene expression of rtTA and Lep in 
perigonadal (PGAT), subcutaneous (SCAT) and brown (BAT) adipose tissues, liver (LIV), 
jejunum (JEJ), and whole hypothalamus (HYPO) was calculated by Lightcycler 480 software 
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(Roche) based on the Second Derivative Maximum method using a standard curve generated 
from a serially diluted pool of cDNA. Gene expression was normalized to the geometric mean of 
the housekeeping genes – Actβ and 36b4. Primers used are listed below: 
Actb Forward 5’-CGGGCTGTATTCCCCTCCAT 
Actb Reverse 5’-GGGCCTCGTCACCCACATAG 
36b4 Forward 5’-ACCTCCTTCTTCCAGGCTGG 
36b4 Reverse 5’-CGAAGGAGAAGGGGGAGGTT 
Lep Forward 5’-CGAGGAATCGTTCTGCAAATCC 
Lep Reverse 5’-GCCAGGTTAAGTGCAGCTATCACA 
rtTA Forward 5’-AGTCATTCCGCTGTGCTCTC 
rtTA Reverse 5’-GCTCCTGTTCCTCCAATACG 
Bioactivity of leptin: Fourteen 10 week old male mice (7 - 1TG, 7 - 2TG) were housed 2-3 per 
cage and given ad libitum access to 200 µg/ml dox water for 10 days. Dox concentration was 
then increased by 5 fold to 1 mg/ml for another 4 days. Body weight and food intake were 
measured daily.  Body composition was measured using EchoMRI at baseline, 7, 10, and 14 days 
of exposure to dox. Blood was collected immediately after body composition measurement at 
baseline, 7 and 14 days of exposure to dox.   
Dox dose response: Thirty 10 week old male mice (12 - 1TG, 18 - 2TG) were exposed to 
increasing concentrations of dox in 5% sucrose water every 2 weeks. Baseline blood was 
collected 1 week prior to dox exposure. The dox concentrations were then provided in the 
following order: 10, 15, 20 ug/ml, increasing every 2 weeks.  
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Plasma collection and assays: Blood was collected into heparinized tubes (Fisherbrand) by 
submandibular bleed at 9am from mice in a fed state (unless otherwise stated) and immediately 
placed on ice; plasma was isolated by centrifugation for 20 min at 2,000 x g at 4°C, aliquoted, 
and frozen at −80°C until time of assay.  Circulating leptin concentrations were measured using 
mouse leptin ELISA (R&D). Leptin in media from the explanted tissue cultures was measured 
using mouse leptin AlphaLISA (PerkinElmer).   
Plasma Leptin concentrations during in utero and postnatal dox exposure: Pregnant 1TG dams 
(carrying 1TG and 2TG fetuses) were exposed to 200 ug/ml of dox in drinking water starting at 
conception through pregnancy.  The pregnant females were euthanized by cervical dislocation, at 
day 16-19 post conception, had blood collected, and the fetuses removed.  Blood was collected 
from individual fetuses along with tissue for genotyping. Nursing 1TG mothers were exposed to 
dox (200 ug/ml) or drug-free water from parturition until weaning.  Mice were bred so that the 
offspring were 1:1 1TG and 2TG. At postnatal day 15 (P15) while the pups were exclusively 
breastfeeding, pups (both 1TG and 2TG and both males and females) and mothers were bled for 
plasma leptin determination. 
 
Results  
Generation and validation of leptin overexpressing ES cells 
Leptin-overexpressing mouse embryonic stem cells were generated using a previously described 
system [27]. Pre-engineered KH2 ES cells that carry a reverse tet-transactivator (rtTA) in the 
Rosa26 locus and an FRT-hygro-pA cassette in the ColA1 locus were co-electroporated with a 
targeting vector containing leptin transgene and FlpE Recombinase expressing vector to allow 
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for site directed recombination. The resulting KH2-Lep cell line contains the R26-rtTA and a 
leptin transgene downstream of the tetracycline-responsive elements (TRE) and the CMV 
promoter (located in the ColA1 locus, Figure 2.1A). In the absence of dox the rtTA present in 
the cell cannot bind to the TRE; when dox is present it binds to rtTA changing its confirmation 
and allowing it to bind to the TRE which in turn activates the CMV promoter and drives the 
expression of transgenic leptin (Figure 2.1B). The expression of leptin is controlled by dox 
concentration. To confirm proper integration of the targeting vector and to validate the 
effectiveness of dox in inducing lep expression, KH2-Lep ES cells were treated with increasing 
doses of dox (Figure 2.2A). In the basal state, prior to dox treatment, KH2-Lep cells did not 
secrete leptin. However, administration of increasing concentration of dox (50, 100, 200, and 400 
ng/ml) in the culture media resulted in KH2-Lep cells secreting leptin into media in a dose-
responsive manner (0.35, 0.92, 2.29, 2.94 ng/ml, respectively, Figure 2.2A) with deviation from 
linearity at the highest concentration, suggesting that the amount of secreted leptin is limited by 
the availability of rtTA or by the rate of production and/or secretion of leptin. Four leptin 
secreting cell lines were selected for cytogenetic analysis of G-banded metaphase cells. One cell 
line was karyotypically normal (Figure 2.2B) and was selected for subsequent generation of a 
transgenic mouse. 
Leptin overexpressing mice 
KH2-Lep ES cells were used to generate leptin transgenic mice via tetraploid blastocyst injection 
[31]. Similar to the KH2-Lep ES cells described above, the mouse reported here requires – for 
leptin expression in response to doxycycline – 2 transgenes: (1) the rtTA in the Rosa26 locus 
(R26-rtTA) and (2) the leptin transgene in ColA1 locus controlled by the TRE and the CMV 
promoter (TRE-Lep).  These mice are referred to here as double transgenic or “2TG”. Single 
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transgenic littermates (segregating for either R26-rtTA OR the TRE-Lep) do not respond to dox 
and are used as controls; they are denoted as “1TG”.  
Prior to treatment with dox, circulating leptin levels were directly proportional to fat mass in 
both the 1TG and 2TG male mice (Figure 2.3A) and there was no difference in either fat mass or 
circulating leptin between the two groups (Figure 2.3A, C-D).  1TG and 2TG mice were then 
given ad libitum access to drinking water containing 50 µg/ml of dox for 7 days. Average daily 
water intake for these mice is ~6 ml [32]; with dox at 50 ug/ml water, the estimated 24h dox 
intake was ~300 ug. At this dox concentration, the amount of circulating leptin increased 25 fold 
in the 2TG mice (2.5 ± 0.28 ng/ml at baseline compared to 60.5 ± 7.1 ng/ml; Figure 2.3B, D).  
This increase was independent of the amount of both baseline circulating leptin and body fat 
(Figure 2.3B-D). After 7 days of dox exposure, 2TG mice lost 27% of their initial body fat (1.2 
± 0.05 g to 0.91 ± 0.06 g; Figure 2.3C); whereas 1TG mice showed a mild gain in fat mass over 
a week as expected in mice at 3 weeks of age. Dox-induced circulating leptin concentration in 
2TG mice was 40 times greater than the amount of endogenous leptin that would be predicted 
from this new level of adiposity [7, 33].  As predicted, circulating leptin concentrations in the 
1TG mice were unchanged by the addition of dox to the water (2.9 ± 0.33 ng/ml vs 2.2 ± 0.22 
ng/ml; Figure 2.3D). 
The induction of leptin with dox in 2TG mice ceased rapidly upon withdrawal of dox (Figure 
2.3E). Twelve week old male 2TG mice were exposed for successive 24 hour intervals to ad 
libitum access to 200 µg/ml of dox in drinking water or drug-free water.  Plasma was obtained at 
the same time each day for five consecutive days.  Within 24h of dox exposure, circulating leptin 
concentrations in 2TG mice increased from 18.06 ± 5.78 ng/ml to 98.61 ± 11.49 ng/ml (Figure 
2.3E). Circulating leptin concentration returned to baseline within 24h of dox removal (16.23 ± 
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6.08 ng/ml; Figure 2.3E).  The results of serial exposures of the same mice are shown in Figure 
2.3E. After two cycles of 24h dox exposure, circulating leptin in 2TG mice returned to 
concentrations seen in dox-free water but these levels were significantly below their 
concentrations at baseline (13.12 ± 5.54 ng/ml vs 18.06 ± 5.78 ng/ml, p<0.01; Figure 2.3C) 
suggesting that overexpression of leptin for 48 hours reduced endogenous leptin production in 
adipose tissue likely due to fat loss.  
To determine the kinetics of leptin overexpression, 2TG mice were gavaged with 400 µg of dox 
(in 400 ul of water; Figure 2.3F); this amount represents roughly the daily amount of dox that a 
mouse allowed ad libitum water intake would receive when exposed to 50 µg/ml dox in water 
assuming 6ml of water intake per 24 hours [32].  Plasma leptin concentration began to increase 
approximately 4 hours after gavage and peaked after 6-8 hours (83.62 ± 18.68 ng/ml; Figure 
2.3F). Within 24 hours after the single dox gavage, plasma leptin concentrations returned to 
baseline, consistent with the sequential dox exposure experiment. The elimination half-life of 
doxycycline administered to mice by gavage is approximately 170 min [34], and the half-life of 
IP-administered leptin is ~40 minutes [35].  This timing implies that dox has to be physically 
present in the cell to promote leptin production; there is no persistence of expression after dox 
exposure is stopped. 
To demonstrate that the 2TG mice respond to dox in a dose-dependent manner, we exposed them 
to escalating concentrations of dox in water. Leptin concentration in 2TG mice increased 
significantly at the lowest dox dose of 10 µg/ml (1.9 ± 0.4 ng/ml to 30.6 ± 5.4 ng/ml; Figure 
2.4A). 1TG control circulating leptin concentration maintained proportionality to fat mass 
(Figure 2.4A).  Inter-mouse variability in response was ~60% at any dose of dox.  Such 
differences are probably due primarily to differences in water intake.  
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The transgenic strategy in this experiment did not explicitly restrict leptin expression to a 
specific cell type (see Discussion).  To determine which tissues in the 2TG mice contributed to 
the dox-induced increases in circulating leptin, we isolated organs from 2TG mice exposed to 
dox (300 µg/ml ad libitum) water for 48 hours and 2TG mice given drug-free water as controls. 
Organs were isolated, washed in PBS, minced, and cultured for 4 hours in M199 medium 
supplemented with insulin and dexamethasone. Leptin expression in the isolated tissues and 
secreted leptin in the culture medium were determined (Figure 2.4B, C).   
Adipose tissue: perigonadal (PGAT), subcutaneous (SCAT), and brown (BAT) were isolated.  
There was no change in either expression or secretion of leptin in any of the adipose depots 
studied (Figure 2.4B, C).  rtTA was expressed in all tissues (Figure 2.4D) so either the dox did 
not reach the fat depots in sufficient quantities to statistically increase the already large 
production of leptin (likely), and/or the adipose tissue was already secreting and expressing at 
the maximum amount possible for the tissue.  
Gastrointestinal tract (GI): The stomach, duodenum, jejunum, and ileum are the first tissues 
exposed to ingested dox. All had little or no endogenous leptin production and all showed large 
increases in both leptin expression and secretion upon dox exposure (Figure 2.4B, C).  This 
suggests that the GI tract is the primary source of the increased plasma leptin in the dox-induced 
2TG mice; this is likely due to both the route of dox administration and the capacity of the gut to 
secrete peptides.  
Liver, lungs and spleen: All of these organs increased expression of leptin in response to dox 
exposure, but only the lungs and spleen increased secretion of leptin (Figure 2.4B, C). 
 49 
 
Hypothalamus: The hypothalamus from 2TG mice showed no increase in leptin expression. 
However, there was a significant increase in low levels (0.07 ng/ml/hr) of apparent secretion of 
leptin in 2TG compared to 1TG mice (0.009 ng/ml/hr, Figure 2.4B, C). This apparent effect 
could be due to contamination with blood and/or cerebrospinal fluid (CSF), or could be caused 
by trace amounts of dox crossing the blood brain barrier. Dox concentration in the CSF of mice 
exposed to dox in food was found to be ~30 fold lower than that in plasma [36]. Exposing 2TG 
mice to a high concentration of dox (1 ug/ml which is at least 3.33 times higher dose than in our 
experiments) resulted in significantly higher expression of the leptin transgene in the 
hypothalami of 2TG mice compared to 1TG mice (Figure 2.4E). Such doses are not required to 
generate plasma leptin concentrations in a physiological range.  
In these transgenic animals, the majority of circulating leptin is apparently secreted from the 
digestive tract. If mice were injected with dox IP or IV, the organs contribution to circulating 
leptin could be different.  Although basal expression of the rtTA transgene is variable by organ, 
expression of rtTA is not altered in any tissue by exposure to dox (Figure 2.4D). rtTA expression 
in subcutaneous adipose tissue (SCAT), perigonadal adipose tissue (PGAT), and jejunum (JEJ) is 
lower than in brown adipose tissue (BAT) and liver (LIV), but leptin expression in response to 
dox is higher in those tissues, indicating that the rtTA presence in the cell is not a limiting factor 
for expression of transgenic leptin.  
1TG and 2TG male mice were housed 2-3 per cage and provided ad libitum access to 200 µg/ml 
of dox in drinking water for 10 days. The dox dose was then increased to 1 mg/ml to assess 
whether a maximal leptin response was achieved.  Body weight and food intake were measured 
daily while plasma leptin concentration and body composition were determined at the beginning 
of the study (baseline), 7, 10 and 14 days of dox exposure. The 2TG mice, when given ad libitum 
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access to 200 µl/ml dox, had significantly lower food intake than the 1TG controls on days 2 and 
3 of dox exposure (day 2: 2TG, 9.12 ± 0.32 kcal/day, 1TG, 12.85 ± 1.0 kcal/day, p<0.05; day 3: 
2TG, 8.68 ±0.03 kcal/day, 1TG, 12.65 ± 1.20 kcal/day, p<0.05; Figure 2.5B). After 14 days of 
dox exposure, 2TG mice lost 2.65 ± 0.35 g of body weight compared to a weight gain of 0.09 ± 
0.28 g in 1TG controls (p<0.001, Figure 2.5A). In 2TG animals both fat mass (-1.52 ± 0.24 g vs 
a gain of 0.34 ± 0.08 g in 1TG, p<0.001, Figure 2.5C) and lean mass (-0.90 ± 0.17 g vs a gain of 
0.13 ± 0.17 g, p<0.001, Figure 2.5D) were reduced.  These results indicate that the dox-induced 
leptin is bioactive and is capable of causing anticipated physiological responses [12, 37, 38]. 
Interestingly, increasing the dox dose by 5 fold doubled the amount of circulating leptin but no 
additional weight loss occurred (Figure 2.5A, E).  
1TG female mice homozygous for the TRE-Lep gene and wild type for the R26-rtTA gene 
(TRE-Lep/TRE-Lep) were crossed to 1TG male mice that were heterozygous for R26-rtTA 
(rtTA/+). This resulted in all offspring being TRE-Lep/+ and half being rtTA/+. Therefore, the 
offspring were predicted to be 1:1 1TG and 2TG. Animals in the breeding cages were provided 
ad libitum access to 200 ug/ml dox or drug-free (controls) water when the crosses were set. 
Exposure of pregnant females to dox or control water was continued throughout gestation; these 
animals were sacrificed between day E16 and E19 to assess plasma leptin concentrations in the 
fetuses.  There were no differences in plasma leptin concentrations between the 1TG pregnant 
females exposed to dox and 1TG controls given drug-free water (Figure 2.6A). Leptin 
concentration in the E16-19 fetuses was significantly elevated only in the 2TG offspring 
conceived by 1TG females exposed to dox water (34.2 ± 13.5 ng/ml vs 0.7 ± 0.1 ng/ml; p<0.01; 
Figure 2.6B); elevation of plasma leptin was not seen in 1TG or 2TG fetuses from females given 
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drug-free water. Therefore, dox is transferred from maternal circulation to the fetuses through the 
placenta.     
1TG females (either TRE-Lep/TRE-Lep or rtTA/+) were exposed to 200 ug/ml of dox water or 
drug-free water (controls) at parturition and continued exposure postnatally throughout the 
nursing period.  The offspring were either 1TG or 2TG in equal numbers (1TG, n= 38, 2TG, 
n=40). On postnatal day 15, blood was collected on both dams and pups to assess plasma leptin 
concentrations. As predicted, 1TG nursing females had plasma leptin concentrations that showed 
no difference between dox and drug-free water exposure (Figure 2.6C).  2TG P15 pups born to 
1TG mothers exposed to dox, had significantly higher plasma leptin concentrations compared to 
their 1TG littermates (202.5 ± 16.9 ng/ml vs. 7.3 ± 0.8 ng/ml; p<0.001; Figure 2.6D) and 
compared to P15 pups born to mothers maintained on drug-free water. Thus, bioactive dox is 
transferred in breast milk.   
 
Discussion 
We have generated a transgenic mouse with doxycycline-titratable (by time and degree) 
overexpression of bioactive leptin. In wild type mice and humans, the major site of leptin 
synthesis and release is adipose tissue. Low levels of leptin expression are detected in brown 
adipose tissue, stomach [39], placenta [40], mammary tissue [41] and ovaries [42]. The 
transgenic mouse described here over-expresses leptin in multiple tissues when exposed to dox.  
The major site of leptin production and release in these animals is the small intestine. 
Interestingly, adipose tissue leptin expression is not increased in these animals. We attempted to 
create an adipose tissue-only overexpressing animal by replacing the rtTA in the Rosa26 locus 
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with the rtTA under the adiponectin promoter; however, exposure to high dox concentrations 
raised circulating leptin modestly and failed to elevate circulating leptin concentrations to those 
seen in DIO mice.       
Leptin produced by the transgene is bioactive and appears to emanate primarily from secretory 
cells in the gut. The transient weight loss of the animals in response to dox appears to be 
proportional to circulating concentrations of leptin, indicating that conventional leptin 
physiology is intact in these animals.  At very high levels of dox, ectopic leptin production in the 
hypothalamus could contribute to the functional consequences of dox exposure.  In some 
experimental circumstances this effect – if it occurs – might constitute an experimental 
confound.  At doses of dox that produce circulating leptin concentrations that are within the 
physiological range, this potential hypothalamic effect is likely not significant.  Production of the 
leptin in the liver of dox-treated animals could possibly influence vagal signaling by paracrine 
effects.  Our data do not suggest that this effect is large if it occurs at all.  
A mouse model overexpressing leptin in response to oral doxycycline offers benefits over 
administration of exogenous leptin. When osmotic mini pumps are used to elevate circulating 
leptin in mice there are limitations to the amount of leptin that can be administered because of 
limited leptin solubility, variability in efficiency of delivery among individual mice, and weight 
loss from surgical recovery [15, 17].  Harris et al. were able to elevate circulating leptin 
concentrations to a maximum of approximately five times baseline [17]. The concentrations of 
plasma leptin in lean mice administered 10 µg/day of exogenous leptin via osmotic pump only 
reached 6.8 ng/ml [17] – much lower than that occurring in DIO mice (~75 ng/ml after 16 weeks 
of HFD feeding) [33]. Achieving a circulating leptin concentration similar to that characterizing 
the DIO mouse is important to being able to distinguish the effects of diet and obesity, from 
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those conveyed by leptin per se. Ravussin et al. administered leptin to mice via osmotic mini 
pumps with maximum exposure limited by the solubility of leptin in the mini-pump [15]. The 
maximum leptin dose deliverable by the pump was 25 µg/day, elevating plasma leptin 
concentration to approximately 50 ng/ml with large variability among animals [15]. 
Daily intraperitoneal (IP) injections are commonly used to deliver leptin to mice. Repeated 
injections cause stress and injecting a bolus of leptin once per day does not recapitulate normal 
circadian physiology. Cole-Burnett et al. estimated that the half-life of injected exogenous leptin 
was 40 minutes: at 30 minutes post IP injections of 3 mg/kg of leptin, plasma leptin 
concentration was 170-fold of baseline and leptin was cleared from the circulation within 4 hours 
[35].  This suggests that, in studies using injections to manipulate circulating leptin 
concentrations, large transients of non-physiological concentration are created followed by 
normal concentrations of leptin for the majority of the 24 hour period [35].  Freely fed male mice 
naturally vary their circulating leptin concentration with an increase of about 60% from the nadir 
at 8AM to 10AM to the peak at 10PM to 2AM [43].  While the leptin-overexpressing mouse 
reported here does not fully recapitulate normal circadian physiology either, the mouse has ad 
libitum access to dox-supplemented water throughout the 24h period.  Since mice drink and eat 
more in the dark cycle, there is some periodicity to variation in leptin concentration with the 
mice producing more leptin at night.   
The leptin-overexpressing mouse described here can be used in studies of the role of leptin in 
various stages of development. Exposing 1TG females to dox in drinking water during 
pregnancy results in overexpression of leptin in the 2TG offspring due to transfer of dox from 
maternal to fetal circulation. Similarly, when nursing 1TG females are exposed to dox in 
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drinking water, dox is transferred in milk to their pups and activates the leptin transgene in the 
2TG pups. This effect enables non-invasive delivery of leptin at all points in development.  
High dose administration of leptin for 24 weeks to human subjects resulted in the development 
of non-neutralizing antibodies in 71% of these individuals [14]. In more recent studies of 
lipodystrophic or obese subjects [44, 45] administration of exogenous metreleptin resulted in the 
development of neutralizing anti-leptin antibodies in the majority of recipients. Chronic (20 
week) exogenous leptin infusion in mice via an osmotic mini-pump resulted in elevated leptin 
concentrations, adjusted for fat mass, 20 weeks after the leptin infusion cessation [15]. Anti-
leptin antibodies were not evaluated in that study; however, it is possible that the mice developed 
neutralizing antibodies to exogenous leptin as has been reported in human studies. We did not 
detect any increases in circulating leptin concentrations in our transgenic mice after cessation of 
a long term dox exposure; leptin concentration returned to amounts predicted by the fat mass 
within 24 hours of dox cessation.        
Qui et al. transgenically overexpressed human leptin in fat cells [24]; Ogawa et al. did the same 
for mouse leptin in hepatocytes [25].  The adipose tissue-specific AP2 promoter was used to 
drive human leptin expression; secondary reductions in fat mass limited the elevations in plasma 
leptin in these mice [24]. In the hepatocyte overexpressors, leptin plasma concentrations reached 
60 ng/ml – consistent with a DIO animal – but could not be turned on or off [25]. In our 
transgenic mouse, leptin was expressed in the liver, however we did not detect any protein in the 
liver culture media from the ex vivo leptin secretion assay. It is possible that the liver secretes 
leptin in vivo, but perhaps the blood flow is necessary to observe this secretion.  
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No change in expression of leptin from the endogenous locus in control compared to 
hyperleptinemic mice indicates that elevated circulating leptin does not down regulate the 
production of endogenous leptin within the adipocytes.         
Another model of hyperleptinemia is the diet induced obese (DIO) mouse.  However, this mouse 
does not disentangle the metabolic effects of excess adiposity from the effects of excess leptin 
per se. Additionally, DIO leads to attenuated leptin signaling in many brain areas previously 
identified to have a role in feeding circuits [23]; however, the mechanism of this decreased leptin 
sensing is unclear. One possibility is that hyperleptinemia per se – the direct consequence of 
increased adiposity – drives the attenuation of the cellular response to leptin. The leptin 
transgenic mouse reported here will allow for testing this hypothesis. 
The leptin 2TG mouse provides the capability to reversibly increase circulating leptin 
concentration to virtually any level at any point in development. The ability to titrate the amount 
of excess leptin and the ability to rapidly terminate exposure are key benefits.  These mice will 
enable studies on the effects of time-limited elevations of circulating leptin per se (in the absence 
of other circulating cofactors accompanying in obesity), on brain development, “set point” 
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Figure 2-1 Schematic of Creation of a tetracycline-inducible leptin overexpressing transgenic 
mouse. 
(A) Construct schematic. KH2 embryonic stem cells, containing a reverse tet-transactivator 
(rtTA) located in the Rosa26 locus and an FRT-hygro-pA “homing” cassette in the ColA1 locus, 
were electroporated with pBS31tetOpgkATGfrt-Lep vector and FlpE Recombinase (pCAGGS-
FLPe) to generate the dox-inducible leptin overexpressing mouse. (B) Tet-ON schematic. In the 
absence of dox the rtTA present in the cell cannot bind to the TRE, thus transgenic leptin is not 
expressed; when dox is present it binds to rtTA changing its confirmation and allowing it to bind 












Figure 2-2 Validation of leptin overexpressing ES cells. 
(A)  Dose dependent doxycycline induced secretion of leptin in the leptin transgenic mouse 
embryonic stem cell line, KH2-lep, into culture media (n=4). (B) Cytogenetic analysis of G-
banded metaphase cells from leptin transgenic mouse embryonic stem cell line, KH2-lep. The ES 
cell clone selected for blastocyst injection was karyotypically normal.  
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Figure 2-3  Induction of leptin with doxycycline exposure in leptin transgenic mice. 
(A) Baseline and (B) dox-induced circulating leptin in 1TG (Ctr, n=18) and 2TG (n=18) mice as 
a function of fat mass. At baseline plasma leptin concentrations are correlated with fat mass 








































































































































[1TG: R2=0.38; 2TG: R2=0.25]. After dox exposure leptin concentrations are independent of fat 
mass in 2TG mice [1TG: R2=0.24; 2TG: R2=1.2e-5]. (C) Mean fat mass and (D) mean circulating 
leptin in 1TG (n=18) and 2TG (n=18) mice at baseline and after 7 days of 50 ug/ml dox 
exposure. (E) Rapid control of leptin expression with two 24h dox exposures in 2TG mice (n=5). 
Baseline circulating leptin, followed by 24h on 200 ug/ml dox levels, then off dox for 24h and 
the cycle repeated. (F): Dynamic induction of circulating leptin after a gavage of 400 ug of dox 
to 2TG mice (n=5). Plasma leptin concentration fully restored to baseline within 24h of gavage.  
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Figure 2-4  Tissue contribution to circulating leptin in transgenic mice. 
(A) Dose response to increasing amount of dox in water in 1TG (n=12) and 2TG (n=18) mice. 
Dox concentration was increased every 2 weeks. (B) Secretion of leptin into culture media from 
various tissues (SCAT – subcutaneous adipose tissue, PGAT – perigonadal adipose tissue, BAT 
– brown adipose tissue, LIV – liver, KID – kidney, STO – stomach, DUO – duodenum, JEJ – 
jejunum, ILE – ileum, SPL – spleen, LUNG, HYPO – hypothalamus), and relative expression of 
(C) lep and (D) rtTA in cultured tissues from 2TG mice exposed to sucrose (n=7) or doxycycline 
(n=7). (E) Relative Lep expression in the hypothalami of 1TG (n=7) and 2TG (n=7) mice 



























































































exposed to high dose of dox (1000 ug/ml). Expression was normalized to housekeeping genes, 
Actb and 36b4. All values are means with SEM. Significant difference calculated with Student t-
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Figure 2-5  Bioactivity of leptin. 
(A) Daily body weight, (B) daily regular chow intake, change in (C) fat mass, (D) lean mass, and 
(E) circulating leptin at baseline (before start of dox exposure), at 7 days and 10 days of 200 
ug/ml dox exposure, and additional 4 days of 1mg/ml of dox in single (1TG controls, n=7) and 
double (2TG leptin overexpressing, n=7) transgenic mice. All values are means with SEM. 
Significant difference calculated with Student t-test, *p<0.05, **p<0.01. ***p<0.001.  
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Figure 2-6  Circulating leptin during in utero and postnatal dox exposure. 
Plasma leptin concentrations in (A) pregnant 1TG females (H2O, n=3; Dox, n=5), (B) 1TG and 
2TG fetuses (n=11-23), (C) nursing 1TG females (H2O, n=4; Dox, n=7), (D) 1TG and 2TG 
suckling pups (n=9-25) on day P15 during in utero and postnatal exposure to 200 ug/ml dox or 
water (control). All values are means with SEM. Significant difference calculated with Student t-
test, ** p<0.01. *** p<0.001. 
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Introduction 
Obesity is a major international public health concern [1]. Prevalence of obesity is at an alarming 
level in both adults [2] and the pediatric population [3]. Childhood obesity is highly correlated 
with future adult obesity [4].  
Leptin is a hormone produced and secreted primarily by the adipose tissue [5]. Under weight-
stable conditions leptin circulates in direct proportion to fat stores in both humans [6] and 
rodents [7] to signal peripheral energy availability to the central nervous system (CNS). Weight 
loss is associated with molecular and physiological leptin-mediated adaptations that promote 
weight regain [8-10]; when circulating leptin in this state is restored to pre-weight loss levels, 
most of the changes associated with weight reduction are alleviated [11], but exogenous leptin 
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administration to lean and obese humans at their normal weights has minimal effects on energy 
intake and expenditure [12, 13]. Conversely, administration of leptin to animals or humans at 
reduced body weight reverses many of the bioenergetics and behavioral consequences of this 
state [11]. In rodents at usual body weight, leptin infusion transiently suppresses body weight 
gain but ultimately body weight is not altered with chronic leptin exposure [14] thus, adiposity in 
mice is inversely related to exogenous leptin response [15]. Dietary fat and adiposity attenuate 
leptin signaling in the CNS [16]; some of the hypothesized factors mediating this effect include 
elevated free fatty acids in the hypothalamus[17, 18], diet-induced hypothalamic inflammation 
[via increased interleukins -1β and -6 (IL-1β and IL-6) and tumor-necrosis factor-α (TNFα)] [17, 
19-21], hypothalamic ER stress [22], decreased transport of leptin from periphery to the CNS 
[23, 24], and increase in circulatory proteins that bind leptin (such as soluble leptin receptor) 
[25].  
There appears to be a CNS “set point” or threshold for minimum adiposity that is influenced by 
genetic and developmental factors [26]. Circulating leptin provides a signal regarding adiposity 
to the cells/circuits mediating this threshold. When leptin falls below this threshold a robust 
physiologic response including reduced energy expenditure and increased hunger is induced to 
oppose the fat loss; however, responses triggered by leptin concentration above this set-point are 
mild and transient [26]. The extent to which the molecular (leptin homeostasis) and 
neuroanatomic (neuronal circuit alterations) processes involved in the establishment of the 
adiposity set point can be influenced by “environmental” factors such as adequacy and quality of 
intrauterine metabolic fuels and endocrine events, postnatal diet, and intercurrent obesity is of 
importance to understanding the causes of obesity. Specifically, can the set point for adiposity be 
altered by perinatal factors, and what are the mechanisms underlying such alterations. Dietary fat 
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content [16], adiposity [16], overfeeding [27], and leptin per se [28] have been implicated in 
such effects, but since these co-vary experimentally, it has been challenging to isolate these 
factors during development.  
In 1990, an English epidemiologist – David Barker – hypothesized that programming by the 
metabolic environment in fetal and infant life has consequences later in life for adult onset 
metabolic disease [29]. His hypothesis was based on historical cohort studies in which he noted a 
strong association between low birth weight or pre-term birth and an increased incidence of 
coronary heart disease in adulthood [29]. Barker’s studies of developmental origins of adult 
disease focused research on the relationship of early development and adult disease.  
The prevalence of obesity in the offspring of obese mothers who undergo bariatric surgery 
decreases by ~50% compared to siblings born pre-surgery [30]. Epidemiological studies indicate 
that maternal obesity increases the risk of the offspring to develop obesity [31-33]. Rodent 
studies have investigated the role of obesity during gestation and/or postnatally and suggest that 
maternal high fat diet feeding during the perinatal period as well as overnutrition during nursing 
(by decreasing litter size) results in obesity and metabolic abnormalities (such as insulin 
resistance or hepatic steatosis) in adult offspring [34-39]. The underlying cellular and molecular 
mechanisms for maternal programming of adult obesity remain unclear.  
Simerly and colleagues identified a role of leptin as a neurotrophic factor that plays a critical role 
in the development of feeding circuits [40]. They showed that a lack of leptin during 
development impairs the formation of projections from the arcuate nucleus of hypothalamus 
(ARH) to other brain regions involved in energy homeostasis [the paraventricular nucleus 
(PVH), the dorsomedial hypothalamic nucleus (DMH), and the lateral hypothalamic area (LHA)] 
[40]. Excess leptin during development could also impair the formation of projections in these 
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circuits [27, 41]. There is precedence for such effects based on the U-shaped association between 
birth weight and BMI later in life.   
Here we investigate the physiological consequences of developmentally timed transient 
hyperleptinemia on apparent set point for adiposity. We generated and used a leptin-
overexpressing transgenic mouse model (Thesis Chapter 2). This transgenic mouse permits non-
invasive induction of hyperleptinemia isolated from obesity per se and its resulting metabolic 
consequences such as elevated FFA and glucose, insulin insensitivity, fatty liver, etc. A TET-ON 
system enables transgenic leptin expression that is regulated by exposure to doxycycline (dox) in 
a dose-responsive manner and can be rapidly turned on and off. Specifically, we evaluated the 
physiological effects of elevated leptin during (1) adulthood, (2) adolescence and (3) postnatal 
period on the defense of body weight (adiposity) later in life and on the susceptibility to gain 




Experiments were carried out with doxycycline (dox)-inducible leptin overexpressing transgenic 
mice generated and described in Chapter 2. Briefly, these transgenic mice use the TET-ON 
system to express leptin in response to dox. Two transgenes are required for leptin expression: 
(1) a leptin transgene (TRE-Lep) downstream of the tet-O responsive elements (TRE) and the 
CMV promoter; and (2) a reverse transactivator rtTA in the Rosa26 locus (R26-rtTA) [42]. 
These mice are denominated: 2TG throughout the manuscript. Mice that segregate for only one 
 75 
 
of the transgenes (denominated: 1TG with either TRE-Lep or R26-rtTA) do not produce excess 
leptin in response to dox, and serve as controls. Dox was administered to mice in drinking water. 
Throughout the study, animals were maintained at room ambient 22-24°C with a 12-h dark-light 
cycle (lights on at 0700h) in a pathogen-free barrier facility. The protocol was approved by the 
Columbia University Institutional Animal Care and Use Committee.  
Experiment 1: Hyperleptinemia in adult mice 
Three groups of mice were studied in this experiment: (1) Double transgenic (2TG) control 
group given 5% sucrose in drinking water but no dox (2TG no dox), (2) single transgenic (1TG) 
control group given dox in 5% sucrose drinking water (1TG +dox), and (3) 2TG experimental 
group given dox in 5% sucrose drinking water (2TG +Dox). Controls and experimental mice 
were raised in the same litters. After weaning, mice were group-housed (3 per cage) with ad 
libitum access to chow (Purina LabDiet 5058) and water. Dox (Doxycycline hyclate, Sigma 
D9891) exposure began at 9 weeks of age and all mice were fed chow (22% calories as fat) 
during this period. Mice were exposed to increasing concentrations of dox in 5% sucrose water 
every 2 weeks. Dox water was changed twice weekly. Baseline blood was collected 1 week prior 
to dox exposure. The dox concentrations in water were: 5, 7.5, 12.5, 17.5, 20, 22.5, 27.5, 35, 40, 
45 ug/ml, increasing every 2 weeks. Circulating leptin concentration was measured from plasma 
isolated from submanibular bleeding every two weeks, 1 week after each dox dose escalation. 
Glucose was measured in submandibular whole blood with a Freestyle Lite glucose meter 
(Abbott) at the same time as blood collection for leptin assay. Dox degrades over time; this was 
observed on week 22 (age of mice) when circulating leptin concentrations were lower than the 
previous period despite higher nominal concentration of dox in the drinking water. A new batch 
of dox was purchased for the 24 week exposure.  
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Body weight and body composition (using an EchoMRI Body Composition Analyzer) was 
measured weekly throughout the experiment. Food was placed on the wire cage tops and food 
intake was measured twice a week for all mice throughout the study (food intake was measured 
on a per cage basis). During dox exposure, water intake was measured twice a week to ensure 
that there was no dox (taste) effect on the amount of water consumed.  
Dox-free water was provided after 20-weeks of dox exposure and mice immediately reverted to 
leptin concentrations of untreated animals. Monitoring of body weight, composition and food 
intake continued weekly after dox exposure was ceased. 5 weeks after release from dox 
exposure, mice were switched from regular chow to high fat diet (HFD; Research Diets, Inc. 
D12492i, 60% kcal from fat). Mice were sacrificed 16 weeks after release from hyperleptinemia.  
Experiment 2: Hyperleptinemia and concurrent high fat diet feeding in adult mice 
As in experiment 1, three groups of mice were studied in the 2nd experiment: (1) 2TG no dox, 
(2) 1TG +Dox, and (3) 2TG +Dox. Experiment 2 was designed similarly to experiment 1; mice 
were group-housed (3 per cage) with ad libitum access to chow and dox exposure started when 
mice were 9 weeks old. The concentration of dox in 5% sucrose water was increased every 2 
weeks in the following order: 10, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 45 ug/ml. The modification 
to this protocol was that after the initial 7 weeks of dox exposure mice were switched from 
regular chow diet to 60% HFD. Plasma Leptin, glucose, body weight and composition, food and 
water intake were measured at the same time points in the same way as experiment 1. Mice were 
released from hyperleptinemia after 20 weeks of dox exposure; at the same time they were 
switched back to regular chow diet. Post release, body weight, composition and food intake (on a 
per cage basis, 3 mice per cage) were monitored weekly. Mice were sacrificed 12 weeks after 
release from hyperleptinemia. 
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Experiment 3: Hyperleptinemia in adolescent mice 
1TG (controls, n=18) and 2TG (dox-inducible leptin overexpressors, n=18) littermates were 
weaned on postnatal day 22 (P22). At weaning pups were separated by genotype and group-
housed (3 mice per cage) with ad libitum access to chow (Purina LabDiet 5058). At the same 
time mice began a 5-week exposure to 50 ug/ml of dox in drinking water. Based on the first two 
experiments described here, addition of dox did not affect water intake in mice, therefore water 
was not supplemented with sucrose. Blood was collected at P15 and at weaning (P22) for 
baseline plasma leptin measurement and every 2 weeks during dox exposure (week 4, 6 and 8 of 
age). At 8 weeks of age, mice were released from dox exposure and continued ad libitum access 
to chow. At 14 weeks (6 weeks post release from dox) both groups, 1TG and 2TG, were 
switched to ad libitum 60% HFD. Body weight and food intake were recorded twice per week. 
Body composition (by EchoMRI) was measured biweekly throughout the experiment. Leptin 
was measured every 2 weeks during dox exposure and every 4 weeks during the post-dox period.  
Experiment 4: Hyperleptinemia in postnatal mice 
1TG females homozygous for the tetracycline responsive elements (TRE)-Lep gene (TRE-
Lep/TRE-Lep; Chapter 2) but non-carriers for the R26-rtTA allele were crossed to 1TG males 
that were heterozygous for R26-rtTA (rtTA/+) but non-carriers for the TRE-Lep insert. This 
strategy resulted in all offspring carrying the TRE-Lep/+ gene and ~half segregating for the 
rtTA/+. The offspring were born with the expected 1:1 ratio of 1TG and 2TG. At parturition, 
mothers were exposed to 200 ug/ml of dox water and exposure continued postnatally throughout 
the nursing period. They were given ad libitum access to chow. While the pups were exclusively 
breastfeeding (P15), and at weaning (P22), pups were bled to measure plasma leptin. At 
weaning, mice were separated by genotype into home cages (group housed, 2-3 mice per cage) 
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with ad libitum access to chow and dox-free water; mice were maintained under these conditions 
until 10 weeks of age. At 10 weeks, mice were switched to ad libitum access to 60% HFD and 
maintained on this diet until the end of the study.  
Plasma collection and assays 
Blood was obtained by submandibular bleed at 9am from mice in a fed state. Plasma was 
collected on ice using heparinized tubes (Fisherbrand) and was isolated by centrifugation for 20 
min at 2,000 x g at 4°C and aliquoted and frozen at −80°C until time of assay. Plasma leptin 
concentration was measured using mouse leptin ELISA (R&D).  
 
Results 
We have generated a dox-inducible leptin overexpressing transgenic mouse (2TG) (Chapter 2) 
which produces leptin in proportion to dox concentration and can be rapidly turned on (within 
8h) or off (within 24h) with no lasting effects on plasma leptin concentration. These mice were 
used throughout this manuscript. 
Experiment 1: Hyperleptinemia in adult mice 
To investigate whether chronic hyperleptinemia affects body weight set point, we exposed adult 
2TG mice fed ad libitum chow to increasing concentrations of dox in drinking water 
supplemented with 5% sucrose (2TG +Dox group). Two control groups were used: 2TG mice 
exposed to 5% sucrose water without any dox (2TG no dox) and 1TG mice exposed to dox in 5% 
sucrose water (1TG +dox). Dox exposure started when mice were sexually mature at 9 weeks old 
and was continued for 20 weeks. The initial dox dose was very low and was escalated on a bi-
weekly basis to mimic the leptin concentration profile seen in a mouse that is exposed to HFD 
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[43]. Circulating leptin concentration in 2TG +dox group was significantly higher than both 
control groups starting at 7.5 ug/ml and 12.5 ug/ml dox dose, respectively, and remained 
significantly elevated for 20 weeks until the end of dox exposure (Figure 3.1A).  
There were no significant differences in body weight among the groups at the start of dox 
exposure or throughout the 20 weeks of hyperleptinemia (Figure 3.1B). Body weights at the 
highest dose of dox (45 ug/ml) were similar in all groups (Figure 3.1B). No difference was seen 
in body composition, fat mass, or lean mass throughout the duration of hyperleptinemia (Figure 
3.1C, D). Food and water intake were also not different in any of the groups throughout dox 
exposure (Figure 3.1E, F). Plasma glucose concentrations did not differ between any of the 
groups (Figure 3.1G).  
Following a 20-week period of gradual elevation of circulating leptin concentrations, dox was 
removed from the drinking water; the leptin concentrations of 2TG +dox mice declined to levels 
appropriately proportional to body fat. Leptin was measured 5 weeks post dox release and 
declined in 2TG +dox mice to control concentrations (Figure 3.1A). Body weight, composition 
and food intake for 5 weeks after the cessation of hyperleptinemia were the same in all three 
groups (Figure 3.2A-D). Mice were then challenged with 60% HFD to determine if formerly 
hyperleptinemic mice were more sensitive to highly palatable food. Mice were monitored for 
additional 11 weeks but did not show any differences in food intake body weight, or body 
composition (Figure 3.2A-D).        
Experiment 2: Hyperleptinemia and concurrent high fat diet feeding in adult mice 
In the second experiment we investigated whether hyperleptinemia combined with HFD feeding 
has distinct consequences for resetting defended body weight/fat. We used the same groups of 
mice as experiment 1: 2TG +dox, 2TG no dox, and 1TG +dox. Mice were exposed to the first 
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dose of dox at 9 weeks of age. In this cohort, 2TG +dox mice significantly elevated circulating 
leptin after the first dose of dox and it remained significantly higher than both controls 
throughout the 20 week dox exposure period.  
In this cohort, mice significantly elevated circulating leptin concentrations more rapidly than in 
the first experiment. As a consequence, the 2TG +dox mice initially lost fat mass and lean mass. 
Fat mass for the 2TG mice +dox group was significantly lower than both control groups for 3 
weeks (week 11-13). Body weight and lean mass for the 2TG mice +dox mice were significantly 
lower than the 1TG +dox control group only. Body weight in the 2TG mice +dox group 
remained slightly lower from week 11 to 15. Food intake was slightly but significantly 
suppressed in 2TG +dox at week 10, a likely result of anorexigenic effects of leptin.  
The 2TG +dox mice caught up in body weight and fat with the controls at 16 weeks of age. At 
this point, mice were switched from regular chow to 60% HFD. All three groups responded 
similarly to the HFD, displaying a similar level of hyperphagia upon exposure to HFD; each 
group initially increased caloric intake by ~50%. Hyperphagia subsided over a few weeks but 
HFD caloric intake remained elevated compared to caloric intake when fed regular chow. 
Following a chronic, gradual, elevation of circulating leptin and concurrent feeding with 60% 
HFD, dox was removed from the drinking water and, at the same time, mice were switched from 
HFD back to regular chow. Body weight was monitored for 11 weeks after the cessation of dox-
induced hyperleptinemia. All mice lost weight after they were switched from HFD to regular 
chow diet and there was no effect of chronic hyperleptinemia on body weight after dox was 
removed (Figure 3.4A). Fat and lean mass were measured weekly for 4 weeks after dox 
cessation; lean mass remained unchanged, but fat mass was decreased in all mice due to the diet 
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switch (Figure 3.4B, C). No difference in caloric intake was detected among any of the groups 
(Figure 3.4D).    
Experiment 3: Hyperleptinemia during adolescence (P22-P56) 
We investigated the effects on body weight of hyperleptinemia in “adolescent” mice. 
Immediately after weaning, mice were separated by genotype and placed in home cages (3 mice 
per cage) with ad libitum access to regular chow. At the same time, 1TG and 2TG mice, began a 
5-week exposure to 50 ug/ml of dox in drinking water. In response to dox, 2TG mice increased 
circulating leptin concentrations by ~25 fold compared to 1TG controls on dox. Leptin remained 
significantly elevated throughout the duration of the exposure (Figure 3.5 A). Food intake was 
significantly reduced in 2TG mice compared to 1TG controls for 2 weeks after the switch to dox 
water and remained slightly, but not significantly, suppressed throughout the 5-week period of 
hyperleptinemia (Figure 3.5F). Consequently, body weight of 2TG mice was significantly lower 
than 1TG from 3 to 8 weeks of age (Figure 3.5B). Fat mass and lean mass were also reduced 
during dox exposure (Figure 3.5D, E).  
At 8 weeks of age, mice were released from dox-induced hyperleptinemia; leptin concentrations 
measured 1 week after dox removal, returned to fat mass proportional levels in 2TG (Figure 
3.1A). In response to the sharp drop in circulating leptin, 2TG mice increased food intake 
significantly for 1 week until their body weights increased to the level of 1TG controls (Figure 
3.5F). Similarly, fat mass and lean mass were restored to the levels of 1TG mice within 1 week 
(Figure 3.5D, E). Once 2TG mice caught up with the controls, body weight, body composition 
and food intake were not different from 1TG controls for the following 6 weeks while mice were 
maintained on chow.  
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Both groups, 1TG and 2TG, were switched from chow to 60% HFD at 14 weeks (6 weeks post 
dox exposure). During the first 2 weeks, the hyperphagia induced by HFD feeding was 
significantly greater in 2TG compared to 1TG mice and their caloric intake remained slightly, 
but not significantly, elevated for the following two weeks. After 4 weeks of HFD feeding, 
caloric intake was identical in both groups and remained the same until the end of the study. No 
statistically significant difference was detected in body weight between 1TG and 2TG mice 
throughout the study but, as expected from their increased caloric intake, 2TG mice gained 
significantly more weight than the 1TG controls in the first 3 weeks of HFD feeding (Figure 
3.5C).  
Experiment 4: Hyperleptinemia during postnatal period (P0-P22) 
We evaluated effects of dox-induced hyperleptinemia in postnatal mice on body weight later in 
life. 1TG dams were given dox in drinking water immediately following parturition until 
weaning of their progeny at P22. Leptin is present in breast milk in small quantities (about 5 fold 
lower concentration than in circulation of a nursing dam and is absorbed by the gastrointestinal 
tract of suckling pups [44, 45]. We previously showed that 1TG mothers do not elevate their 
circulating leptin when exposed to dox, but nursing 2TG pups have significantly higher 
circulating leptin concentrations than 1TG littermates, indicating that dox crosses to the pups 
through mother’s milk and induces expression of transgenic leptin in 2TG pups (Thesis Chapter 
2).  
Plasma leptin concentration in 2TG pups at P15 and P22 was elevated versus 1TG littermates 
(Figure 3.6A) and was higher on P22 than on P15 possibly as a result of mice ingesting dox 
through drinking water directly at P22 as opposed to dox transfer exclusively through mother’s 
milk at P15.   
 83 
 
Fat mass was lower in 2TG compared to 1TG controls at 3 weeks of age; at this age mice have 
little body fat but 2TG animals had ~50% the amount of fat of 1TG mice (Figure 3.6E). Lean 
mass was the same in both groups (Figure 3.6F). The small difference in fat mass was not 
detected in body weight at 3 week of age (Figure 3.6C). At P22, pups were caged by genotype (3 
mice per cage) with ad libitum access to regular chow and dox-free water. One week after 
release from hyperleptinemia, circulating leptin concentrations were not different in 2TG mice 
compared to 1TG (Figure 3.6A). Fat mass also recovered in 2TG mice and at 4 weeks old was 
not different than 1TG littermates (Figure 3.6E).  
Until 10 weeks of age (7 weeks after release from dox exposure) mice were fed ad libitum chow 
and no group differences in body weight, composition and food intake were seen. Mice were 
then switched to 60% HFD. Both groups of mice increased food intake by ~50% in the first 3 
days. No significant difference in caloric intake was detected between the two groups (Figure 
3.6G); however, the relative hyperphagia in 2TG mice (defined as caloric intake after switch to 
HFD divided by caloric intake on the last week of regular chow before the switch) was 
significantly higher in the first 3 days and the following 4 days (Figure 3.6H). Within the first 3 
days of HFD feeding, 2TG mice gained more weight than controls (2TG: 2.6 ±0.2g, 1TG: 1.6 
±0.2g, p<0.01) and continued to gain body weight at a velocity greater than 1TG; at the end of 
the study (mice were 38 weeks old) the difference in body weight gain was 5.7g (Figure 3.6D). 
Absolute body weight difference reached significance 6 weeks after the start of HFD feeding 
(Figure 3.6C). 2TG animals remained significantly heavier than 1TG until the end of the study at 
38 weeks (1TG: 49.9 ±1.3 g; 2TG: 55.4 ±1.5 g; p-value<0.05) (Figure 3.6C). Lean mass did not 
statistically differ between 1TG and 2TG mice throughout the study (Figure 3.6F). Fat mass was 
significantly higher in 2TG mice 2 weeks after diet switch and remained relatively higher until 
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the end of the study (Figure 3.6E). Circulating leptin was measured 4 and 18 weeks after the start 
of HFD exposure and was significantly higher in 2TG mice after 18 weeks of HFD feeding 
(1TG: 122.9 ±8.0 ng/ml, 2TG: 172.6 ±9.5 ng/ml; p<.001). After 18 week HFD exposure, 2TG 
mice (dox-induced hyperleptinemic postnatally from 0-3 weeks of age) have a higher fat mass 
than 1TG mice, therefore they secrete more leptin, but leptin secretion is still in proportion to fat 
mass (Figure 3.6B).  
 
Discussion 
With large increases in obesity prevalence, maternal obesity has become more common and 
potentially could have a long lasting impact on future generations. Genetic predispositions are 
important contributors to the risk of obesity. Heritability studies suggest that ~40-70% of the 
variation in adiposity among individuals reflects genetic factors [45, 46]. However, genetics 
cannot explain the rapid increase in obesity prevalence within the past 4 decades. It is likely that 
interactions between our genes and energy-dense, palatable food work in synergy to increase 
individual risk of obesity. Rodent models that evaluate maternal obesity and HFD feeding during 
gestation and/or lactation provide insight into the physiological effects on offspring but are not 
well suited to investigate the mechanisms that mediate these effects. One of the signals 
associated with increased obesity and HFD feeding is increased circulating leptin – which may 
contribute per se to the phenotypes observed in the offspring. Animal models of exogenous 
leptin administration are confounded because postnatal interventions are highly disruptive to the 
environment of the pups (daily handling for injections, maternal stress, etc.). The transgenic 
model of dox-controlled leptin overexposure we utilized circumvents these problems and 
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provides close control over neonatal leptin exposure without disturbing the neonatal 
environment.  
We evaluated the effects of hyperleptinemia on body weight and subsequent responses to highly 
palatable food at 3 distinct developmental periods. We found that (1) inducing chronic 
hyperleptinemia in adult mice, with or without concurrent HFD exposure, does not increase the 
set point of defended body weight when excess leptin is removed; (2) hyperleptinemia during 
“adolescence” transiently increases the hyperphagic response to a HFD; but ultimately does not 
alter body weight thereafter; and (3) transient elevation of circulating leptin in the immediate 
postnatal period increases the hyperphagic response to a highly palatable diet and renders 
animals more susceptible to obesity as adults. These results emphasize the importance of the 
timing of exposure to hyperleptinemia on the phenotypes of progeny. We identify the immediate 
postnatal period as a critical time window during which exposure to elevated leptin per se 
increases the body weight in adult offspring under conditions of ad libitum access to highly 
palatable food.   
Knight et al. attempted to distinguish the effects of HFD from the effects of hyperleptinemia as a 
result of HFD feeding in the development of apparent hypothalamic leptin resistance [47]. 
Exogenous leptin was chronically infused with subcutaneous Alzet mini-pumps into leptin-
deficient (Lepob/ob) mice to generate plasma concentrations comparable to those of a wild type 
(WT) mouse fed regular chow. These mice were then switched from low to high fat diet but the 
leptin infusion rate was held constant [47]. Over the ensuing 20 weeks of HFD feeding, WT and 
leptin-infused Lepob/ob mice gained weight at the same rate, despite circulating leptin 
concentrations in the HFD fed WT mice continuously increasing [47]. At the same level of 
adiposity as the WT mice (but lower leptin concentrations), leptin-infused Lepob/ob displayed 
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greater leptin sensitivity – assessed by leptin induced hypothalamic pSTAT3 – compared to HFD 
fed WT mice, indicating that hyperleptinemia in HFD-fed mice is necessary to reduce 
hypothalamic cellular responses to leptin [47].    
The current study demonstrates that extended elevation of plasma leptin in adult mice – by itself 
or in combination with HFD feeding – does not alter body weight set point. Upon initial dox-
induced leptin elevation in Experiment 2, 2TG mice transiently decreased food intake and body 
weight, but, within 4-6 weeks, food intake and body weight in these mice were not different from 
control mice (1TG +Dox and 2TG no dox). The response to increased circulating leptin that was 
only seen in the 2nd cohort of adult mice exposed to hyperleptinemia is possibly due to (1) initial 
leptin induction in experiment 2 was much higher than seen in experiment 1; it is likely that with 
a more gradual elevation of leptin, mice accommodate to higher leptin without physiological 
response; and (2) mice in experiment 1 were slightly fatter than mice in experiment 2 at the start 
of dox exposure; fatter mice are less sensitive to leptin [15].  
Experiment 1 confirms previous chronic hyperleptinemia experiments in adult WT mice which 
showed no changes in body weight after mouse release from elevated leptin [28]. In that study, 
exogenous leptin or saline was chronically infused via Alzet mini-pumps in adult WT mice for 
18 weeks. Following cessation of leptin administration, body weight, composition and food 
intake were monitored [28]. Chronic elevation of circulating leptin concentrations, per se, did not 
lead to metabolic or behavioral “defense” of a higher body weight [28]. Some limitations of this 
study included: (1) the amount of exogenous leptin delivered via a mini-pump is limited due to 
low leptin solubility at high concentrations, (2) a large variation in delivery efficiency of 
exogenous leptin in individual mice, and (3) weight loss caused by repeated surgeries to replace 
mini-pumps. All of these issues are avoided with the transgenic mouse model used in this study.     
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Experiment 3 demonstrated that inducing hyperleptinemia during the “adolescent period” in 
mice does not affect body weight set point after leptin concentration is normalized. As reported 
in experiment 2, dox exposure in 2TG mice at 5 weeks of age triggered an anorectic response. 
Mice decreased food intake compared to 1TG controls and consequently lost both fat and lean 
mass. Circulating leptin during dox exposure was significantly higher in 2TG than in 1TG group, 
the 2TG leptin concentrations fell within the typical physiological range induced with HFD 
feeding. When challenged with HFD at 14 weeks, 2TG mice transiently increased food intake 
and gained more weight than 1TG controls within the first 4 weeks of HFD exposure but, 
ultimately, no difference in long term body weight was detected between the 1TG and 2TG 
groups. Increased hyperphagia in response to highly palatable food in the 2TG mice suggests that 
exposure to hyperleptinemia during adolescence may have altered leptin responsive neural 
circuitry.  
In mice, a physiologic leptin surge (5-10 fold increase in circulating leptin concentrations) occurs 
between P8-P12 independent of pup fat mass and food intake [48]. This surge – the mechanism 
of which is unclear – is a major developmental signal which affects the outgrowth of neuronal 
projections from the ARH to PVH, DMH, and LHA involved in feeding circuits [40]. Maternal 
HFD feeding during nursing causes the surge to start earlier with higher intensity and to last for a 
longer period of time [41]. Casabiell et al. reported that leptin is transferred from maternal 
circulation to breast milk and absorbed intestinally by neonatal pups [44]. In a separate 
experiment, orally administered leptin was detected in the circulation of suckling pups [44]. The 
amount of leptin administered orally was 10 ug – well above physiological levels (leptin in 
human milk has a concentration of 1.35 ug/L) [44]. In humans, some studies have detected a 
correlation between leptin concentration in maternal circulation and breast milk, however, leptin 
 88 
 
concentrations in breast milk are significantly lower than the concentrations reported in either 
maternal or infant circulation [49-52]. Therefore, even if ingested leptin enters the offspring’s 
circulation, it is unlikely that the direct contribution to circulating infant leptin is physiologically 
significant. While the concentration of leptin in the breast milk of obese post-partum women is 
significantly higher than in lean women [53], rodent data suggest that elevated leptin in postnatal 
pups born to DIO dams is due, at least partially, to increased leptin production from the adipose 
tissue of the pups [41]. This finding suggests that the HFD and/or maternal obesity per se 
conveys leptin-trophic molecules. Other physiological and molecular changes are induced in 
dams as a consequence of obesity and/or HFD feeding such as increased circulating free fatty 
acids, elevated glucose, decreased insulin sensitivity, increased circulating insulin, fatty liver, 
etc. The transgenic mouse model used in this study isolates hyperleptinemia per se in the pup 
from other confounds of HFD feeding and/or maternal obesity. Another advantage of this model 
is that by breeding 1TG dams homozygous for the leptin transgene but no rtTA to 1TG males 
that are heterozygous for the rtTA gene, the resulting progeny have a ~1:1 ratio of 1TG to 2TG 
where all mice have one copy of the leptin transgene and ~ half also have one copy of the rtTA 
gene. This produces ideal littermate controls. When the 1TG dam is exposed to dox in drinking 
water immediately post parturition – the mother herself does not elevate leptin – dox is 
transferred to the offspring in breast milk, therefore 2TG pups increase leptin expression, while 
1TG littermates do not.    
In experiment 4 we show that isolated hyperleptinemia during the postnatal period predisposes 
mice to be more hyperphagic when exposed to highly palatable food later in life resulting in 
increased weight gain when given access to HFD. At 3 weeks of age, while 2TG mice are still 
producing excess leptin, 2TG mice had half the amount of somatic fat of the 1TG mice. 
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Exogenous leptin in mice does not suppress food intake during the first 3 weeks of life [54, 55], 
but is an important neurotrophic factor affecting the development of ARH projections to 
downstream hypothalamic targets [40]. Although no difference in body weight was detected at 3 
weeks, decreased fat mass in hyperleptinemic 2TG compared to 1TG mice may be a confound 
with regard to leptin-specific effects in the CNS, since postnatal undernutrition in rodents causes 
growth retardation and decreases body weight throughout life even when animals are 
subsequently exposed to high fat diet [56, 57]. 2TG mice in this study had the same body 
weights as 1TG controls while maintained on chow diet, hence it is unlikely that they had 
experienced postnatal undernutrition. It is possible that, at P22, leptin is just beginning to acquire 
its function as an anorectic signal [54, 55] and that some of these effects are apparent as 
decreased fat mass at the time of weaning. One week after release from hyperleptinemia, 1TG 
and 2TG mice were indistinguishable in body weight and composition; they remained identical 
in this regard until 10 weeks of age when they were switched to 60% HFD. Immediately 
following HFD exposure, 2TG mice gained significantly more weight than 1TG littermates. The 
hyperphagia (caloric intake relative to food intake on chow) in 2TG mice was 17% greater 
compared to the 1TG mice during the first week. By the end of the study, 2TG mice had 
increased body weight (11%) and fat mass (19%) relative to the 1TG mice. The fat difference is 
approximately 4 grams per mouse after 14 weeks on HFD when most of the fat difference 
between 1TG and 2TG groups has been accrued, and it represents a delta of only 38 kcals out of 
approximately 1300 kcals ingested over this same period or an imbalance of 3%. We do not have 
the resolution to determine if this is from food intake or energy expenditure. 
Increased fat mass in 2TG mice after 18 weeks of ad libitum HFD access resulted in increased 
circulating leptin but there was no effect on leptin secreted per unit of fat mass. There is no 
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indication that mice produce anti-leptin antibodies or that there is any impact on leptin produced 
per unit of fat mass after dox cessation. In an earlier study in which exogenous leptin was infused 
in adult mice by Alzet mini-pump, several months following cessation of exogenous leptin 
exposure, some mice exhibited disproportionately increased (relative to fat mass) circulating 
leptin concentrations [28]. This finding suggested the possibility that mice may have generated 
anti-leptin antibodies. In the present study, dox-induced hyperleptinemic mice returned to their 
fat mass-appropriate circulating concentrations of leptin at the first post-dox measurement (1-5 
weeks post dox release) and leptin concentration remained proportional to fat mass at every time 
point following cessation of dox.  
Three other groups have reported on the physiological consequences on body weight of postnatal 
exogenous leptin supplementation in rats; these studies varied in the timing and route of leptin 
administration and reported conflicting effects on body weight depending on the route of leptin 
administration. Pico et al. administered leptin orally to rats from P0 to P20. At weaning, rats 
were switched to HFD; at 6 months the leptin fed rats had lower body weight than vehicle-
treated control rats [58]. Plasma leptin concentrations in leptin-supplemented pups were not 
reported, therefore, it is unclear whether oral leptin elevated circulating leptin. Maternal HFD 
feeding increases leptin expression in neonatal adipose tissue [41] and this effect was possibly 
absent with the oral leptin administration. Another group administered leptin to neonatal rats via 
IP injections either during the first or last 10 days of nursing and showed that, by 16 weeks of 
age, leptin injected rats had higher body weight than controls while maintained on normal chow 
[59]. Vickers et al. injected suckling rats with IP leptin from P3 to P13; leptin supplemented rats 
gained more weight than controls after they were switched to high fat diet [60]. The latter two 
studies are consistent with results reported in this manuscript.  
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By what mechanisms might elevated circulating leptin during the postnatal period affect 
developmental programming of body weight? Simerly and colleagues demonstrated leptin’s 
neurotrophic role in the development of feeding circuitry [40]. In Lepob/ob mice, ARH projections 
to other hypothalamic regions are greatly reduced compared to the WT mouse, and the formation 
of these pathways is temporally delayed (i.e. in WT mice ARH innervate the PVH on P12, 
whereas in Lepob/ob littermates no axons from the ARH are detected at this time) [40]. Postnatal 
(P4-P12) administration of leptin to Lepob/ob mice restores the density of the innervation from the 
ARH to the PVH to the levels of a WT control. However, administering leptin to adult Lepob/ob 
mice does not rescue the density of AgRP and α-MSH immunoreactive innervation in the PVH 
to those seen in WT mice, indicating that there is a restricted neonatal time window in which 
ambient leptin impacts the formation of ARH connections [40]. Kirk et al. showed that the 
offspring of dams exposed to HFD during gestation and lactation gain more weight than controls, 
and display decreased hypothalamic leptin sensitivity (determined by leptin-induced pSTAT3 in 
the ARH and VMH) at P30 and P90. The density of AgRP immunoreactive fibers in the PVH 
was decreased in the offspring of HFD dams compared to chow fed dams [41]. The authors 
hypothesized that early hyperleptinemia induces leptin resistance thereby attenuating leptin 
signaling and impairing the development of hypothalamic projections [41]. Vogt et al. showed 
that the most critical period for the effects of maternal HFD feeding on offspring body weights is 
during postnatal period (birth to weaning) and that the fiber density of AgRP and α-MSH from 
ARH to three downstream hypothalamic areas: PVH, DMH and LHA is reduced [27]; these 
alterations in hypothalamic circuits are similar to those reported in Lepob/ob mice [40]. We found 
the pre-weaning period to be critical for the effects of hyperleptinemia on body weight later in 
life. It is plausible that the neurobiological changes seen in the offspring of HFD-fed dams result, 
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at least in part, from hyperleptinemia associated with the obese state. Thus, investigating the 
density of AgRP and α-MSH fibers from the ARH to the PVH, DMH and LHA in our transient 
hyperleptinemic mouse model is critical to decipher whether these circuits are affected by 
elevated leptin per se.  
Metabolic signals other than leptin (in particular insulin and ghrelin) have also been suggested to 
act as a neurotrophic factor during pre-weaning. Insulin injected directly into the hypothalamus 
of P8 rats causes a decrease in neuronal density of the VMH in pups at P15 and results in 
elevated body weight gain in adulthood [61]. Carmody et al. demonstrated that HFD feeding, in 
addition to maternal insulin resistance (dams were heterozygous for a null allele of the insulin 
receptor, Insr+/-), increases the number of POMC-expressing cells by 20% in the ARH of P9 
offspring [39]. This suggests that insulin can influence the specification of POMC neurons in 
response to maternal HFD feeding. Vogt et al. showed that maternal HFD-induced 
hyperinsulinemia disrupts the projections from the ARH POMC neurons to the preautonomic 
compartment of the PVH [27]. Deletion of the insulin receptor specifically in POMC neurons in 
the offspring, under conditions of maternal HFD feeding, restores normal development of POMC 
projections in this circuit and corrects glucose intolerance [27], implicating insulin in the 
development of hypothalamic circuits involved in glucose homeostasis.  
Ghrelin’s role has also been studied during mouse postnatal development. Ghrelin is an appetite 
stimulating circulating hormone, synthesized primarily by the stomach, which signals through 
the growth hormone secretagogue receptor (GHSR) [62, 63]. GHSR is expressed in the 
hypothalamus and administration of ghrelin activates neurons in the ARH, VMH, and PVH – 
nuclei known to control feeding [64]. Steculorum et al. investigated physiological and 
neurobiological effects of excess and deficiency of ghrelin during pre-weaning period [65]. 
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Blocking ghrelin signaling from P4 to P22 results in increased density of AgRP and α-MSH 
immunoreactive fibers in the PVH; whereas supplementing exogenous ghrelin from P4 to P12 
has opposite effects – innervation in the PVH is reduced [65]. Surprisingly, both interventions 
result in increased body weight, fat, and blood glucose. While the overall density of AgRP and 
αMSH fibers in the PVH are affected in the opposite way by ghrelin and anti-ghrelin treatment, 
the ratio of orexigenic AgRP to anorexigenic α-MSH is increased in both conditions which could 
explain the increase in body weight due to both manipulations [66]. These data emphasize that 
appropriate timing and magnitude of ghrelin’s action is important in proper formation of 
hypothalamic neurocircuits and in control of body weight in adulthood [65].  
Other potential mechanisms linking hyperleptinemia during the postnatal period to 
developmental programming include epigenetic modifications, hypothalamic inflammation and 
neuroanatomic changes in the hedonic or reward circuits. Over-nutrition of weanling rats (by 
decreasing litter size) during the perinatal period results in hypermethylation of the hypothalamic 
POMC promoter [67] which is negatively correlated with hypothalamic POMC expression 
adjusted for circulating leptin. When mice are exposed to highly palatable food they massively 
overeat in the first 1-2 weeks. This response is mediated, at least in part, by hedonic, reward-
based mechanisms that can override homeostatic regulation during abundant food availability, 
and drive the increased desire to consume highly palatable foods in the absence of hunger [68]. 
One of the most critical brain reward pathways is the mesolimbic dopamine (DA) system. The 
anatomic core of this system is located in a subset of DA neurons in the ventral tegmental area 
(VTA)/substantia nigra (SN) which project to the striatum (nucleus accumbens (NAc), 
caudate/putamen), amygdala, and prefrontal cortex [69]. Maternal HFD feeding decreases the 
function of the mesolimbic DA system [70]. Specifically, adult offspring born to HFD-fed 
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mothers have decreased DA release in NAc and locomotor responses when administered 
amphetamine (which acts via the DA transporter, dopamine active transporter, DAT, to promote 
DA efflux) [71, 72]. Ong et al. demonstrated that maternal high-fat, high-sugar diet from before 
pregnancy through weaning increases high-fat and high-sugar foods preference in the offspring. 
This increased preference was associated with expression changes in molecules critical in the 
mesolimbic reward pathway [including tyrosine hydroxylase (TH, enzyme which catalyzes the 
rate-limiting step in DA synthesis), dopamine receptors, DAT, and µ-opioid receptor] [73]. Other 
studies demonstrate that maternal HFD feeding alters food preference in the offspring toward 
highly palatable foods [34, 74] and is associated with DNA hypomethylation of DAT (transports 
DA from the synapse back to the nerve terminal, hence decreasing dopamine activity) promoter 
which subsequently increases expression of Dat in the mesolimbic dopamine system, specifically 
in the VTA, NAc and prefrontal cortex [34, 74].  
Leptin receptors (LepRb) are expressed in the VTA and the SN [75] and leptin suppresses the 
reward value of food (controlled by the mesolimbic DA system) [76]. TH expression and DA 
content in the VTA and NAc is decreased in Lepob/ob mice [77, 78]. Administration of 
amphetamine to Lepob/ob mice does not induce normal locomotor activity, treatment with 
exogenous leptin restores Lepob/ob mice responsiveness to amphetamine [77]. Perry et al. 
demonstrated that a single ip injection of leptin to wt mice does not change expression but 
acutely increases DAT and TH activity [79]. Infusion of leptin directly into the VTA decreases 
food intake and aspects of food reward such as motivation to work for a food reward [80-82]. 
Additionally, LepRbs are expressed in the lateral hypothalamic area (LHA) and these LHA 
LepRb GABAergic/inhibitory neurons were shown to innervate the VTA [78]. Direct LHA 
leptin injection confirms leptin action on the LHA LepRb neurons by decreasing food intake and 
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body weight over a period of 24 hours [78]. Morabito et al. reported changes in leptin sensitivity 
(by leptin-induced pSTAT3 immunohistochemistry) in the NAc and SN in response to weight 
loss by diet switch or caloric restriction [16]. Similar to hypothalamic feeding circuit 
development, the central reward circuitry – projections from the VTA to the NAc – in rodents 
mature postnatally by the 3rd week of life [83, 84]. These findings suggest that DIO during 
gestation and/or lactation could influence the anatomy and cellular function of elements of both 
homeostatic and hedonic circuits in the offspring and that leptin may be involved in this maternal 
programming. 
Finally, studies by Schwartz and colleagues implicate a role of hypothalamic inflammation in 
diet- induced obesity. Thaler et al. demonstrated that within 1-3 days of HFD feeding, prior to 
substantial weight gain, mice develop hypothalamic inflammation characterized by activation of 
local microglia and astrocytes (also referred to as gliosis) [85]. Microglia and astrocytes are 
subtypes of glial cells – the most abundant cell type in the CNS involved in various processes 
that support the function of neurons [86]. Interventions that decrease inflammation in neurons 
and glia reduce food intake and weight gain associated with HFD exposure [87]. In rodents, glia 
cell number in the brain at birth is relatively small, and markedly increases postnatally during the 
second and third week of life, coinciding with the leptin surge [88]. Lepob/ob mice become 
severely obese on chow diets, however, they display a decrease in activated microglia compared 
to WT mice on chow or on HFD [89] indicating that leptin is at least a partial mediator of gliosis. 
Astrocytes express LepRb [90, 91]. Administration of leptin between P8-P12 increases 
proliferation of astrocytes in the hypothalamus; whereas deletion of LepRb from astrocytes 
decreases astrogenesis [92]. Conditional deletion of LepRb in astrocytes in adult mice results in 
altered astrocyte morphology and increased synaptic inputs onto hypothalamic POMC and AgRP 
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neurons [90]. Additionally, leptin-induced suppression of food intake is reduced in the astrocyte-
specific LepRb adult knockout mice [90]. Martin Myers and colleagues showed that 10-days of 
continuous systemic leptin infusion in WT mice fed a chow diet was sufficient to induce 
microglial and astrocyte activation in the hypothalamus (personal communication). These data 
suggest that high ambient hypothalamic leptin during development may influence the 
susceptibility to HFD later in life via its effects on proliferation and activation of astrocytes.   
Rodents experience a transient peak in plasma leptin concentrations during the 2nd week of life 
[48] which impacts the development and function of the feeding circuits [40]. In humans, 
maternal circulating leptin reaches its maximum at around the 36th week of pregnancy and 
decreases postpartum [93]. From a developmental standpoint, the postnatal period in mice is 
more analogous to the 3rd trimester of human (or primate) gestation (i.e. in rodents the 
hypothalamic circuitry is immature until the 3rd week of life whereas in primates it matures 
functionally in utero) [40, 94]. From this perspective, studies investigating the effects of HFD 
feeding and obesity in postnatal rodents may be more relevant to maternal obesity/metabolic 
status during human gestation.  
Nutritional changes during critical developmental periods can have lasting effects on energy 
homeostasis. The hypothalamus is particularly sensitive to changes in the hormonal milieu (as 
described earlier, changes in circulating leptin [40], insulin [27, 39] and ghrelin [65] alter the 
architecture of key hypothalamic centers involved in energy and glucose homeostasis); these 
developmental mechanisms remain unclear. Many physiological and molecular changes are 
triggered by obesity and HFD feeding; however, the direct contributors to phenotypes observed 
in the offspring are largely unknown. Leptin is increased as a consequence of obesity/HFD and 
plays a role in determining the feeding circuitry of a developing rodent brain. In this study we 
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isolated and investigated the effects – in mice – of transient hyperleptinemia per se on the 
regulation of body weight during 3 distinct time periods. We identified the immediate postnatal 
period as a critical time window where exposure to hyperleptinemia alters the future response to 
highly palatable food. Even 12 weeks after leptin exposure had ended, mice that were previously 
exposed to elevated circulating leptin in the immediate postnatal period gained more fat and 
body weight than control mice when allowed ad libitum access to HFD. Further studies are 
needed to determine the mechanism(s) by which hyperleptinemia per se during the postnatal 
period mediates the developmental programming of the body weight in offspring. We 
hypothesize that elevated leptin during development permanently alters hypothalamic neuronal 
projections in the feeding circuits including AgRP and POMC innervation from the ARH to 
PVH, DMH and LHA. Other alterations may include epigenetic changes in genes relevant to 
energy balance, differences in proliferation of astrocytes and/or microglia during postnatal period 
which may affect hypothalamic inflammation in response to HFD feeding, and fiber density 
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Figure 3-1  Experiment 1: Dox-induced chronic hyperleptinemia in adult mice. 
(A) Circulating leptin concentrations, (B) body weight, (C) fat mass, (D) lean mass, (E) daily 
food intake in kcals per mouse, (F) daily water intake per mouse, and (G) glucose in 2TG 
controls given 5% sucrose (gray), 1TG controls given dox in 5% sucrose (black open circles), 
and 2TG leptin overexpressors given dox in 5% sucrose (black closed circles) during 20 weeks 
of escalating dose of dox exposure. All values are means ± SEM. N per group in A-D and G: 
2TG no dox, n=12; 1TG +Dox, n=19; 2TG +Dox, n=24. N per group in E and F: 2TG no dox, 
n=4; 1TG +Dox, n=4; 2TG +Dox, n=6. No significant differences between any of the groups 
were detected with a two-way ANOVA in any of the parameters except for circulating leptin. *P 































Figure 3-2  Experiment 1: Body weight, body composition and food intake after release from 
dox. 
(A) Body weight, (B) fat mass, (C) lean mass, (D) daily caloric food intake per mouse after mice 
were released from hyperleptinemia. Five weeks after dox cessation mice were switch from 
chow to 60% HFD. All values are means ± SEM. N per group in A-C: 2TG no dox, n=9; 1TG 
+Dox, n=14; 2TG +Dox, n=20. No significant differences between any of the groups were 
detected with a two-way ANOVA in any of the parameters.   
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Figure 3-3  Experiment 2: Dox-induced chronic hyperleptinemia with concurrent HFD 
feeding in adult mice. 
(A) Circulating leptin concentrations, (B) body weight, (C) fat mass, (D) lean mass, (E) daily 
food intake in kcals per mouse, (F) daily water intake per mouse, and (G) glucose in 2TG 
controls given 5% sucrose (gray), 1TG controls given dox in 5% sucrose (black open circles), 
and 2TG leptin overexpressors given dox in 5% sucrose (black closed circles) during 20 weeks 
of escalating dose of dox exposure. All values are means ± SEM. N per group in A-D and G: 
2TG no dox, n=9; 1TG +Dox, n=12; 2TG +Dox, n=18. N per group in E and F: 2TG no dox, 
n=3; 1TG +Dox, n=4; 2TG +Dox, n=6. Significant difference calculated with Student t-test, *p < 
0.05 between 2TG +dox and at least one of the control groups. 
  





























Figure 3-4  Experiment 2: Body weight, body composition and food intake after release from 
dox. 
(A) Body weight, (B) fat mass, (C) lean mass, and (D) daily caloric food intake per mouse after 
mice were released from hyperleptinemia and HFD feeding (switched back to regular chow). All 
values are means ± SEM. N per group in A-C: 2TG no dox, n=9; 1TG +Dox, n=12; 2TG +Dox, 
n=18. No significant differences between any of the groups were detected with a two-way 
ANOVA in any of the parameters. 
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Figure 3-5  Experiment 3: Dox-induced hyperleptinemia during “adolescent” period (P22-
P56) followed by 60% HFD exposure at 14 weeks. 
(A) Circulating leptin concentrations, (B) body weight (C) body weight gain, (D) fat mass, (E) 
lean mass, (n=18 per group in A-E) and (F) daily caloric food intake (n=6 per group) of 1TG 
controls (black) and 2TG leptin overexpressing (red) mice throughout the study. All values are 
means ± SEM. Significant difference calculated between 1TG and 2TG groups with Student t-
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Figure 3-6  Experiment 4: Dox-induced hyperleptinemia during postnatal period (P0-P22) 
followed by 60% HFD exposure at 10 weeks. 
(A) Circulating leptin concentrations of 1TG controls (black) and 2TG leptin overexpressing 
(red) mice throughout the study. (B) Regression of fat mass vs. circulating leptin concentrations 
of 1TG and 2TG mice at 28 weeks of age, after 18 weeks of HFD feeding. (C) Body weight (D) 
body weight gain, (E) fat mass, (F) lean mass, (G) daily caloric food intake and (H) fold increase 
in caloric intake after the initiation of HFD feeding of 1TG and 2TG mice. All values are means 
± SEM. N per group in A-F: 1TG, n=15; 2TG, n=13; in G and H, n=5 per group. Significant 
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In rodents and humans with an intact leptin axis, changes in body weight imposed by either 
overfeeding or dietary restriction are rapidly reversed when ad libitum feeding is resumed by 
coordinate reduced energy expenditure and hyperphagia [1, 2]. In addition, when non-obese 
individuals undergo liposuction, adipose tissue is redistributed to other depots, leading to the 
same overall level of adiposity within a year [3]. These observations support the concept that 
individuals regulate their body weight and adiposity at a level (“set point”) influenced by 
genetics, developmental factors, and the environment. In a weight-reduced state, both humans [4, 
5] and mice [6, 7] become hyperphagic and their energy expenditure decreases more than 
predicted by their smaller body size; both phenotypes are largely reversed by physiological doses 
of exogenous leptin [8]. These observations suggest that reduction of circulating leptin is a major 
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signal responsible for the metabolic and behavioral responses that lead to regain of lost weight. 
However, despite their congenital absence of leptin, Lepob/ob mice reduce their energy 
expenditure when calorically restricted [9]. Following surgical excision of fat, ad libitum-fed 
Lepob/ob mice regain lost fat in other depots and eventually achieve the same level of adiposity as 
sham-operated Lepob/ob mice [10]. In the current study we found that Lepob/ob mice, weight 
reduced by transient caloric restriction, regained lost weight to the level of ad libitum fed 
controls; unlike wild type mice that overeat for a period of time after release from restriction, the 
Lepob/ob mice did this without any transient overeating compared to ad libitum controls. These 
observations suggest that Lepob/ob mice regulate adiposity via a leptin-independent pathway. The 
striking resistance to dietary weight loss reported in rare humans homozygous for inactivating 




48 Lepob/ob six week old male mice fed ad libitum on (Purina LabDiet 5058) chow diet were 
obtained from Jackson Laboratory (Bar Harbor, ME). Upon arrival, mice were group-housed (3 
mice per cage) with ad libitum access to chow and water for a two week acclimation period. 
Throughout the study, animals were maintained at room ambient 22-24°C with a 12-h dark-light 
cycle (lights on at 0700h) in a pathogen-free barrier facility. The protocol was approved by the 





6 Lepob/ob male mice at 8 weeks of age were either weight reduced by 20% (CR, n=3) via caloric 
restriction, or fed chow ad libitum (AL, n=3). Body weight and food intake were monitored 
daily. Upon reaching 80% of their initial body weight, CR mice were released to ad libitum 
feeding.  
Large cohort - study design 
Study design is outlined in Figure 4.1. After the two week acclimation period, at 8 weeks of age, 
half of the mice were assigned to the control group and fed ad libitum chow (AL group; n=21); 
the other half were calorie restricted to achieve 80% of initial body weight (CR group, n=21).  
Cages were assigned so that the two groups had no differences in starting weight, adiposity, or 
variance of those variables. After achieving 20% weight loss (approximately 2 weeks), the CR 
Lepob/ob mice were stabilized at 80% of initial body weight, by titrated feeding, for two weeks 
and then released from food restriction. 
Twenty percent weight reduction was achieved by feeding mice 1g of chow daily. During the 
weight maintenance phase, food intake was increased to 2-3g per day per mouse (the amount of 
food was adjusted daily when % of initial body weight of a mouse deviated from 80% by more 
than 2%).  Calorically-restricted mice were provided with food twice daily, 1/3 of the total daily 
calories in the morning (09:00-9:30h) and 2/3 in the evening (18:00-18:30h). Body weight and 
food intake were monitored daily. During the second week of weight maintenance, mice were 
placed individually in metabolic cages to assess their energy expenditure (EE; TSE calorimetry 
system). They were then released to ad libitum feeding and EE was measured for another week. 
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Mice were monitored for eight weeks until the body weight of the previously calorie restricted 
group reached that of with the never-restricted controls at which point mice were sacrificed.  
Body weight, body composition, food intake, and body temperature 
BW was measured (± 0.1 g) daily in all mice throughout the experiment using an Ohaus Scout 
Pro 200g scale (Nänikon Switzerland, between 09:00-09:30h). Body composition [fat mass 
(FM), fat-free mass (FFM), and extracellular fluid] was measured by time-domain-NMR 
(Minispec Analyst AD; Bruker Optics, Silberstreifen, Germany) [12] once per week. Food was 
placed on the top of the cages and food intake was recorded daily for all mice throughout the 
study. Since mice were housed 3 per cage, food intake data was monitored on a per cage basis. 
Group housing the Lepob/ob mice (3 per cage) reduced stress and the individual mice lost body 
weight at the same rate. 24 hour core body temperature of mice was measured during the first 
week of the weight maintenance phase (Figure 4.1). Rectal core body temperature was measured 
every 3 h for 24 h using a Thermalert Monitoring Thermometer starting at 1500.  
Plasma assays 
Blood was collected on ice using heparinized tubes (Fisherbrand).  Plasma was isolated by 
centrifugation for 20 min at 2,000 x g at 4°C and frozen at −80°C until assay.  Mice were bled at 
11 weeks of age prior to transfer to the calorimeters (Figure 4.1). Blood from CR mice was 
collected before feeding (fasted overnight) while AL group was bled in a fed state. Insulin was 






Energy expenditure was measured individually with a LabMaster-CaloSys-Calorimetry System 
(TSE Systems, Bad Homburg, Germany) from 1 week before the release of the CR group 
through 1 week of the body weight regain phase (Figure 4.1). Concentrations of cage oxygen 
(O2) and carbon dioxide (CO2) were measured from every mouse every 17 minutes during the 
two weeks of calorimetry.  To mitigate the effects of stress associated with exposure of mice to a 
new environment, the first 24 hours of data were excluded. Resting energy expenditure (REE; 
kcal/24hr) was defined as the lowest one hour period of energy expenditure during the day; this 
value was extrapolated to 24 hours.  This value was taken instead of the lowest period in 24 
hours because, for the CR mice, the 24 hour nadir occurred during nocturnal torpor [9] which 
depressed the REE.  Torpor suppression of energy expenditure in CR mice was calculated by 
subtracting the lowest one hour period of energy expenditure during the night from the REE and 
multiplying it by the percent of time the mouse spent in torpor during any given 24 hour period.  
Non-resting energy expenditure (NREE; kcal/24hr) was calculated by subtracting REE from 
TEE and adding torpor suppression (for mice that entered torpor) (NREECR = TEE – REE + 
Torpor suppression; NREE=TEE-REE when no torpor).   
Physical activity was determined with an infrared beam system integrated with the TSE 
LabMaster system. Total activity (number of infrared beam breaks) in X, Y, and Z axis was 
recorded in 17 minute time intervals and a corresponding TEE was measured at the end of each 
interval. To assess the instantaneous TEE as a function of activity, every reading for every 
mouse was categorized as occurring during the day (between 7am and 7pm) or night (between 
7pm and 7am) and then combined by group (AL, CR, or POST CR). To determine if energy 
expenditure was conserved at a given activity level in the groups, each group was sorted by day 
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[0700-1900] and night [1900-0700] from lowest to highest activity [beam breaks] with 
contemporaneously measured TEE.  Measured TEE and beam breaks were assigned to bins of 
100 beam breaks.  Means and standard deviations of both activity and TEE were determined for 
each bin.   
Average weekly energy expenditure after release from calorie restriction until the body weight of 
CR mice recovered to AL levels was calculated for individual mice per mean value for each cage 
using the energy balance equation: TEE = FI − (Δ somatic Fat Energy + Δ somatic Fat−Free 
Energy) [13]. Weekly food intake and weekly change in fat and lean mass were used in the 
calculation.   
 Statistical analysis 
Data are expressed as means ± SEM. Statistical analysis was performed using GraphPad PRISM 
software. Student t-tests (2-tailed) were conducted to compare AL and CR groups.  P alpha < 
0.05 was taken as significant. To determine whether the increased energy expenditure efficiency 
in the CR and post-CR state occurred in the dark or light cycle and if they were due to 
differences in physical activity, plots of TEE as a function of movement were made. Regression 
of instantaneous TEE as a function of movement was analyzed by first smoothing the data with a 
Lowess curve (with 5 points per smoothing window) then calculating the difference in TEE 
between the groups followed by a repeated measure one way ANOVA and post hoc Bonferroni's 
multiple comparisons test to determine the difference between the AL and CR (during and post 
CR) curves.   
Several mice were excluded from the analysis. Two mice died during body composition 
measurement (one from each group). One mouse was found dead in its cage (CR group). Four 
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mice (two from each group) were removed from the study because they were not gaining weight 




At baseline (7 week of age) Lepob/ob mice were similar in body weight (Figure 4.2A) and 
consumed the same number of calories per day (Figure 4.2B). One cage of three mice was 
restricted to 1 g of food per day per mouse and lost weight at an average rate of 0.6 g per day, 
these CR mice achieved 20% weight loss in 2 weeks. In parallel, AL mice gained body weight at 
a steady rate of approximately 0.3 g per day, for a total weight gain of 4 g over 2 weeks. CR and 
AL groups had significantly different body weights throughout the calorie restriction phase 
(Figure 4.2A). After release from caloric restriction, CR mice immediately returned to their pre-
CR food intake and never overate relative to the never-restricted control mice (Figure 4.2B). The 
CR group re-gained their lost body weight within 8 days of ad libitum feeding (Figure 4.2A).  
Despite the re-gain of body weight, the CR group had a significantly lower BW compared to AL 
group since the ad libitum mice continued to increase body weight throughout the experiment 
(Figure 4.2A). Mice were allowed to continue eating ad libitum for another 4 weeks. By the end 
of the study, CR mice fully caught up with AL group and did so without any detectable 
difference in food intake. Neither energy expenditure nor body temperature were monitored in 
this pilot study but body weight and food intake data suggest that weight reduced mice had 




Large Cohort Experiment 
Body weight and composition: Upon arrival from JAX at 6 weeks of age the average weight of 
the Lepob/ob male mice was 34.72±0.38 g.  At 8 weeks of age, Lepob/ob mice were assigned to 
either a calorie restriction group (CR, n=15) or ad libitum fed group (AL, n=15) so that the 
groups did not differ in mean body weight (AL: 42.19±0.6 g; CR: 43.30±0.54 g; p = 0.19; Table 
4.1, Figure 4.3A) or body composition (fat mass, AL: 18.54±0.40 g; CR: 19.5±0.30 g, p=0.07; 
and lean mass, AL: 19.69±0.27 g; CR: 20.03±0.22 g, p=0.35; Table 4.1, Figure 4.3C-D). Mice 
were group-housed (3 per cage) therefore food intake was measured on a per cage basis. The 
mean baseline 24h chow intake (3.45 kcal per g) per mouse during the week prior to the start of 
CR was 7.30±0.18 g and 7.51±0.36 g in AL and CR groups, respectively (Table 4.1, Figure 
4.4A). Mice in the CR group were calorie restricted to 1 g of chow per mouse per day and lost 
weight at an average rate of 0.7 g per day; mean weight loss per animal by cage was the same as 
for individual mice. All mice in the CR group reached 20% weight loss within 12 days of CR 
and lost a total of 8.5 g on average. At the same time, AL mice steadily gained body weight at an 
average rate of approximately 0.4 g per day, with a total 4.5 g weight gain over 12 days. After 
the first day of CR, body weight was significantly lower in the CR mice compared to AL mice 
(AL: 42.70±0.62 g; CR: 40.23±0.47 g; p = 0.0047; Figure 4.3A) and remained significantly 
lower throughout the calorie restriction phase. Upon reaching 20% weight loss, body weight of 
CR group was 34.75±0.43 g compared to 46.73±0.80 g in AL group (Table 4.1, p <0.001). Both 
fat mass and lean mass were significantly decreased in CR mice compared to AL (fat mass, AL: 
22.03±0.48 g; CR: 15.37±0.23 g, p<0.001; lean mass, AL: 20.87±0.24 g; CR: 15.37±0.32 g, 
Table 4.1, p<0.001). At 10 weeks of age, CR mice entered the body weight stabilization phase to 
maintain reduced body weight for two weeks. Food intake in the CR group during this phase was 
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titrated up from 1 g per day per mouse to 1.5-2.5 g per day with individual body weight and trio 
food intake monitored daily and appropriate food intake adjustments made to maintain the body 
weight of CR mice at 80% of their initial weight. Average 24h food intake of AL group mice at 
10 weeks of age was 6.58±0.27 g (Table 4.1, Figure 4.4A). 
At 11 weeks (Figure 4.1) of age ad libitum fed controls and CR mice were placed individually in 
metabolic cages. At 12 weeks of age CR mice were released from calorie restriction and allowed 
to eat ad libitum. Mice in the CR group re-gained their lost body weight within 8 days of ad 
libitum feeding (CR: 43.19±0.71 g; Figure 4.3A). Despite the re-gain of their body weight, CR 
group had a significantly lower BW compared to AL group since the AL mice continued 
increasing body weight throughout time the CR mice were  calorie restricted (AL: 50.60±1.04 g; 
p<0.001; Figure 4.3A). It took CR mice another 5 weeks of ad libitum feeding to achieve body 
weights not significantly different from AL mice (age 18 weeks; AL: 60.18±0.95 g; CR: 
57.55±0.91 g; p = 0.058; Table 4.1, Figure 4.3A). Lean mass in CR group was regained sooner 
than body weight and fat mass. One week after release from caloric restriction, CR group mice 
regained most of their lean mass (AL: 20.36±0.26 g; CR: 19.33±0.41 g, p=0.04) but were still 
significantly lower in lean mass than AL group. At 16 weeks of age the difference in lean mass 
between CR and AL groups was no longer significant (lean mass, AL: 24.07±0.20 g; CR: 
24.66±0.27 g; p = 0.087; Figure 4.3D). Fat mass in CR group did not differ from AL group 6 
weeks after release from calorie restriction (age 18 weeks; fat mass, AL: 29.52±1.04 g; CR: 
27.87±0.47 g; p = 0.12; Table 4.1, Figure 4.3C).  
Mice were allowed to continue eating ad libitum for another 2.5 weeks before they were 
sacrificed at 21 weeks of age, reaching final weights of 62.54±0.97 g and 60.64±0.92 g in AL 
and CR groups (p=0.17), respectively.   
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Food intake: The mean baseline 24h food intake per mouse at 8 weeks of age (prior to start of 
CR) was 7.30±0.18 g and 7.51±0.36 g in AL and CR groups, respectively. During caloric 
restriction phase mice in CR group were provided with an average of 1 g of chow per day until at 
target weight and then food intake was titrated up to an average of 1.5-2.5 g per day per animal 
during reduced weight maintenance phase. At 11 weeks of age, during the last week of the 
weight maintenance phase, all mice were placed individually in metabolic cages to assess their 
energy expenditure for two weeks. The mean 24 hour food intake during the first week after 
release from caloric restriction was 5.10±0.36 g and 5.46±0.35 g in AL and CR groups, 
respectively (p=0.50; Figure 4.4A). Food intake was monitored daily until the end of the study 
(when mice reached 21 weeks of age) and was not different between AL and CR groups (Figure 
4.4A-B). Over the 9 week period following the release of CR mice to ad libitum feeding (until 
the end of the study) cumulative food intake calculated for each group was 338.75±9.99 g and 
335.86±7.40 g in AL and CR groups, respectively (p=0.83; Figure 4.4B). Despite the difference 
in weight gained over this 9 week period (14.10 g in AL vs  26.92 g in POST CR), formerly 
calorie restricted mice did not increase their food intake relative to the control animals, 
suggesting that the CR animals re-gained weight  solely as a result of their reduced energy 
expenditure in part due to their smaller size. Interestingly, for both groups, the amount of food 
ingested was inversely correlated to their age and weight. The mean 24h food intake at the 
beginning of the study, when mice were 8 weeks of age, was 7.41±0.20 g compared to 5.05±0.14 
g by the end of the study at 21 weeks of age (p<.001) despite weighing almost 50% more (~62 g 
vs ~43 g) .  
Plasma glucose and insulin concentrations: plasma was obtained from AL and CR mice at 11 
weeks of age, while CR group was weight stable at 80% of initial body weight. Blood was 
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collected in the morning before CR mice were fed (hence an overnight fast) but AL were in the 
fed state. Despite a 14g lower body weight, plasma insulin in CR mice did not differ from the AL 
group (AL: 20.95±5.62 ng/ml; CR: 38.53±7.46 ng/ml; p = 0.07, Figure 4.4C). Plasma glucose 
was significantly lower in CR compared to AL group (AL: 332.6±39.21 mg/dl; CR: 149.5±26.50 
mg/dl; p <0.001) – consistent with their feeding status (Figure 4.4D). Unlike mice with intact 
leptin axis [14, 15], leptin-deficient mice showed no correlation between fat mass and plasma 
insulin concentration in both the reduced weight and ad libitum fed states (Figure 4.4E).  
Body temperature: 24 hour core body temperature was measured every 3 hours for 24 hours 
during the initial weight maintenance phase. AL mice maintained their body temperature 
between 32.8°C and 36.8°C with the lowest temperatures measured between 9am and 12pm. CR 
group maintained their body temperature within normal range during the day between 9 am and 
9 pm. Between 9 pm and 6 am CR mice dropped their body temperature significantly; the lowest 
temperature recorded was 28.2°C at 6 am a few hours before the morning feeding (compared to 
34.8°C in AL group, p<0.001; Figure 4.5).  
Energy expenditure: Mice were placed in metabolic cages during reduced weight maintenance 
phase to measure their energy expenditure for one week while still calorically restricted. They 
were then released to ad libitum feeding to compare energy expenditure during the body weight 
regain phase. During the reduced weight maintenance phase, absolute mean 24h total energy 
expenditure (TEE) was 36% lower in CR group compared to AL (AL: 10.10±0.20 kcal/24h; CR: 
6.42±0.31 kcal/24h; p < 0.001; Figure 4.6A). Decreased TEE was accounted for by nocturnal 
periods of torpor in addition to decreased resting and non-resting energy expenditure (Figure 
4.6A). In wild type mice, we have defined resting energy expenditure (REE) as the lowest one 
hour period of energy expenditure during each 24h period [6]. However, periods of torpor should 
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not be included in estimates of REE. To address this problem, in calorie-restricted Lepob/ob mice, 
we defined REE as the lowest one hour period of energy expenditure during the day (mice did 
not enter torpor during daytime). Absolute resting energy expenditure (REE) during reduced 
weight maintenance phase was decreased by 39% in CR compared to AL group (AL: 6.94±0.12 
kcal/24h; CR: 4.26±0.17 kcal/24h; p < 0.001; Figure 4.6A); NREE was 18% lower in CR mice 
than in AL (AL: 3.16±0.15 kcal/24h; CR: 2.59±0.17 kcal/24h; p < 0.05; Figure 4.6A); 
additionally, CR mice conserved 0.43 kcal/24h by entering torpor. NREE was decreased in CR 
mice despite significantly higher total activity compared to AL mice (AL: 26,433±3,358 beam 
breaks per 24 hours; CR: 66,844±8,754 beam breaks per 24 hours; p < 0.001; Figure 4.6B). The 
regression of instantaneous TEE as a function of movement (individual mouse total activity 
during the period that was used for the TEE calculation) shows that this movement was achieved 
at lower energy cost (i.e. mice were more energetically efficient) during calorie restriction than 
in the AL group; this was true during both day and night (Figure 4.6C-D). CR mice were more 
active than AL mice during the day but were comparably active at night. The decreased body 
temperature and total activity at night suggests that CR mice entered torpor but had increased 
activity during the day, likely due to increased food seeking behavior. 
Energy expenditure was also measured for 6 days after the CR group was released to ad libitum 
feeding and entered the body weight re-gain phase.  The TSE indirect calorimetry system uses 
the Weir’s equation to calculate the heat production from the volume of O2 consumed and CO2 
produced which assumes that the respiratory exchange ratio (RER) of animals is  between 0.7 
and 1.0 [16]. During the body weight re-gain phase, the CR mice were actively gaining muscle 
and fat; their RER at that time was above 1, consistent with their anabolic state (1.03 on average 
but 1.05 at night). As a result of RER being outside of range for the Weir equations heat 
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estimate, the TEE obtained from the TSE system is inaccurate. Therefore, we calculated the 
mean total energy expenditure for individual mice using energy balance equation [TEE= FI − (Δ 
somatic Fat Energy + Δ somatic Fat−Free Energy)] [13]  in AL and CR mice in the 5 weeks 
following release from caloric restriction until the CR group regained lost weight (Figure 4.7A). 
Using this method, TEE in CR mice was significantly lower than in the AL group during the 2nd 
week post release from CR (Figure 4.7A). Results were similar when average energy 
expenditure was calculated on a per cage basis (average of 3 mice per cage).  
In addition, the regression of TEE as a function of movement (total activity) shows that, after CR 
mice were released to ad libitum feeding, they were still significantly more efficient with regard 
to the energy cost of motion than AL mice but this increased efficiency was apparent only during 
the dark phase (Figure 4.6C-D). The total activity increase found in the CR compared to the AL 
mice persisted despite ad libitum access to food (AL: 327.2±47.0 beam breaks; CR: 622.6±46.0 
beam breaks; p < 0.001; Figure 4.6C).  
Respiratory exchange ratio (RER or RQ) fluctuates throughout the day but the amplitude was 
more pronounced in the CR state compared to AL (Figure 4.7B). The 24 hour RER of the 
weight stable CR mice was equal to the diet quotient of the chow (both 0.89).  At night, when 
AL mice primarily eat, the RER was elevated and it fell significantly during the day when mice 
eat less.  In the CR state, mice ingest their food rapidly after the twice-daily feeding. This pattern 
of feeding imposes on these animals extended periods of fasting, leading to reduced RER both 
during the day and the night compared to the AL mice (Figure 4.7B-D). RER increased 
dramatically when the CR mice were released from caloric restriction; the POST CR mice had 
consistently higher RER at every time point (Figure 4.7B-D). 
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In the Lepob/ob mice at reduced weight and during ad libitum re-feeding there was no correlation 
between total or resting energy expenditure and lean mass, fat mass, or both combined over the 
ranges observed (Figure 4.8).  In humans and rodents with an intact leptin axis, energy 
expenditure is highly correlated with metabolic mass [6].  
 
Discussion   
 In humans and rodents with intact leptin signaling, weight reduction imposed by caloric 
restriction reduces energy expenditure more than predicted by remaining metabolic mass [4, 6, 8, 
9, 17]. We find that this response is significantly amplified in leptin-deficient mice. The TEE of 
weight-reduced Lepob/ob mice in this study was almost 40% lower than the ad libitum fed mice. 
These effects were conveyed by reductions in REE (approximately 73% of the reduction), 
enhanced efficiency of motion (about 16%), and periods of torpor (about 12%). About 50 % of 
energy expenditure of a mouse maintained at room temperature of 22-24°C is used to maintain 
body temperature [9]. Under conditions of restricted access to food, Lepob/ob mice dramatically 
lower their body temperature at night and enter torpor; energy expenditure in CR mice was 39% 
less than in ad libitum fed controls. In comparison, diet induced obese wild type mice reduce 
resting energy expenditure by 25% when calorie restricted [9]. In wild type mice, circulating 
leptin follows a circadian rhythm that peaks in the middle of the night [18] and this peak 
coincides with the trough in body temperature that was detected in the CR Lepob/ob mouse.  
Like Lepob/ob mice, the A-ZIP/F1 mice have greatly reduced circulating leptin and enter torpor 
when fasted [19]. But, unlike Lepob/ob mice, the leptin deficiency of A-ZIP/F1 mice is due to 
absence of white adipose tissue. Administration of leptin prevents fasting- induced torpor and 
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hypothermia in Lepob/ob mice [20],  but not in A-ZIP/F1 mice, suggesting that, in addition to low 
leptin, torpor in mice may be dependent on  adipose signal(s) that are independent of leptin[19].  
In Lepob/ob mice, REE was calculated as the lowest energy expenditure during the day (Lepob/ob 
mice did not enter torpor with the lights on) and torpor suppression is the amount of energy that 
is conserved at night beyond the REE due to torpor-related lowering of body temperature.  
Defining NREE as TEE minus REE plus torpor suppression, the restricted Lepob/ob mice have 
approximately the same NREE as the AL mice, despite 2.5 times greater movement (beam 
breaks).  The increased physical activity persists in the CR mice after they are released to ad 
libitum feeding; we speculate that this persistence is due to increased food seeking behavior. 
 In AL mice, physical activity is highest at night and reduced during the day. CR mice display an 
inverted pattern in which highest activity is during the day while at night they enter torpor and 
show almost no physical activity. Compared to wild type mice, Lepob/ob mice exhibit less 
physical activity. The same TSE system was used to measure physical activity in these studies. 
Lepob/ob consistently moved less than wild type mice fed regular chow ad libitum. As reported 
here, caloric restriction resulted in a significant 2.5 fold increase in physical activity in Lepob/ob 
animals. An increase in movement is also apparent in wild type mice that are food restricted but 
the magnitude of the effect is much smaller (~20%) [6].    
Data in Figure 4.6C-D demonstrate that the CR mice, prior to release, are more energy efficient 
in spontaneous physical activity.  Once released from caloric restriction, this increased efficiency 
is restricted to the lights-off period despite the released mice no longer going into torpor.   
The ad libitum fed previously CR Lepob/ob mice gained weight at a faster rate than the AL mice 
despite no detectable difference in energy intake. The TEE in the formerly restricted mice 
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(estimated using changes in somatic energy content over a 7 day period [21]) was significantly 
lower in CR animals during the second week of ad libitum feeding, but not thereafter.  
Wild type mice are hyperphagic following release from caloric restriction [7, 22]. On the first 
day post restriction – while wild type calorie restricted mice are significantly lighter (-25% body 
weight) than ad libitum fed controls – food intake is almost doubled [7].  This relative 
hyperphagia decreases over the ensuing 7 days, at which point the intake of the weight-reduced 
animals equals that of the controls [7]. In study of Lepob/ob mice reported here, food intake in the 
immediate post restriction period was identical in the released mice and the never-restricted AL 
groups despite the increased food seeking behavior of the formerly restricted mice. Figure 4.4 
shows that total food intake does not increase as Lepob/ob mice age and gain weight.  
Additionally, Figure 4.8 demonstrates that there is no correlation between somatic mass and 
energy expenditure in either the CR or the AL state in Lepob/ob animals over the range of this 
study. Since there is no relationship between mass and energy expenditure in Lepob/ob animals, 
CR mice, released to ad libitum feeding, should have gained weight at the same rate as the never-
restricted mice unless there is an increase in energy efficiency that persists after release. The 
absence of post-restriction hyperphagia is not due to mice reaching their physical (e.g. stomach 
capacity) maximum daily energy intake since the same mice ate greater amounts earlier in the 
study (7.51 ± 0.36 g per day at 8 weeks of age vs. 5.46 ± 0.35 g per day at 13 weeks of age after 
release from restriction; p<0.01). Another argument against Lepob/ob mice having reached a 
physical maximum of food intake is that Lepob/ob mice are capable of further increasing food 
intake when suitably provoked.  For example, the FAT-ATTAC transgenic mouse segregates for 
a myristoylated caspase 8-FKBP fusion protein enabling adipocyte apoptosis to be induced by 
administration of a chemical dimerizer for 1-2 weeks [23].  Lepob/ob mice segregating for this 
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transgene, following administration of the dimerizer,  increase daily food intake of chow from 5 
g to 9 g  (6 weeks of treatment) [23].  
As extensively discussed in literature, expressing food intake in terms of calories per gram of 
body weight is problematic especially when the animals being compared differ significantly in 
body mass. For example, normalizing food intake of a Lepob/ob mouse to body weight would 
suggest that such mouse is hypophagic relative to a wild type mouse [24]. Others have 
recommended that energy intake be analyzed by multivariate regression [25, 26]; or that both 
energy intake and expenditure be normalized using the same method [27, 28]. In the AL Lepob/ob 
group, food intake at 8, 9, and 10 weeks of age was significantly higher than food intake at the 
end of the study when mice were 21 weeks old and 20 grams heavier. This observation further 
supports the inference that food intake should not be normalized to body weight in these mice 
over the body weight ranges in this study. Energy intake and expenditure in the AL group 
decreased gradually from 8 to 12 weeks of age and appeared to stabilize after week 12; higher 
energy expenditure in Lepob/ob mice during this time may be related to maximal growth rate 
during this time.  Despite the mice having 35% more mass at 21 weeks, there was no increase in 
calorie intake after 12 weeks of age; there was no correlation between energy expenditure and 
fat, lean, or total mass in any of the groups of leptin deficient mice over the range measured.  In 
aggregate, these data suggest that leptin is required for the regulation of energy intake, but is not 
essential for regulation of energy expenditure.    
Lepob/ob mice develop without exposure to leptin leading to congenital neuronal alterations [29, 
30]. Compensatory pathways could develop as a result of congenital leptin deficiency and this 
leads to an important caveat that the responses to the weight perturbations reported here may be 
unique to these animals. 
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Kaiyala et al. reported that Lepob/ob mice adjust energy expenditure but not food intake in 
response to changes in ambient temperature [31]. In contrast, wild type mice increase food intake 
when ambient temperature is decreased and reduce energy intake under thermoneutral 
conditions. In addition, wild type mice display a strong inverse relationship between ambient 
temperature and energy expenditure [31]. These data are consistent with our finding that Lepob/ob 
mice reduce energy expenditure but do not increase food intake in response to imposed weight 
reduction.  
The CR Lepob/ob regained most of their lean mass within one week of release to ad libitum 
feeding, probably due to rehydrating of the muscle, whereas their fat mass took several weeks to 
reach the level of AL group. Mice regained lost lean mass quickly but did not exceed the amount 
of lean mass in the AL mice.  Hambly et al. reported body composition of wild type mice post 
release from caloric restriction; like our Lepob/ob, following release wild type mice regained lean 
mass more rapidly than the fat mass [7].  Both of these rapid recoveries in lean mass are likely 
due to both the rehydrating of muscle and the lower energy demand to gain 1 g of lean mass 
compared to gaining 1 g of adipose tissue.  
The CR mice displayed a decline in RER reflecting an appropriate reliance on fat stores for 
provision of metabolic need, and indicating that leptin is not required for this important 
metabolic accommodation.  
Lepob/ob mice utilize energy in an age dependent but an apparent/composition mass (lean, fat or 
both) independent manner over the range of body mass/composition studied here.  Unlike 
humans [4] or mice with intact leptin axis [6] figure 4.8 indicates there is no apparent 
relationship between energy expenditure and fat, lean, or a combination of both in our Lepob/ob 
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mice.  Energy expenditure in Lepob/ob mice is only dependent on the feeding status of the mice; 
CR mice use significantly fewer calories than the AL controls but within either the CR or AL 
groups, in the size range that we observed, they use a non-detectably different number of calories 
regardless of size.  Max Kleiber showed that across a wide range of body sizes, energy 
expenditure scales to the 3/4th power of body mass [32]. In Lepobob mice, over the size range 
studied, this relationship is not apparent due to methodological limitations.  Using a multivariate 
regression model for 24h energy expenditure, Kaiyala et al. found that in leptin-deficient mice 
lean and fat mass were not significant contributors to variation in energy expenditure [20]. 
However, when leptin was administered to Lepob/ob mice, lean mass became an independent 
predictor of EE, suggesting that leptin is necessary to render the positive relationship between 
lean mass and EE detectable.  Weight-reduced humans and rodents exhibit hypometabolism 
resulting from – at least in part – relative leptin insufficiency due to lost body fat [4, 6, 8].  This 
decrease in energy expenditure is due in part to increased skeletal muscle work efficiency and 
can be reversed with administration of physiological (“replacement”) doses of leptin [8, 33], 
further suggesting a role for leptin in the slope of the correlation between lean mass and EE.  In 
the studies reported here, the lower energy expenditure in calorically restricted Lepob/ob mice is 
driven by a combination of torpor, a dramatic decrease in REE, and a decrease in NREE.  In 
weight- reduced leptin-deficient mice the increased energy efficiency is more pronounced than in 
a weight reduced wild type mouse.  
Insulin, in addition to its critical role in glucose homeostasis, is a known regulator of food intake 
and adiposity [34]. In leptin competent humans and mice, circulating insulin concentrations 
correlate directly with body weight and adiposity. However, in mice that lack leptin, this 
relationship is interrupted. [35-37]. Several experiments provide evidence of a direct regulation 
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of insulin secretion by leptin. Leptin administration suppresses beta cell insulin release, and 
reduces preproinsulin mRNA in multiple models including islets isolated from Lepob/ob mice [38, 
39], rats [40] and humans [40, 41] and a rat pancreatic β-cell line [42]. Administration of 
exogenous leptin to Lepob/ob mice decreases circulating insulin and fasting plasma glucose 
concentrations even at doses that do not induce reductions in body weight [43]. Similarly, in 
mouse models of lipodystrophy – characterized by severe hypoleptinemia and hyperinsulinemia 
– treatment with low doses of recombinant leptin significantly improved insulin sensitivity [44, 
45]; chronic food restriction does not normalize circulating insulin concentrations in these mice 
[44, 45].  These data suggest that in lipodystrophic mice leptin modulates insulin sensitivity and 
glucose homeostasis independently of either food intake or body weight. Evidence from mouse 
models of Congenital Generalized Lipodystrophy (CGL) support the role of leptin deficiency in 
the insulin resistance found in this condition [44, 45]. As reported here, (and in leptin receptor-
deficient fa/fa rats [46]), ad libitum fed Lepob/ob mice have elevated circulating insulin 
concentrations that are not normalized by caloric restriction. Hyperinsulinemia in AL Lepob/ob 
mice is not corrected by reducing fat mass (Figure 4.4D). The absence of circulating leptin in 
Lepob/ob mice is accompanied by a loss of the normal (Figure 4.4E) relationship between fat 
mass and circulating insulin.       
In this study, Lepob/ob mice weight reduced by transient caloric restriction regained lost weight to 
the level of ad libitum controls. They did so by reduced energy expenditure; unlike wild type 
mice, there was no compensatory relative hyperphagia.  Their reacquisition of lost body fat 
suggests that factors other than leptin are involved in regulating body weight of the Lepob/ob 
mouse. The adiposity “set point” in the Lepob/ob mouse is apparently higher than that of a wild 
type mouse, and this higher level is defended when the mouse is challenged with caloric 
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restriction.  Other circulating and/or neural factors inform the CNS about aspects of energy 
intake and somatic energy stores. Some of these have their predominant effects on either energy 
intake (insulin, ghrelin, CCK, GLP-1, PYY) or expenditure (thyroid hormone). Others almost 
certainly exist [47].  For example, when a wild type mouse is parabiosed to a leptin receptor 
deficient mouse (Lepdb/db) with high (but adipose mass-appropriate) circulating concentrations of 
leptin the wild type mouse starves to death [48, 49].  However, administering a similar amount of 
leptin to a wild type mouse only transiently reduces food intake and the animal does not starve 
[50]. These results support the possible existence of another circulating factor – a starvation 
signal – that is present in a Lepdb/db because the mouse is unable to properly sense its energy 
stores. Such a signal might account for the hypometabolic response of the Lepob/ob mouse to 
















Figure 4-1  Study Design Schematic. 
After a two week acclimation period, at 8 weeks of age, half of the mice were assigned to the 
control group and fed ad libitum chow; the other half were calorie restricted to achieve 80% of 
initial body weight.  After achieving 20% weight loss (approximately 2 weeks), the CR Lepob/ob 
mice were stabilized at 80% of initial body weight for two weeks and then released from food 










































Table 4-1  Body weight, body composition, and food intake of AL and CR mice. 
Mean body weight, fat mass, lean mass and food intake with SEM at baseline (8 weeks of age), 
during calorie restriction (10 weeks of age) and after CR group re-gained body weight (18.5 
weeks of age; fat mass, lean mass and food intake measured at 18 weeks of age) in mice fed ad 
libitum throughout the study (AL) and mice calorically restricted to 80% of initial body weight 
then released to ad libitum feeding (CR).   
  
Baseline (8 wks old) During CR (10 wks old) BW regained (18-18.5 wks old)
AL CR p-value AL CR p-value AL CR p-value
Body weight (g) 42.19±0.60 43.3±0.54 0.19 46.73±0.80 34.75±0.43 <0.001 60.18±0.95 57.55±0.91 0.06
Fat mass (g) 18.54±0.40 19.50±0.30 0.07 22.03±0.48 15.37±0.23 <0.001 29.52±1.04 27.87±0.47 0.12
Lean mass (g) 19.69±0.27 20.03±0.22 0.35 20.87±0.24 15.37±0.32 <0.001 26.13±1.19 26.16±0.32 0.98


















Figure 4-2  Body weight and food intake of AL and CR mice in a pilot study. 
(A) Mean body weight ±SEM (g) and (B) Mean 24h food intake in mice fed ad libitum 
throughout the study (AL) and mice calorically restricted to 80% of initial body weight then 
released to ad libitum feeding. P values: *<0.05, **<0.01.  
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Figure 4-3  Body weight and composition of AL and CR mice. 
(A) Mean body weight, (B) body weight gain, (C) fat mass, (D) lean mass ±SEM (g) in mice fed 
ad libitum throughout the study (AL, n=13) and mice calorically restricted (CR, n=13) to 80% of 
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Figure 4-4  Food intake, plasma glucose and insulin in CR and AL mice. 
(A) Mean 24h food intake ±SEM (g) and (B) Cumulative food intake over 8 weeks of body 
weight re-gain in mice fed ad libitum chow throughout the study (AL, n=5) and mice calorically 
restricted (n=5) to 80% of initial body weight then released to ad libitum feeding. (C) Mean 
glucose and (D) insulin ±SEM in ad libitum fed (AL, n=13) or calorically restricted (CR, n=12) 
mice measured at 12 weeks of age while CR mice were calorically restricted to maintain 80% of 
initial body weight. (E) Regression of circulating insulin concentrations against fat mass in the 
AL (n=13) and CR (n=12) groups of mice at 11 weeks of age while CR were weight stable at the 























Figure 4-5  Body temperature of AL and CR mice. 
Body temperature of mice fed ad libitum chow throughout the study (AL, n=10) and mice 
calorically restricted to 80% of initial body weight (CR, n=13) measured during the weight 

































































Figure 4-6  Energy expenditure and activity of AL and CR mice. 
(A) Energy expenditure during calorie restriction in mice fed ad libitum chow throughout the 
study (AL) and mice calorically restricted to 80% of initial body weight (CR). Energy 
expenditure during calorie restriction was measured in the TSE metabolic chambers. Included 
are the following: TEE – total energy expenditure, REE – resting energy expenditure, NREE – 
non resting energy expenditure and torpor suppression. (B) Physical activity in AL and CR mice 
during CR and after release to ad libitum feeding. Activity was measured in the TSE system. 
Regression of instantaneous TEE as a function of movement (C) during the day and (D) at night 
in mice fed ad libitum chow throughout the study (AL), mice calorically restricted to 80% of 
initial body weight (CR) and the CR group after release to ad libitum feeding. N in each group: 
AL, n= 10; CR, n=12. P values: *<0.05, ***<0.001.  
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Figure 4-7 Total energy expenditure and respiratory exchange ratio. 
(A) Total energy expenditure after release from calorie restriction in mice fed ad libitum chow 
throughout the study (AL) and calorically restricted (CR) mice. TEE post-restriction was 
calculated using the energy balance equation: TEE= FI − (Δ somatic Fat Energy + Δ somatic 
Fat−Free Energy). (B) average respiratory exchange ratio (RER) measured at each time interval 
and (C) average 24-hour RER during the day and (D) and at night during and post calorie 
restriction in mice fed ad libitum chow throughout the study (AL) and mice calorically restricted 
then released to ad libitum feeding. N in each group: AL, n= 10; CR, n=12. P values: **<0.01, 
***<0.001. 
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Figure 4-8 Correlations of energy expenditure with body composition in AL and CR mice. 
Regression of (A,C) lean mass and (B, D) fat mass against (A, B) total and (C, D) resting energy 
expenditure in the AL and CR groups of mice during the weight maintenance segment of the CR 
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Abstract 
Leptin is an adipocyte-secreted hormone, the circulating levels of which correlate closely with 
overall adiposity. Although rare mutations in the leptin (LEP) gene are well known to cause 
leptin deficiency and severe obesity, no common loci regulating circulating leptin levels have 
been uncovered. Therefore, we performed a genome-wide association study (GWAS) of 
circulating leptin levels from 32,161 individuals and followed up loci reaching P<10−6 in 19,979 
additional individuals. We identify five loci robustly associated (P<5 × 10−8) with leptin levels 
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in/near LEP, SLC32A1, GCKR, CCNL1 and FTO. Although the association of the FTO obesity 
locus with leptin levels is abolished by adjustment for BMI, associations of the four other loci 
are independent of adiposity. The GCKR locus was found associated with multiple metabolic 
traits in previous GWAS and the CCNL1 locus with birth weight. Knockdown experiments in 
mouse adipose tissue explants show convincing evidence for adipogenin, a regulator of 
adipocyte differentiation, as the novel causal gene in the SLC32A1 locus influencing leptin 
levels. Our findings provide novel insights into the regulation of leptin production by adipose 
tissue and open new avenues for examining the influence of variation in leptin levels on 
adiposity and metabolic health. 
 
Introduction 
Leptin is an adipocyte-secreted hormone that influences long-term regulation of energy 
homeostasis by informing the brain about the amount of stored body fat1,2. Circulating leptin 
levels correlate closely with measures of adiposity, such as body fat mass and body mass index 
(BMI)3. Yet, at any given level of adiposity, there is substantial variation in circulating leptin 
levels4, of which estimated 30–50% is explained by genetic factors5,6,7. 
Rare homozygous loss-of-function mutations in the leptin-encoding gene (LEP) cause leptin 
deficiency that leads to hyperphagia and severe obesity, which can be corrected by exogenous 
leptin administration8. Leptin-deficient children are born with a normal birth weight but exhibit 
rapid weight gain in the first few months of life. They show marked abnormalities of T-cell 
number and function, and have high rates of childhood infection9. Hypothalamic hypothyroidism 
is present, characterized by a low free thyroxine and high serum thyroid-stimulating hormone 
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levels10. Pubertal development generally does not occur due to hypogonadotropic 
hypogonadism10. Individuals heterozygous for leptin mutations exhibit a partial leptin deficiency 
with higher body fat than control individuals11. 
Candidate gene studies, typically small in size, have reported associations of two common 
variants (A19G (rs2167270, minor allele frequency (MAF) 35%) and G2548A (rs7799039, MAF 
49%)) in the promoter or 5′-untranslated region of LEP with circulating leptin levels in the 
general population, but these results are inconclusive12,13,14,15,16. The same LEP variants have 
been studied for association with obesity, but a meta-analysis of the published results (nA19G=918 
and nG2548A=2,174) found no evidence of such association
17. Candidate gene studies of LEP were 
published before the human genome sequence was extensively characterized and are therefore 
restricted to the variants known at that time. Furthermore, although LEP is an obvious candidate, 
variants in other genes may also influence circulating leptin levels by regulating leptin 
production, secretion, clearance or response. Identification of such leptin-regulating genes could 
provide novel insights into mechanisms that regulate energy homeostasis and neuro-endocrine 
function1,2. 
In this study, we sought to identify genetic loci associated with circulating leptin levels by a 
genome-wide meta-analysis. Given the strong correlation between leptin and adiposity, we also 
examined genome-wide associations with circulating leptin levels adjusted for BMI, to identify 







Study design. We conducted a two-stage meta-analysis to identify leptin-associated loci in adults 
of European ancestry. In stage 1, we performed a meta-analysis of 23 GWAS (n=32,161) 
(Supplementary Table 5.1) for BMI-unadjusted and BMI-adjusted circulating levels of leptin. 
Stage 2 included 13 additional studies (n=19,979), which provided either de novo or in 
silico data for the lead SNPs of the independent loci reaching P<1 × 10−6 in Stage 1 
(Supplementary Table 5.5). Secondary meta-analyses were conducted in men (n=13,363) and 
women (n=18,698) separately, and with adjustment for body fat percentage (assessed by dual-
energy X-ray absorptiometry or bioimpedance analysis) instead of BMI (n=18,980). The study-
specific descriptive statistics are presented in Supplementary Table 5.23. 
Stage 1 genome-wide association analyses. Following study-specific quality control measures, 
the genotype data were imputed using the HapMap Phase II CEU reference panel 
(Supplementary Table 5.24). Directly genotyped and imputed variants were then tested for 
association with logarithmically transformed leptin (ng ml−1), adjusting for age, age2 and any 
necessary study-specific covariates (for example, genotype-derived principal components) in a 
linear regression model. The analyses were performed with and without additional adjustment 
for BMI. In studies that had assessed body fat percentage with bioimpedance analysis or dual-
energy X-ray absorptiometry, additional analyses were performed with adjustment for body fat 
percentage. The analyses were performed in men and women separately. In studies that included 
closely related individuals, regression coefficients were also estimated in the context of a 




Before performing meta-analyses on the data from individual studies, SNPs with poor imputation 
quality scores (r2-hat <0.3 in MACH, proper-info <0.4 in IMPUTE, INFO <0.8 in PLINK) or 
with a minor allele count <6 were excluded for each study (Supplementary Table 5.24). The 
genotype data for the leptin-associated lead SNPs was of high quality with a median imputation 
score of ≥0.94 (Supplementary Table 5.26). The fifth percentile for all SNPs was ≥0.80, except 
for the previously established rs900400 SNP near CCNL1. 
All individual GWAS were genomic control corrected before meta-analyses. Individual study-
specific genomic control values ranged from 0.977 to 1.051. Fixed effects meta-analyses were 
then conducted using the inverse variance-weighted method implemented in METAL. The 
genomic control values for the meta-analysed results were 1.050, 1.026 and 1.022 in the BMI-
unadjusted meta-analyses of all individuals, men and women, and 1.046, 1.022 and 1.015 in the 
BMI-adjusted meta-analyses, respectively. Using the LD score regression method67 in the Stage 
1 meta-analyses suggests that the observed inflation is not due to population substructure. The 
regression intercept, which estimates inflation after removing polygenic signals, was 0.994 for 
BMI-unadjusted and 1.004 for BMI-adjusted meta-analyses of men and women combined. 
Selection of SNPs for follow-up. We used a pairwise distance criterion of ±500 kb and r2<0.1 
between SNPs that reached P<10−6in the meta-analysis of BMI-adjusted or -unadjusted meta-
analysis of leptin levels in Stage 1 in men and women combined or separately, to select loci 
forward for follow-up in Stage 2. We tested the association of the lead SNPs in up to 19,929 
adults of white European ancestry in Stage 2. 
Stage 2 follow-up of the loci reaching P<10−6 in Stage 1. Association results were obtained from 
13 studies that had not been included in the Stage 1 meta-analyses (Supplementary Table 5.5). 
Samples and SNPs that did not meet the quality control criteria defined by each individual study 
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were excluded. Minimum genotyping quality control criteria were defined as Hardy–Weinberg 
equilibrium P>10−7, call rate >90% and concordance >99% in duplicate samples in each of the 
follow-up studies. 
We tested the association between the SNPs and leptin in each Stage 2 study using approaches 
similar to those described for the Stage 1 studies. We subsequently performed a meta-analysis 
of β-coefficients and s.e. from Stage 2 using the inverse variance fixed effects method. The final 
meta-analysis combined GWAS results from Stage 1 with the Stage 2 results. The 
conventional P-value threshold of <5 × 10−8 in the combined Stage 1 and Stage 2 meta-analysis 
was used to determine genome-wide significance. 
Identifying genes and biological pathways at associated loci 
Cross-trait look-ups. To further examine the relationship between the leptin-associated loci and 
anthropometric and metabolic parameters, we acquired association results for the loci in or 
near LEP, SLC32A1, GCKR, CCNL1 and COBLL1 from nine GWAS meta-analysis consortia: 
ADIPOGen (BMI-adjusted adiponectin), BCGC (body fat percentage), DIAGRAM (type 2 
diabetes), Early growth genetics (birth weight, early-onset obesity), ICBP (systolic and diastolic 
blood pressure), GIANT (height, BMI, waist–hip ratio adjusted for BMI), GLGC (circulating 
levels of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides 
and total cholesterol), MAGIC (fasting glucose, fasting insulin) and ReproGen (age at menarche) 
(Supplementary Table 5.7). 
National Human Genome Research Institute GWAS Catalog look-ups. To identify the 
associations of the leptin-associated loci in published GWAS, we extracted previously reported 
GWAS associations within 500 kb and r2>0.7 with any of the lead leptin-associated SNPs, from 
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the GWAS Catalog of the National Human Genome Research Institute 
( www.genome.gov/gwastudies) (Supplementary Table 5.11). 
Overlap with functional regulatory elements. We used the Uncovering Enrichment Through 
Simulation method to combine the leptin association data with the Roadmap Epigenomics 
Project segmentation data54. The pipeline chose 10,000 sets of random SNPs among HapMap2 
SNPs with a MAF>0.05 and that matched the original input SNPs based on proximity to a 
transcription start site and the number of LD partners (r2>0.8 in individuals of European ancestry 
in the 1000 Genomes Project). The LD partners were combined with their original lead SNP to 
create 10,000 sets of matched random SNPs and their respective LD partners. These sets were 
intersected with the 15-state ChromHMM data from the Roadmap Epigenomics Project and 
resultant co-localizations were collapsed from total SNPs down to loci, which were then used to 
calculate an empirical P-value when comparing the original SNPs with the random sets. In 
addition to examining overall enrichment for all leptin-associated loci combined, we examined 
the variant-specific overlap with regulatory elements for each of the leptin-associated index 
SNPs and variants in strong LD (r2>0.8). 
Expression quantitative trait loci. We examined the cis-associations of the leptin-associated loci 
with the expression of nearby genes in the lymphocytes, skin, liver, omental fat, subcutaneous fat 
and brain tissue (Supplementary Table 5.8). Conditional analyses were performed by including 
both the leptin-associated SNP and the most significant cis-associated SNP in the association 
model for a given transcript. To minimize the potential for false positives, we only considered 
associations that reached study-specific Bonferroni-corrected significance threshold 




GRAIL analyses: We used GRAIL to identify genes near the leptin-associated loci having 
similarities in the published scientific text using PubMed abstracts as of December 2006 (ref. 53). 
The leptin loci were queried against HapMap release 22 for the European panel and we 
controlled for gene size. 
DEPICT analyses: We used DEPICT to identify the most probable causal gene at a given 
associated locus, reconstituted gene sets enriched for BMI associations, and tissues and cell types 
in which genes from associated loci are highly expressed52. We clumped GWAS-based meta-
analysis summary statistics using 500 kb flanking regions, LD r2>0.1 and excluded SNPs 
with P≥1 × 10−5. HapMap Project Phase II CEU genotype data were used to compute LD and 
genomic coordinates were defined by genome build GRCh37. 
Knockdown of genes in mouse adipose tissue explants 
Materials. Expression analyses were performed on PGAT and SCAT from 4-month-old 
C57BL/6J mice (derived from Jackson, Stock number 000664) fed chow (Purina PicoLab 5058) 
or high-fat diet (Research Diets, Inc., D12492i, 60% kcal from fat), to increase adiposity and 
circulating leptin levels. We measured expression of genes located ±100 kb of each lead variant 
or genes including SNPs with r2>0.4 with the lead variant. Tiparp was included after its 
identification by eQTL analysis, and Ucn and Mpv17 were included based on their proximity to 
variants with r2>0.4 with the lead variant. 
For knockdown experiments, 15-week-old male C57BL/6J mice fed high-fat diet ad 
libitum starting at 6 weeks of age were purchased from Jackson Laboratory (Stock Number 
380050, Bar Harbor, ME). Animals were maintained at Columbia University animal facility for 
up to an additional 5 weeks until they reached ∼30% fat mass as determined by time-domain 
NMR (Minispec Analyst AD; Bruker Optics, Silberstreifen, Germany). 
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Mice were maintained at an ambient temperature of 22 °C–24 °C with a 12-h dark–light cycle 
(lights on at 0700, h) in a pathogen-free barrier facility. The protocol was approved by the 
Columbia University Institutional Animal Care and Use Committee. 
Electroporation and culture of adipose tissue explants. Non-fasted mice were killed at around 20 
weeks of age at ∼1000, h. PGAT was dissected and minced into 1- to 2-mm fragments. These 
fragments were evenly distributed into three replicates per control or knockdown condition. 
Approximately 7–11 fragments were added per well (for a total amount of ∼80 mg tissue) in 12-
well culture dishes containing 1 ml M199 with Antibiotic-Antimycotic (Anti-Anti, 5 × ; 
Invitrogen). Following a 20-min incubation in 5 × Anti-Anti media, tissue fragments were 
washed twice with 1 ml PBS and then transferred to 4 mm Gene Pulser cuvettes (Bio-Rad) and 
electroporated in 400 μl PBS with 1 nmol siRNA 
against Lep, Adig, Ift172, Mpv17, Tiparp or Cobll1 (Stealth siRNA, Invitrogen). Non-targeting 
sequences were used as negative controls (Invitrogen). Electroporation was performed with a 
Gene Pulser XceII (Bio-Rad) using 50 V, 102 wave pulses, with a pulse length of 30 ms and 
0.1 ms between pulses68. The tissue fragments were subsequently cultured at 37 °C in 5% CO2 in 
12-well plates for 20 h in basal media consisting of M199 media with 10% fetal bovine serum 
(Invitrogen) plus 1 × Anti-Anti before stimulation for 12 h with basal media plus 7 nM insulin 
and 25 nM dexamethasone (both from Sigma), to maintain leptin expression in the explants at 
levels comparable to those of in vivo tissues69. Knockdown was considered successful if 
candidate expression was decreased by ≥30%. The effect of insulin and dexamethasone on 




Measuring mRNA levels and leptin and adiponectin secretion. Total RNA was isolated using 
TRIzol reagent (Invitrogen) and reverse transcribed using Transcriptor First Strand cDNA 
Synthesis Kit (Roche) using both OligoDT and random hexamer primers. Lightcycler 480 SYBR 
Green I Master was used for quantitative PCR assays (Roche). Expression of murine homologues 
of candidate genes in PGAT and SCAT was determined using the 2(−ΔΔC(T)) method70. Gene 
expression in the knockdown experiments was calculated by Lightcycler 480 software (Roche) 
based on a standard curve. Primers used are listed in Supplementary Table 5.25. Culture media 
was collected from the same samples used for RNA analyses. Following the 12 h 
insulin/dexamethasone stimulation, secreted leptin and adiponectin were measured using the 
Perkin-Elmer AlphaLISA kits for mouse leptin and adiponectin (according to the manufacturer's 
protocol). Not all samples were included for adiponectin measurement due to the discontinuation 
of the AlphaLISA kit by Perkin-Elmer. 
Statistics. Each gene knockdown was tested on tissue from 5 to 13 different mice, as indicated. 
Control and knockdown samples from each mouse were treated as matched pairs. Each data 
point represents the mean of three replicates from a single mouse. Differences between control 
and knockdown conditions were calculated by two-way repeated measures analysis of variance 
using GraphPad Prism 6. P-values <0.05 were considered significant. 
 
Results 
Stage 1 genome-wide meta-analysis in 32,161 individuals 
We first performed a meta-analysis of the results from genome-wide associations between ∼2.5 
million genotyped and HapMap-imputed single-nucleotide polymorphisms (SNPs) and 
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circulating leptin levels, including up to 32,161 individuals of European descent from 23 studies 
(Supplementary Table 5.1). After logarithmic transformation that normalized the distribution of 
leptin levels and adjusting for age and sex, we carried out association analyses within each study 
and subsequently meta-analysed the study-specific results. To identify loci associated with 
circulating leptin levels independently of adiposity, we performed a meta-analysis of genome-
wide associations in which we additionally adjusted for BMI. We also performed secondary 
genome-wide meta-analyses in men (n=13,363) and women (n=18,698) separately, as women 
generally have higher leptin levels than men, primarily due to larger percentage of body fat and 
greater subcutaneous fat storage18. 
Two loci, near the LEP and SLC32A1 genes, reached genome-wide significance (P<5 × 10−8) in 
the BMI-adjusted meta-analysis of men and women combined (Table 5.1). To confirm these 
associations and to identify additional leptin-associated loci, we took forward all independent 
(pairwise distance >500 kb and r2<0.1) SNPs reachingP<10−6 with leptin levels with or without 
adjustment for BMI in meta-analyses of all individuals combined, men only or women only, for 




Stage 2 follow-up in 19,979 individuals identifies five loci 
We examined the associations of the loci taken forward from stage 1 in up to 19,979 additional 
individuals of European descent from 13 studies (Supplementary Table 5.5). All studies 
performed the same association analyses as described in Stage 1; that is, with and without 
adjustment for BMI and in men and women combined, as well as separately. Finally, after 
performing a joint meta-analysis of the stage 1 and stage 2 results, five independent SNPs 
reached genome-wide significance (P<5 × 10−8) in the combined meta-analyses of men and 
women (Table 5.1). In the BMI-adjusted meta-analysis, we confirmed genome-wide significant 
associations for the loci near LEP and SLC32A1, and identified an additional locus in GCKR. In 
the BMI-unadjusted meta-analysis, we identified two additional loci near CCNL1 and in FTO. A 
locus in COBLL1, previously identified for association with BMI-adjusted waist–hip ratio 
(WHRadjBMI)
19, blood triglycerides20 and risk of type 2 diabetes21, reached P=1 × 10−6 with BMI-
unadjusted leptin and P=2 × 10−6 with BMI-adjusted leptin levels, with the leptin-increasing 
allele being associated with lower WHRadjBMI, triglycerides and risk of type 2 diabetes. 
The estimated effects of five of the six loci (in/near LEP, SLC32A1, GCKR, CCNL1 or COBLL1) 
on leptin levels did not markedly differ in magnitude between the BMI-unadjusted and BMI-
adjusted models, suggesting that these associations are not mediated by adiposity per se (Figure 
5.1). In contrast, the association between the FTO locus and leptin levels was completely 
abolished after adjusting for BMI, indicating that the association with leptin is entirely mediated 
by the well-established association between FTO and BMI22 (Figure 5.1). 
BMI is the most commonly used index of adiposity, but it is not a direct measure of adiposity 
and it does not distinguish between lean and fat body mass. To assess whether adjustment for a 
more direct measure of adiposity could enhance our ability to identify adiposity-independent 
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loci, we performed secondary analyses in 13 studies that had data on both BMI and body fat 
percentage assessed by dual-energy X-ray absorptiometry or bioimpedance analysis (n=18,980 
or 59% of stage 1 sample). The analysis showed no marked differences in the effect sizes 
between the BMI and body fat percentage-adjusted results for the leptin-
associated LEP, SLC32A1, CCNL1, GCKR, COBLL1 and FTO loci (Supplementary Table 5.6), 
suggesting that adjustment for BMI as compared with a more direct measure of adiposity did not 
compromise our ability to identify adiposity-independent leptin-associated loci. 
Effects on other traits and potential functional roles 
We took forward the genome-wide significant leptin loci near LEP, near SLC32A1, in GCKR and 
near CCNL1, to examine their associations with obesity-related and metabolic traits and to more 
directly assess their putative roles in the control of circulating leptin. We also took forward the 
locus near COBLL1, given its robust association with WHRadjBMI
19, even though it just missed 
the genome-wide significance threshold for association with BMI-adjusted and BMI-unadjusted 
leptin levels (Table 5.1). As the FTO-leptin association was completely accounted for by FTO's 
association with BMI (Figure 5.1), extensively described in the literature23, we did not include 
this locus in our follow-up analyses. 
To examine the associations of the identified loci with obesity-related and metabolic traits, we 
performed look-ups in the data from relevant genetic consortia (Supplementary Table 5.7). To 
study the associations of the leptin-associated loci with the expression of nearby genes, we 
performed cis-expression quantitative trait locus (eQTL) analyses in several human tissues, 
including the subcutaneous (n=776) and omental fat (n=742), liver (n=567), lymphocytes 
(n=778), brain (n=193) and skin (n=667) (Supplementary Table 5.8). We also examined the 
regulatory functions of these loci by studying their enrichment with functional genomic elements 
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in data from the Roadmap Epigenomics Project24. Finally, to identify the causal genes in the 
leptin-associated loci, we performed ex vivo knockdown studies of adipocyte-expressed genes 
using small interfering RNA (siRNA) in explanted mouse adipose tissue. 
Common variation near LEP regulates leptin levels 
The rs10487505 variant (MAF 49%) is located 21 kb from LEP (Figure 5.2a) and is in modest 
linkage disequilibrium (LD) (r2=0.4,D′=0.8) with the A19G (rs2167270, MAF 35%) variant that 
has been extensively studied in candidate gene studies but whose associations with increased 
levels of leptin and obesity have been inconclusive13,16. The leptin-increasing allele of the 
rs10487505 variant has been nominally associated with weight regain after bariatric surgery in a 
candidate gene-based analysis of 1,443 patients25. Look-ups in consortium data showed a 
nominally significant association for the leptin-decreasing allele of rs10487505 with higher BMI 
in the GIANT Consortium (P=0.03, N=221,677), as well as with increased risk of early-onset 
obesity (P=0.04, N=13,848) and higher birth weight (P=0.02, N=26,836) in the EGG Consortium 
(Supplementary Table 5.7). Although LEP is an obvious candidate gene to account for the 
association with circulating leptin levels, the rs10487505 variant was not associated 
with LEP messenger RNA expression in the omental or subcutaneous adipose tissue (SCAT), 
liver, lymphocytes, brain or skin (Supplementary Tables 8 and 9). 
A variant in strong LD with rs10487505 (rs6979832, r2=0.98) overlapped with predicted 
enhancer elements in all three adipose cell lines of the Roadmap Epigenomics Project24. Further, 
a previous study identified a 465-bp adipocyte-specific enhancer region 4.5 kb upstream from 
the LEP transcription start site by using luciferase assays and chromatin state mapping26. This 
region harbours rs10249476 that is in modest LD with rs10487505 (r2=0.4,D′=0.8) and reached 
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the second most significant association with BMI-adjusted leptin levels in stage 1 meta-analysis 
(P=3 × 10−10;n=30,810) (Figure 5.2a). 
Collectively, although the locus near LEP overlaps with predicted enhancer elements, the lack of 
association with LEP transcript expression in the fasting state suggests that other mechanisms 
may be involved in mediating the association of this locus with leptin levels, such as an effect 
on LEP expression in the fed state27 or an effect on leptin protein secretion. 
To validate our knockdown strategy for subsequent analyses of candidate genes in loci other than 
the locus near LEP, we used siRNA against Lep in mouse adipose tissue explants. 
Electroporation of the perigonadal adipose tissue (PGAT) explants with siRNA 
against Lep resulted in a 92% decrease in Lep mRNA (P<1 × 10−4) and a 92% decrease in 
secreted leptin (P=4 × 10−4) (Figure 5.4a,b, Supplementary Figure 5.1C,D and Supplementary 
Table 5.10). In addition, to determine whether electroporation with siRNA altered other 
secretory function(s) of the perigonadal explants, we measured secretion of adiponectin and 
found no changes associated with Lep knockdown (Figure 5.4d and Supplementary Figure 5.1E). 
ADIG may regulate leptin expression 
The intergenic rs6071166 variant, ∼20 kb from the SLC32A1 gene (Figure 5.2c), reached 
genome-wide significance for association with BMI-adjusted leptin levels and has not been 
previously identified for association with any other traits. In look-ups of genome-wide 
association study (GWAS) consortium data, we did not find significant association with other 
obesity-related or metabolic traits (Supplementary Table 5.7). The rs6071166 variant was not 
associated with the mRNA expression of nearby genes in the adipose tissue, liver, lymphocytes, 
brain or skin (Supplementary Tables 5.8 and 5.9). 
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To identify the potential causal gene in this locus using the mouse PGAT explant model 
described above, we first measured the expression levels of murine homologues of genes 
surrounding the lead variant associated with circulating leptin levels. We tested PGAT and 
SCAT of 4-month-old C57BL/6J mice fed chow or high-fat diet (Figure 5.3c,d). In addition, we 
analyzed candidate gene expression in other tissues (liver and hypothalamus) that we predicted 
could play a role in circulating leptin levels via effects on leptin clearance or response 
(Supplementary Figure 5.7). Genes were considered strong candidates if they were highly 
expressed in adipose tissue and/or if they were regulated by high-fat diet feeding in a manner 
similar to Lep. This analysis identified adipogenin (Adig) as a candidate gene in 
the SLC32A1 locus; Adig is highly expressed in the adipose tissue, in contrast to other nearby 
genes. To test whether Adig affected Lep expression, we performed ex vivo knockdown studies 
using siRNA against Adig in mouse PGAT explants. We found that knockdown 
of Adig decreased Lep expression by 26% (P=4 × 10−4) and leptin secretion by 23% (P=0.003), 
consistent with a causal role for ADIG in control of circulating leptin levels (Figure 
5.4a,b and Supplementary Figure 5.2C,D). 
ADIG is located ∼116 kb from the rs6071166 variant and encodes a cytoplasmic adipocyte 
protein adipogenin, that is, similar to leptin, highly and specifically expressed in the adipose 
tissue28,29,30 and upregulated by treatment with insulin and glucose30. Adig expression is also 
strongly upregulated in murine 3T3-L1 preadipocytes during in vitro differentiation into 
adipocytes28,29. Two studies have investigated the effect of Adig knockdown on the 
differentiation of 3T3-L1 cells and expression of Pparγ2, a master regulator of adipocyte 
differentiation, but with conflicting results; whereas the first study found Adig knockdown to 
block adipocyte differentiation and decrease Pparγ2 expression28, a later study found no similar 
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changes30. When we measured Pparγ2 expression following Adig knockdown in PGAT explants 
containing mature adipocytes, we did not see a change as compared with controls 
(Supplementary Figure 5.2F). 
Common variation in GCKR regulates leptin levels 
Variants (r2≥0.9 with our lead SNP rs780093) of the leptin-associated locus in GCKR have 
previously shown genome-wide significant associations with more than 25 metabolic traits; the 
leptin-increasing allele has been associated with increased fasting glucose and fasting insulin but 
decreased 2-h glucose and higher high-density lipoprotein cholesterol, and lower total 
cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein and circulating 
uric acid levels, among others (Supplementary Table 5.11). The GCKR gene encodes a 
regulatory protein in the liver that inhibits the activity of glucokinase, the enzyme responsible for 
regulating the uptake, metabolism and storage of circulating glucose31. A putative causal variant 
in this gene is the common nonsynonymous Pro446Leu variant (rs1260326), for which rs780093 
acts as a good proxy (r2=0.9). Carriers of the glucose-lowering Leu allele have a reduced ability 
to sequester and inhibit glucokinase and a blunted response to fructose 6-phosphate, both of 
which favour the generation of free and active cytoplasmic glucokinase32. 
The mechanisms that might link changes in GCKR function to leptin levels are not known. As 
insulin increases leptin secretion from adipocytes33 and the GCKR locus is strongly associated 
with circulating levels of insulin34, the association of the GCKR locus with leptin levels could be 
the consequence of the GCKR locus' effect on insulin levels. The leptin-increasing allele of the 
rs780093 variant was significantly associated with higher levels of fasting insulin in studies 
included in our stage 2 meta-analyses (P=2 × 10−5, N=8,953). To test whether insulin mediated 
the association of rs780093 with circulating leptin levels, we analysed the association of 
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rs780093 with leptin, while adjusting for fasting insulin levels. Although the effect size was 
somewhat attenuated, the association of rs780093 with BMI-adjusted leptin levels remained 
significant after adjustment for fasting insulin (β=0.047, P=2 × 10−4 versusβ=0.034, P=0.004 
before and after the adjustment, respectively), suggesting that the association of the GCKR locus 
with leptin is at least in part independent of effects on insulin levels. 
Although GCKR's function renders it a potential candidate among the genes in this region, cis-
eQTL analyses showed association of the leptin-increasing allele of rs780093 with increased 
expression of the nearby IFT172 in the liver (P=7 × 10−30), omental fat (P=6 × 10−64) and 
subcutaneous fat (P=3 × 10−52) (Supplementary Table 5.9). The rs780093 variant is, however, 
only in moderate LD (r2=0.4) with the peak SNP influencing IFT172 expression in the region 
and the peak SNP remained significantly associated with IFT172expression after adjustment 
for  rs780093, whereas the association of rs780093 was abolished after adjustment for the peak 
SNP (Supplementary Table 5.9). 
Because of the observations in human tissues, we examined Ift172 in the mouse explant 
model.  Ift172 was not highly expressed in mouse PGAT or SCAT and levels were not 
upregulated by high-fat diet (Figure 5.3e,f). Ift172 was, however, upregulated in the liver under 
high-fat diet feeding (Supplementary Figure 5.7E). Knockdown of Ift172 in PGAT explants 
decreased Lep mRNA expression by 22% (P=0.02), but did not decrease leptin protein secretion 
(P=0.6) (Figure 5.4a,b and Supplementary Figure 5.3C,D). IFT172 is known to play a major role 
in assembly and maintenance of primary cilia that act as critical signaling hubs for cellular 
pathways during development35. Knockout of Ift genes in central neurons causes obesity in 
mice36and obesity is a clinical feature in two human ciliopathic syndromes, the Alström and 
Bardet–Biedl syndromes37,38. In the hypothalamus, alterations in the function of the primary 
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cilium lead to impaired leptin signalling39. Therefore, we cannot exclude a role for IFT172 in the 
regulation of circulating leptin levels. 
Another nearby gene, MpV17 mitochondrial inner membrane protein, is a potential candidate in 
the region based on its expression in mice fed chow or high-fat diet; Mpv17 expression was 
increased by high-fat diet, in a manner similar to Lep (Figure 5.3c,d). However, knockdown 
of Mpv17 did not change Lep mRNA expression (P=0.2) or leptin secretion (P=0.2) by PGAT 
explants (Figure 5.4a,b and Supplementary Figure 5.4C,D), suggesting that the involvement 
of MPV17 in leptin regulation is unlikely. 
Locus near CCNL1 regulates leptin levels and birth weight 
The leptin-decreasing allele of rs900400, located 67 kb upstream from CCNL1 (Figure 5.2d), was 
previously reported for its association with lower birth weight40. This cross-phenotype 
association could indicate a mechanism that is shared between birth weight and leptin levels in 
adulthood. Fetal adipose tissue is capable of producing leptin41 and fetal leptin levels are 
correlated with fetal fat mass42,43. Placenta provides an additional source of leptin for the fetus, 
however, and it has been suggested that leptin could mediate fetal growth44,45. Assuming that 
leptin levels track from birth through adulthood, increased leptin levels could drive the 
association of the CCNL1 locus with birth weight. Other studies suggest that leptin production is 
decreased in cultured adipocytes from men born with a low birth weight46. Therefore, the 
association of the CCNL1 locus with leptin levels in adulthood could be mediated by its 
association with birth weight. 
Although CCNL1 is the nearest gene to rs900400, our cis-eQTL analyses identified rs900400 as 
the variant most significantly associated with the expression of another nearby 
gene, TIPARP (Supplementary Table 5.9). The TIPARP gene encodes a poly (ADP-ribose) 
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polymerase involved in DNA repair. The leptin-increasing allele of rs900400 was associated 
with lower TIPARP expression in omental fat (3 × 10−30) and subcutaneous fat (P=7 × 10−58) 
(Supplementary Table 5.9). Tiparp was also implicated as a causal gene by our expression 
analysis of mouse adipose tissue and its expression was increased in SCAT and liver in mice fed 
with high-fat diet (Figure 5.3h and Supplementary Figure 5.7G). Knockdown of Tiparpin mouse 
PGAT explants did not,  however, significantly alter the expression of Lep mRNA (P=0.7) or 
leptin secretion (P=0.8) (Figure 5.4a,b and Supplementary Figure 5.5D,E). Although we 
attempted to use SCAT for explant knockdown studies, high intra-depot variability compromised 
this approach. Interestingly, stimulation of the explants with insulin and dexamethasone 
increased explant expression of Tiparp by 50% (P=0.003) over incubation in basal media alone, 
in a manner similar to Lep expression (Figure 5.4c and Supplementary Figure 5.5A). 
Collectively, although TIPARP remains a putative causal gene within the locus near CCNL1, 
further evidence is required to confirm its role in the regulation of circulating leptin levels. 
COBLL1 or GRB14 may regulate leptin levels 
The intronic rs6738627 variant in COBLL1 (Figure 5.2e) did not reach genome-wide 
significance for the association with leptin levels (Figure 5.1 and Table 5.1). However, as 
previous GWAS have shown robust associations of the leptin-increasing allele with a lower 
WHRadjBMI
19, we chose to take it forward for follow-up analyses, to examine the role of leptin 
levels in the previous associations. 
Look-ups in data from genetic consortia showed a strong association of the leptin-increasing 
allele of rs6738627 with higher body fat percentage (P=2 × 10−8, n=76,338; Supplementary 
Table 5.7). As reported previously, the rs6738627 variant was also strongly associated with 
decreased WHRadjBMI (P=2 × 10
−8, n=174,672; Supplementary Table 5.7), suggestive of a 
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preferential gluteal rather than abdominal fat storage, which may contribute to the association of 
rs6738627 with increased leptin levels47. 
In PGAT and SCAT expression analyses in mice, we found an upregulation of Cobll1 in high-fat 
diet-fed mice in both depots (Figure 5.3i,j). Although knockdown of Cobll1 in the perigonadal 
explants did not influence Lep mRNA expression (P=0.2), it did decrease leptin protein secretion 
by 16% (P=3 × 10−4, Figure 5.4a,b), suggesting a potential causal role for Cobll1. In addition, 
stimulation of explants with insulin and dexamethasone increased explant expression 
of Cobll1 by 78% (P=0.004) over incubation in basal media alone (Figure 
5.4c and Supplementary Figure 5.6A). COBLL1 is known to be involved in neural tube 
formation48, but its possible functions in adipose tissue are unknown. 
In human eQTL analyses, the leptin-increasing allele of the COBLL1 locus showed an 
association with lower expression of GRB14 in omental fat (P=5 × 10−12) and subcutaneous fat 
(P=3 × 10−5) (Supplementary Table 5.9). We did not, however, find high expression of Grb14 in 
PGAT or SCAT explants from mice and the levels were not regulated by high-fat diet feeding 
(Figure 5.3i,j). The protein product of GRB14 is the growth factor receptor-bound protein 14 that 
binds directly to the insulin receptor and inhibits insulin signalling49. The adipose tissue 
expression of GRB14 may play a role in regulating insulin sensitivity50. Grb14-deficient mice 
exhibit improved glucose tolerance, lower circulating insulin levels and increased incorporation 
of glucose into glycogen in the liver and skeletal muscle51. Both COBLL1 and GRB14 are thus 
possible candidates to account for the association of the COBLL1 locus with leptin levels. 
Enrichment with pathways and regulatory elements 
We used the Data-driven Expression Prioritized Integration for Complex Traits (DEPICT) 
software52 to identify enrichment of gene sets and pathways across loci reaching P<1 × 10−5 for 
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association with leptin levels. However, none of our findings reached the false discovery rate 
threshold of 5% (Supplementary Tables 12–17). Next, we used the Gene Relationships Across 
Implicated traits (GRAIL) tool53 to identify genes near the leptin-associated loci having 
similarities in the text describing them within published article abstracts. However, no 
statistically significant results were found in these analyses either (Supplementary Tables 18 and 
19). Finally, we used the Uncovering Enrichment Through Simulation method54 to test for the 
overall enrichment of leptin-associated loci reaching P<10−5 with ChromHMM annotations for 
adipose and brain tissues available from the Roadmap Epigenomics Project24. However, we did 
not find significant enrichment of our leptin-associated loci in any chromatin states once 
corrected for multiple testing (Supplementary Table 5.20). The lack of significant findings may 
be due to the small number of loci identified and the limited knowledge available on leptin-
regulating pathways in adipose tissue. 
Established adiposity loci and leptin 
Circulating leptin levels correlate closely with BMI and other measures of adiposity3. The most 
recent GWAS meta-analysis for BMI, including nearly 340,000 individuals, identified 97 loci 
that reached genome-wide significance22. Of the 97 BMI-increasing loci, 89 showed a 
directionally concordant association with increased BMI-unadjusted leptin levels (Pbinomal=2 × 
10−18), of which 25 reached nominal significance (Supplementary Table 5.21). Previous GWAS 
of extreme and early-onset obesity have identified 12 genome-wide significant loci55,56,57,58. Of 
these, ten showed a directionally consistent association with increased BMI-unadjusted leptin 
levels (Pbinomal=0.04), of which five reached nominal significance (Supplementary Table 5.21). 
We also examined leptin associations for 49 loci identified in GWAS for WHRadjBMI, a measure 
of body fat distribution independent of overall adiposity19. Of the 49 WHRadjBMI-increasing loci, 
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only 24 showed a directionally concordant association with increased BMI-adjusted leptin levels 
(Supplementary Table 5.22). As the distribution of body fat differs between men and women, we 
also examined the leptin associations for the 49 WHRadjBMI loci in men and women separately. 
There was no enrichment of leptin associations in either of the sexes, with 27 loci showing a 
directionally concordant association with increased leptin levels in men and 20 loci in women 
(Supplementary Table 5.22). 
 
Discussion 
In a meta-analysis of genetic association data in up to 52,126 individuals, we identified 5 
common loci associated with circulating leptin levels. In addition, a locus near COBLL1, 
previously identified for association with a lower WHRadjBMI
19, reached P=1 × 10−6 for 
association with increased leptin levels. Even though leptin correlates strongly with adiposity, we 
did not identify loci previously associated with BMI, other than FTO, despite having a sample 
size similar to early GWAS meta-analyses of BMI that identified multiple loci59. On the 
contrary, five of the six loci we identified were associated with leptin independently of BMI or 
body fat percentage. Our findings indicate that genetic mechanisms not influencing adiposity 
may have an important role in the regulation of circulating leptin levels. 
Our strongest adiposity-independent leptin signal was near LEP, but we also identified leptin-
associated variants in four other genomic loci, providing evidence that mechanisms other than 
those that involve LEP per se may regulate leptin production and release from adipose tissue. In 
one of these loci, near SLC32A1, our knockdown studies indicated a role for adipogenin, a gene 
involved in the regulation of adipocyte differentiation28,29. Although adipogenin was identified as 
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a potent regulator of adipogenesis a decade ago28,29, our results provide the first evidence linking 
this function to leptin regulation. We anticipate that our findings will motivate and inform 
eventual testing of Adig by transgenic manipulation in mice. 
No clear effect on leptin production was seen following knockdown of candidate genes in 
the GCKR and CCNL1 loci, which may indicate that the gene implicated by position plays no 
role in the phenotype, or that the effect was undetectable in our experimental conditions. 
Alternatively, the association with leptin levels may be explained by effects of non-coding 
elements on other genes outside the implicated genetic interval, or by inter-species differences. 
Furthermore, although adipose tissue is the most direct contributor to circulating leptin levels, 
the effect of the causal gene may be conveyed by another tissue; leptin production and secretion 
are influenced by insulin, catecholamines and other hormones, as well as paracrine effects of 
local inflammatory cells on adipocytes60. 
Although the locus near SLC32A1 had not been identified previously for association with other 
traits, the leptin-associated loci in/near GCKR, CCNL1 and COBLL1 have been associated with 
multiple obesity-related and metabolic traits19,20,34,40,61. These cross-phenotype associations may 
either reflect pleiotropy, where a gene product influences multiple traits, and/or mediation 
effects, where one phenotype is causally related to a second phenotype. For example, the 
association of the pleiotropic GCKR locus with leptin levels may be partly mediated 
through GCKR's role in the regulation of glucose homeostasis and insulin levels34,61, which may 
influence leptin production and secretion in adipose tissue33. The COBLL1 locus is strongly 
associated with decreased WHRadjBMI, indicative of a preferential accumulation of gluteal 
subcutaneous fat, which may contribute to the observed association with circulating leptin 
levels47. The identification of the birth weight locus, CCNL1, as a leptin-regulating locus may 
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provide an intriguing link between leptin regulation and fetal growth, albeit such a link remains 
to be more firmly established45. 
Unraveling the polygenic basis of leptin production could provide opportunities for targeted 
leptin supplementation in obese individuals. Although leptin therapy is an efficient weight-loss 
treatment for obese individuals with congenital leptin deficiency, the beneficial effects of leptin 
supplementation do not translate to all obese patients62. Sensitivity to changes in circulating 
concentration of leptin may be enhanced at very low values11 where a relatively small increase in 
leptin production may be sensed by the homeostatic feedback system that controls energy 
balance. As a substantial minority of individuals with common forms of obesity, not associated 
with leptin mutations, have relatively low levels of circulating leptin63, augmenting leptin levels 
in this subgroup could be therapeutically worthwhile. Identification of leptin-regulating loci may 
provide new tools for identifying obese individuals with susceptibility to low leptin levels and 
who may benefit of leptin treatment. 
In 2010, Sun et al.64 identified two common non-synonymous SNPs in the leptin receptor 
(LEPR) gene associated with leptin receptor levels. Leptin receptor plays an essential role in 
mediating the physiological effects of leptin. Although some studies have described abnormally 
high circulating leptin levels in carriers of rare LEPR mutations65, others have not66. We did not 
find association between LEPR variants and circulating leptin levels, suggesting that common 
variants in LEPR are not important regulators of circulating leptin levels. 
Our meta-analyses were limited by the number of available studies with leptin data, imputation 
by HapMap reference panel for autosomal chromosomes and the fact that we examined additive 
effects only. In addition, we corrected for adiposity by adjusting for BMI, which is a 
heterogeneous measure of adiposity as it does not account for individual differences in body fat 
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and lean mass. Future discovery efforts in extended sample sizes based on genome-wide 
imputation of 1000 Genomes reference panels, which include X and Y chromosomes and which 
also test for recessive and dominant inheritance, will allow for the discovery of more and lower-
frequency variants, and for refining association signatures of already established leptin-
associated loci. 
In summary, we identified six genetic loci associated with circulating leptin levels, of which five 
showed associations independently of adiposity. Our findings represent a step forward in the 
understanding of biological mechanisms regulating leptin production in adipose tissue and open 














Table 5-2  Meta-analysis results in men and women combined for the 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5-1  Association of genome-wide significant loci. 
Association of genome-wide significant loci and the locus in COBLL1 with BMI-adjusted and 



























Figure 5-2  Regional plots for the loci associated with circulating leptin concentrations. 
 
Regional plots for the loci in or near LEP (a), GCKR (b), SLC32A1 (c) and CCNL1 (d), which 
reached genome-wide significance in the combined meta-analysis of Stage 1 and Stage 2 for 
BMI-unadjusted or BMI-adjusted leptin levels. The COBLL1 locus (e) that reached P=1 × 
10−6 with BMI-unadjusted and P=2 × 10−6 with BMI-adjusted leptin levels is also shown. For 
the locus near LEP (A), the rs10249476 SNP, located in a previously identified adipocyte-




































































































































































































































































































































Figure 5-4  Candidate gene knockdown studies in PGAT explants. 
Changes in Lep mRNA expression (a) and secretion into media (b) following candidate gene 
knockdown in PGAT explants following stimulation with insulin and dexamethasone for 12 h. 
Gene expression induced by stimulation with insulin and dexamethasone (c) N=5–13 mice per 
group (3 replicates/condition/mouse). Secreted adiponectin was measured as a control for non-
leptin secretory function (d) N=5 mice per group. Two-way repeated measures analysis of 
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Supplementary Figure 5-1  Effects of Lep knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
Lep transcription (A) and secretion (B) by explants in the basal or Ins/Dex stimulated state. N=5 
mice per group. Lep knockdown (C) decreased LEP secretion (D) following stimulation with 
insulin and dexamethasone for 12 hours. Adiponectin secretion (E) remained unchanged. N=5 
mice per group. Each point represents the average of 3 samples. 2 way repeated measures 


















Supplementary Figure 5-2  Effects of Adig knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
Adig expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Adig knockdown (B) decreased both Lep expression (C) and leptin secretion (D) following 
stimulation with insulin and dexamethasone for 12 hours. N=12 mice per group. Adiponectin 
secretion (E) remained unchanged. N=7 mice per group. Pparg2 expression (F) was unchanged 
as well. N=6 mice per group. Each point represents the average of 3 samples. 2 way repeated 


















Supplementary Figure 5-3  Effects of Ift172 knockdown on leptin transcription and secretion 
in perigonadal adipose tissue explants from mice fed with high fat diet. 
Ift172 expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Ift172 knockdown (B) decreased Lep expression (C) but did not change leptin secretion (D) 
following stimulation with insulin and dexamethasone for 12 hours. N=9 mice per group. 
Adiponectin secretion (E) remained unchanged. N=6 mice per group. Each point represents the 




















Supplementary Figure 5-4  Effects of Mpv17 knockdown on leptin transcription and secretion 
in perigonadal adipose tissue explants from mice fed with high fat diet. 
Mpv17 expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Mpv17 knockdown (B) did not change Lep expression (C) or secretion (D) following stimulation 
with insulin and dexamethasone for 12 hours. Adiponectin secretion (E) remained unchanged. 
N=12 mice per group. Each point represents the average of 3 samples. 2 way repeated measures 



















Supplementary Figure 5-5  Effects of Tiparp knockdown on leptin transcription and secretion 
in perigonadal adipose tissue explants from mice fed with high fat diet.   
Tiparp expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Tiparp knockdown (B) did not change Lep expression (C) or secretion (D) following stimulation 
with insulin and dexamethasone for 12 hours. Adiponectin secretion (E) remained unchanged. 
N=9 mice per group. Each point represents the average of 3 samples. 2 way repeated measures 


















Supplementary Figure 5-6  Effects of Cobll1 knockdown on leptin transcription and secretion 
in perigonadal adipose tissue explants from mice fed with high fat diet. 
Cobll1 expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Cobll1 knockdown (B) did not change Lep expression (C) but decreased Lep secretion (D) 
following stimulation with insulin and dexamethasone for 12 hours. N=13 mice per group. 
Adiponectin secretion (E) remained unchanged. N=8 mice per group. Each point represents the 
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Abstract 
Objective: The physiology of the weight-reduced (WR) state suggests that pharmacologic agents 
affecting energy homeostasis may have greater efficacy in WR individuals. Our aim was to 
establish a protocol that allows for evaluation of efficacy of weight maintenance agents and to 
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assess the effectiveness of AZD2820, a novel melanocortin 4 receptor (MC4R) agonist in such a 
paradigm. 
Design and Methods: MC4R agonist was administered in stratified doses to mice who were 
either fed high-fat diet ad libitum (AL) throughout the study; or stabilized at a 20% reduced body 
weight (BW), administered the drug for 4 weeks, and thereafter released from caloric restriction 
while continuing to receive the drug (WR).  
Results: After release of WR mice to AL feeding, the high-dose group (53.4 nmol/day) regained 
12.4% less BW than their vehicle-treated controls since the beginning of drug treatment. In WR 
mice, 10.8 nmol/day of the agonist was sufficient to maintain these animals at 95.1% of initial 
BW versus 53.4 nmol/day required to maintain the BW of AL animals (94.5%). 
Conclusions: In the WR state, the MC4R agonist was comparably efficacious to a five-fold 
higher dose in the AL state. This protocol provides a model for evaluating the mechanisms and 
quantitative efficacy of weight-maintenance strategies and agents. 
 
Introduction 
Using diet and exercise many obese individuals are capable of losing weight but are unable to 
maintain this reduced body weight (BW) for extended periods of time [1]. Resistance to the 
maintenance of a weight reduced (WR) state results from the coordinate action of systems 
regulating energy intake and output to favor weight regain. WR individuals and rodents are 
hyperphagic and their energy expenditure is decreased beyond what would be predicted for their 
lower body mass and composition [2-4].  Changes in neuroendocrine axis, decreased circulating 
concentrations of leptin and bioactive thyroid hormones, and decreased sympathetic nervous 
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system tone and increased parasympathetic nervous system tone promote the BW regain [2]. In 
rodents, weight reduction decreases the proportion of excitatory synapses on anorexigenic 
POMC neurons in the arcuate nucleus of the hypothalamus [3]. Behavioral studies indicate that 
WR humans are hungrier, have decreased perception of how many calories they have eaten and 
have reduced satiation [5]. These phenotypes are associated with characteristic changes in fMRI 
activity in regions of the brain mediating homeostatic and hedonic responses to food [6, 7].  
Most of the physiological and neuro-functional changes that accompany maintenance of a 
reduced BW in either lean or obese individuals can be reversed with low doses of exogenous 
leptin sufficient to return the circulating leptin levels to those present at the usual BW [6-9]. 
These responses are similar to those seen in patients with congenital leptin deficiency [10-12]. 
Administration of exogenous leptin to obese or never-obese humans at their usual weights - even 
at doses sufficient to raise circulating leptin concentrations to supraphysiological levels - has 
modest or no effect on BW [13]. Similar to the effects of leptin, WR individuals may have 
increased sensitivity to other relevant molecules, influencing strategies for the design and 
application of weight-maintaining pharmacologic agents. 
The melanocortin (MC) system is a downstream target of leptin [14]. The MC4 receptor (MC4R) 
is a G-protein-coupled receptor expressed primarily in paraventricular hypothalamus (PVH), 
dorsal motor nucleus of the vagus (DMV), thalamus and hippocampus [15, 16].  In addition, 
MC4Rs are also found outside of the CNS including in the nodose and dorsal root ganglia [17, 
18]. Two major neuronal populations in the hypothalamus, the anorexigenic 
proopiomelanocortin (POMC) and orexigenic Agouti-related protein (AgRP)/Neuropeptide Y 
(NPY)/GABA neurons, are activated and inhibited by leptin, respectively, to reciprocally 
mediate energy balance through the MC4 receptors [14]. α-MSH, one of the peptides released 
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from POMC neurons, is an agonist of MC4R whereas the AgRP is an inverse agonist of this 
receptor. Mc4r-null mice are obese due to both increased food intake and reduced energy 
expenditure [19]. Mice overexpressing α-MSH display increased energy expenditure [20]. 
Administration of MC4R agonists to mice or rats promotes weight loss by decreasing food intake 
and/or increasing energy expenditure, identifying MC4R as a potential pharmacological target 
[21, 22]. 
Physiologically, the weight-reduced state is one of relative leptin deficiency in which the 
expression of hypothalamic AgRP and NPY neuropeptides is increased [23, 24] and Pomc 
expression is decreased [25]. These changes can be largely normalized with administration of 
exogenous leptin [26]. In the WR state, treatment with MC4R agonist might be efficacious as 
well. Leptin has little or no efficacy when administered at a usual BW [13]; MC4R agonist might 
also be expected to have greater efficacy in the weight-reduced state.  
In this study we examined the long term effects of a potent and selective cyclic peptide MC4R 
partial agonist (AZD2820; MC4R: EC50 1nM in cAMP generation assay, 38% efficacy vs. 
NDP-α-MSH, and MC3R: binding Ki 9nM, no agonist efficacy detected (AstraZeneca data on 
file) [27] on induction of weight loss and on maintenance of reduced BW in diet induced obese 
(DIO) mice. We found that, in the weight-reduced state, the dose required for equal efficacy of 








18 week old male mice C57BL/6J fed high fat diet (HFD; Research Diets, Inc. D12492i, 60% 
kcal from fat) starting at six weeks of age were obtained from Jackson Laboratory (Bar Harbor, 
ME). Throughout the study, animals were maintained at room ambient 22-24°C with a 12-h 
dark-light cycle (lights on at 0700h) in a pathogen-free barrier facility. The protocol was 
approved by the Columbia University Institutional Animal Care and Use Committee. 
Study Design (schematized in Figure 1) 
After the 5-week acclimatization period, mice were randomly assigned to one of the following 
groups:  1.) Maintained on HFD ad lib (AL group; n=40) throughout the study or 2.) Weight 
reduced (WR group, n=40) to 80% of their initial weight by caloric restriction (CR).  Eight 
weeks after the WR group entered the CR phase, both AL and WR groups were further 
randomized to receive either low (2.64 nmol/day), intermediate (10.8 nmol/day) or high (53.4 
nmol/day) dose of AZD2820 dissolved in 5% mannitol solution or vehicle (5% mannitol 
solution; n=20 per treatment; n=10 WR and n=10 AL) via implanted subcutaneous mini-osmotic 
pumps (Alzet Model 2004) to allow for delivery at a steady infusion flow rate (0.25 μl/h). The 
pumps were replaced at 4 week intervals throughout the experiment for a total of 12 weeks of 
treatment. Four weeks following the initiation of drug administration (week 17; Figure 6.1), WR 
mice were released from CR and returned to ad lib food access (weight re-gain phase).  AL 
group continued ad lib HFD feeding. During the last week of drug administration (11-12 weeks 
following the onset of drug administration) mice were placed in metabolic cages for 72 hours to 
assess their energy expenditure (EE) and were then sacrificed immediately following removal 
from metabolic chambers.  
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Food intake was measured over 48 hours every 2-3 weeks in all AL mice throughout the study.  
The first week after release of WR mice from CR, food intake was measured daily (see 
Supplementary Methods). 
Mini-pump implantation  
Three mini-osmotic pump implantations (at 4 week intervals) were performed in each mouse 
over the 12 weeks of AZD2820 administration according to the manufacturer’s 
recommendations (see Supplementary Methods).  
Body weight, body composition, and food intake 
BW was measured (± 0.1 g) weekly in AL groups throughout the experiment and daily in the 
WR groups during CR phase using an Ohaus Scout Pro 200g scale (Nänikon Switzerland, 08:00-
08:30h). Body composition  was measured by time-domain-NMR (Minispec Analyst AD; Bruker 
Optics, Silberstreifen, Germany) [28] prior to the initiation of CR (week 5), before the insertion 
of each mini-pump (weeks 13, 17, and 21) and at the time of sacrifice (week 25). Food intake 
was recorded daily for the WR mice during the CR phase (week 5-17) and every 2-3 weeks for 
AL mice over 48 hours by weighing feeding baskets that were designed specifically to reduce the 
food spillage.    
Serum or plasma assays 
Blood was obtained by retro-orbital bleed following a 4.5-h fast at several time points [weeks 5, 
13, 17, 24 and 25 (Figure 6.1)]. The plasma concentrations of AZD2820 were determined after 
protein precipitation, by liquid chromatography with mass spectrometric detection (LLOQ 2 
nmoles/L). Leptin was assayed using Quantikine ELISA kit (R&D Systems and insulin using the 
Crystal Chem Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem). Glucose was measured 
 199 
 
at the same time as blood collection using the FreeStyle Lite Blood Glucose Monitoring System 
(Abbott Laboratories; see Supplementary Methods).   
Indirect calorimetry 
Energy expenditure and physical activity were measured with a LabMaster-CaloSys-Calorimetry 
System (TSE Systems, Bad Homburg, Germany) at the end of the study (week 25, immediately 
prior to sacrifice; see Supplementary Methods).                 
 
Results  
Body weight and body composition. Prior to food restriction, BW of all groups were equal (by 
design). 40 mice were maintained on HFD ad lib throughout the study (AL group) and their 
weights are reported as percent initial BW - defined as BW (g) on any given day divided by BW 
(g) on day 0 of the experiment (when the first mini-pump was implanted; Figure 6.2A). 40 mice 
fed a HFD were calorically restricted to reduce their weights by 20%. Weights are reported as 
percent initial BW which in the case of WR mice is defined as  BW (g) on any given day divided 
by BW on the day prior to start of the calorie restriction (CR)  phase (on day 0 when the first 
mini-pump is implanted; Figure 6.2B). 
Mice maintained on the ad lib feeding regimen for the duration of the study lost weight when 
treated with high drug dose (53.4 nmol/day) compared to their vehicle-treated controls (5% 
mannitol). The high dose-AL lost 5.5 ± 4.2% vs. control-AL which gained 3.5 ± 1.8% (p= 0.042; 
Figure 6.2A). Intermediate drug dose (medium; 10.8 nmol/day) treated mice also lost weight 
(1.0 ± 2.5%) but were not significantly different from the vehicle treated controls (Figure 6.2A). 
There was a dose-response relationship regarding drug efficacy in WR mice (Figure 6.2B). 
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Eight weeks after WR mice were released from CR and allowed AL access to HFD, the high 
dose group regained 10.0 ± 2.6%  of their BW since the beginning of the drug treatment 
compared to 22.4 ± 2.2% in the vehicle-treated control group (p= 0.0027; Figure 6.2B). In WR 
mice, an intermediate dose of the agonist was sufficient to maintain these animals at 95.1 ± 3.7% 
of initial BW vs. 94.5 ± 4.2% in the high dose-AL mice (Figure 6.2C). Similarly, low dose 
AZD2820 (2.64 nmol/day) in WR mice kept them at 98.4 ± 3.0% of initial BW compared to 99.0 
± 2.5% in the medium dose-AL mice (neither group was significantly lower than their respective 
controls, but both show a trend towards lower % initial BW; Figure 6.2D). Whereas weight-
reduced animals are sensitive to the agonist even in the lowest concentration rate (Figure 6.3B), 
mice fed AL require an agonist concentration of >10 nM to produce weight loss (Figure 6.3A). 
Thus, mice in the WR state were more sensitive to the MC4R agonist and required an ~5-fold 
lower dose of the agonist to achieve a response comparable to that required in the AL state 
(Figure 6.2C-D). 
The change in BW in response to MC4R agonist administration was primarily accounted for by 
changes in fat mass. Following the MC4R agonist treatment, fat mass stratified according to 
changes in BW (Figure 6.4A-B). The WR group treated with high drug dose had a significantly 
lower body fat mass after 8 weeks of drug administration compared to their vehicle-treated 
controls (at 8 weeks of drug: high-WR: 11.9 ± 0.6 g vs. control-WR: 15.8 ± 1.5 g; p= 0.030; data 
not shown; at 12 weeks of drug: high-WR: 12.2 ± 0.5 g vs. control-WR: 16.5 ± 1.6 g; p= 0.015; 
Figure 6.4B). Mice fed AL and given high dose, as well as medium dose-treated mice (in both 
AL and formerly WR state), showed a trend towards reduced fat mass at 8 and 12 weeks of drug 
treatment (Figure 6.4A). Lean mass of WR mice was lower than AL mice only during the CR 
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phase; no difference was noted among any of the groups in response to AZD2820 treatment after 
the release of WR mice to AL feeding (Figure 6.4C-D). 
Plasma hormones and glucose. As expected, fasting plasma leptin and insulin levels maintained 
proportionality to fat mass following weight loss (Figures 6.5-6). By the end of the study  both 
AL and formerly WR mice treated with high-dose MC4R agonist had significantly lower 
circulating leptin levels compared to their respective vehicle-treated controls (Figure 6.5A-B). 
Circulating insulin concentrations were significantly reduced in high dose-WR mice compared to 
WR controls (Figure 6.6B). Medium dose-treated mice showed a trend towards a decrease in 
circulating leptin and insulin levels (Figure 6.5A-B, 6.6A-B). At 4 weeks of drug treatment, 
while WR mice were still calorie restricted, their plasma leptin concentrations were increased 
relative to fat mass when compared to a regression of leptin vs. fat mass in the vehicle treated AL 
fed mice (Figure 6.5C). This increase in leptin levels was not correlated with MC4R agonist 
dose, occurred only in WR animals, and was reversed after formerly WR mice had returned to 
AL feeding for 8 weeks (Figure 6.5D). Fasting blood glucose levels were not different among 
groups throughout the study (Figure 6.6C-D). 
Food Intake. No difference was found between any of the groups in the 24hr food intake 
measurements taken one week after the first mini-pump implantation and every 2-3 weeks 
thereafter (data not shown). Food intake was also measured more precisely at the end of the 
study when mice were housed in metabolic chambers for 48hr (Figure 6.7). Similarly, there 
were no differences detected in food intake.   
Energy Expenditure. Immediately prior to sacrifice, mice were placed in metabolic chambers for 
assessment of energy expenditure. Absolute total and resting EE did not differ among treatment 
groups which did not differ significantly in lean body mass; fat mass was lower in the WR high 
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dose treated mice compared to the controls (Figure 6.8D) but their TEE and REE was the same 
(REE in high-WR: 10.1 ± 0.3 kcal/24h vs. control-WR: 10.4 ± 0.3 kcal/24h; TEE in high-WR 
13.3 ± 0.4 kcal/24h vs. control-WR: 13.3 ± 0.3 kcal/24h; Figure 6.8A-B). The limited number of 
mice in the control group (n=10) and the low variation in lean mass among all mice limited 
power to build a significant regression model to calculate the residual EE values for the 
treatment groups. Ratio of TEE and REE (Figure 6.8E) to lean mass was not different among the 
treatment groups.  However, the ratios of TEE and REE to BW were higher in high dose (WR 
and AL combined) treated animals (REE in high dose: 0.226 ± 0.005 kcal/g/24h vs. control: 
0.209 ± 0.005 kcal/g/24h; p=0.02; TEE in high dose 0.294 ± 0.006 kcal/g/24h vs. control: 0.272 
± 0.006 kcal/g/24h; p=0.012; data not shown). Respiratory exchange ratio (RER or respiratory 
quotient, RQ) and physical activity were not different among treatment groups (data not shown).  
Drug delivery verification: AZD2820 plasma concentrations measured after 4, 11, and 12-13 
weeks of drug treatment were indistinguishable between AL and WR groups. AZD2820 
treatment caused penile erection in all mice regardless of drug dose but was not observed in 
vehicle-treated mice. Every mouse was assessed visually three times throughout the study. There 
was no sign of drug tolerance as the penile erection persisted until the end of the study.   
 
Discussion 
The purpose of this study was to establish a study protocol to enable evaluation of the 
efficacy of weight maintenance agents, and to assess the effectiveness of a novel MC4R partial 
agonist (AZD2820) [27] in the maintenance of reduced BW. We found that in the WR state a 5x 
lower drug exposure is sufficient to maintain mice at a reduced weight versus the dose required 
 203 
 
to induce that degree of weight loss. Mice in the WR state are consequently more sensitive to the 
MC4R partial agonist.   
We were unable to detect quantitatively significant differences in food intake or energy 
expenditure related to the AZD2820 administration.  However, these studies were conducted 
relatively late in the treatment (11-12 weeks post start of agent).  Also, subtle differences in food 
intake too small to measure (especially in mice) can accumulate into significant weight change. 
The ultimate differences in body mass and composition indicate that differences in energy 
balance must have occurred.     
The effects of MC4R agonists on energy homeostasis have been assessed in animal 
studies [21, 29-31]. Food intake is initially suppressed - most strongly in the first day of 
treatment, and lasting for about a week - but then returns to control levels. In longer term studies 
[21, 22, 32],  weight loss occurs initially as a result of decreased food intake but persistence of 
weight loss throughout the drug treatment period suggests that relative elevation of energy 
expenditure plays a role in sustaining the reduced BW. Hamilton, et al. showed that, in DIO rats, 
FI was significantly suppressed during the first week of continuous 28-day MTII (MC4R and 
MC3R full agonist) treatment, whereas EE was increased 3 days after the start of agonist 
administration [22]. An eight-week treatment with a novel MC4R agonist in DIO Rhesus 
macaques caused weight loss (13.5%), due to decreased food intake (~25-35%) for the first two 
weeks. EE was measured at baseline and at 8 weeks after drug treatment and showed a 14% 
increase suggesting that reduced food intake is an initial transient response,  and that elevated EE 
may explain the persistence of reduced BW and contribute to the weight loss as well [32].    
Using a paradigm similar to the one used here, DIO rats were either fed ad libitum 
throughout the study or fed calories reduced (CR) by 30% or 60% (versus ad lib) for 2 weeks, 
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followed by 4 weeks of MTII  treatment (at either low [0.3 mg/kg/day] or 10 fold higher dose) 
[33].  In the AL state, both MTII doses were equally efficacious in inducing weight loss; but in 
the CR groups (both 30% and 60% CR), the effectiveness of MTII in maintaining reduced BW 
was greater with the higher dose; the drug was more dynamically efficacious in the WR state. 
This is similar to the current study where AZD2820 was more efficacious in the WR state. The 
lack of difference in efficacy of low or high doses of the MTII in AL rats suggests that the low 
dose induced maximal weight loss in the AL state [33]. 
Circulating leptin concentrations were, as expected, significantly lower in all WR groups 
compared to control AL mice when measured at 4 weeks of AZD2820 treatment, while WR mice 
were still calorie restricted. Interestingly, leptin concentration per fat mass was increased in WR 
mice compared to AL control group, independent of drug dose, found only in WR animals, and 
reversed after mice had returned to ad lib feeding for 8 weeks. High dose-treated mice showed 
decreases in leptin and insulin plasma concentrations; these changes are likely a reflection of 
weight loss and not drug itself. Blood glucose concentration was only lower during the CR phase 
while WR mice were maintaining 80% of their initial BW. It was not affected by the MC4R 
agonist per se.     
Therapies for obesity are focused primarily on inducing weight loss.  Since weight 
regain, and not the inability to lose weight, is what defeats most efforts at obesity treatment [1], 
sustaining the weight-reduced state deserves more attention. Induction of weight loss is 
physiologically different than maintenance of a reduced BW [2, 8, 34]. The weight-reduced state 
in both humans and mice is characterized by hyperphagia and reduction in energy expenditure 
greater than predicted by lower body size [2, 4, 8], phenotypes that are largely reversed by 
administration of low “replacement” doses of leptin [6, 7]. These observations, congruent with 
 205 
 
those described in this report, suggest that the pharmacology of the weight-reduced state 
deserves greater attention as a therapeutic target in obesity treatment. Similarly to effects seen in 
WR individuals treated with low levels of leptin, MC4R agonists might be efficacious in 
maintenance of weight loss. However, MC4R agonists would be expected to be less effective due 
to increased levels of endogenous MC4R antagonist/inverse agonist (AgRP) which could 
potentially interfere with MC4R agonism. 
Drugs found to be modestly efficacious in the induction of weight loss, may be more 
useful in the maintenance of reduced BW; those agents effective in producing weight loss, but 
problematic by virtue of off-target effects, may be helpful in maintaining reduced BW at much 
lower doses.  This protocol could be used to examine agents for efficacy in maintenance of 
reduced BW.   
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Animals and study design: 
Upon receipt of mice from Jackson Laboratory, they were separated into individual cages and 
fed the same HFD ad-libitum with free access to water for a five week acclimatization period. 
During this period, body weight (BW) was monitored on a weekly basis. 
20% weight reduction was achieved by feeding mice 50% of their ad-libitum daily caloric intake 
until they reached 80% of initial value (defined as BW immediately before the start of CR 
phase). Subsequently, mice were switched to ~80% of their ad libitum daily food intake and the 
number of calories provided were adjusted (when % of initial BW of a mouse deviated from 80% 
by more than 1%, the daily amount of food intake was adjusted by 0.1g = 0.524 kcal) on a daily 
basis in order to weight stabilize each mouse at 80% ±1% of their original weight. WR mice 
were provided with food twice daily, 1/3 of the total daily calories in the morning (08:00-8:30h) 
and 2/3 in the evening (18:00-18:30h). BW was monitored daily or weekly in WR and AL 
groups, respectively. WR mice were determined to be weight stable at 80% of their initial weight 
when their BW did not deviate by more than ±1% of the value reported on the previous day (with 
no changes in food given) for 4 consecutive days at which point the value for their daily 
provision of HFD was fixed for the remaining of the CR phase. 
The doses of the MC4R agonist in this study were chosen based on previous studies in DIO mice 
showing a ~10% BW loss with the drug vs. vehicle over a 2-w infusion period (AstraZeneca data 
on file). 
During the course of the experiment, some of the mice developed skin lesions which were treated 
with topical antibiotics. Skin lesions were primarily found in the AL group of mice as a likely 
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consequence of ad libitum access to the HFD. To reduce the progression of skin lesions and 
development of new ones, all mice were washed in warm water with a pet shampoo (Ferret 
Glow) twice during the drug treatment. 
Mini-pump implantation  
The mini-pumps (ALZET Model 2004) held 200 μL and release the solution at a nominal rate of 
0.25 μl/hr over 28 days. Mini-pumps were filled with solution sterilely and soaked in PBS at 
37°C for 40 hrs prior to surgery according to the manufacturer’s recommendations.  Animals 
were anesthetized with inhaled isoflurane (2-3.5%) in oxygen. Skin was shaved and wiped with 
betadine and alcohol pads, followed by a small incision (0.5-1 cm) in the interscapular region. 
The pump was inserted into a small pocket that was formed by spreading the subcutaneous 
connective tissue apart with a hemostat. The pump was positioned with the flow moderator 
facing caudally.  Care was taken not to disrupt BAT tissue.  The incision was closed with two 
wound clips followed with application of triple antibiotic to minimize the risk of infections. 
During the second and third mini-pump surgeries (weeks 17 and 21), the existing pumps were 
explanted and replaced with a fresh pump. 
Serum and plasma collection 
Blood was obtained by retro-orbital bleed following a 4.5-h fast at several time points. Blood 
from the first two bleeds was allowed to clot for 2 h at room temperature, centrifuged at 4°C for 
20 min at 2,000 x g, and serum was collected and frozen at −80°C until time of assay. For the 
remaining three bleeds, plasma was collected on ice using heparinized capillary tubes 
(Fisherbrand) in order to protect the integrity of the MC4R agonist. A protease inhibitor 
(Protease inhibitor cocktail set 1, Calbiochem, USA) was added to the aliquots (1 part to10 parts 
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plasma of the 50x solution) used for assaying the drug concentration.  Plasma was obtained by 
centrifugation for 10 min at 1,500 x g at 4°C and frozen at −80°C until time of assay. 
Indirect calorimetry 
Measurements of oxygen (O2) and carbon dioxide (CO2) concentrations were taken every 26 
minutes during a 72 hour period while mice had AL access to HFD and water.  To diminish the 
effects of stress associated with exposure of mice to new environment data points collected 
during the last 48 hours were used to calculate the average total 24-hour energy expenditure 
(TEE; kcal/24hr) and respiratory exchange ratio (RER = VCO2/VO2) [3]. Resting energy 
expenditure (REE; kcal/24hr) was defined as the lowest one hour period of energy expenditure, 
coinciding with the lowest one hour of total ambulatory activity during the 48-hour period; this 
value was extrapolated to 24 hours. Non-resting energy expenditure (NREE; kcal/24hr) was 
calculated as the difference between TEE and REE over the 48 hour period.  
Physical activity was measured by an infrared beam system integrated with the LabMaster 
system. Total activity (infrared beam breaks) in X, Y, and Z axis was recorded every 26 minutes. 
The system is designed to differentiate between fine motor movement (a single X or Y axis beam 
break), ambulatory movement (simultaneous breaking of two adjacent X or Y beams), and 
rearing (Z axis beam break). 
Sacrifice 
After a 5-6 hour fast on the day of sacrifice, mice were anesthetized with isoflurane, the last 
mini-pump was removed, and the body composition was measured immediately prior to 
sacrifice. Mice were sacrificed by carbon dioxide asphyxiation and had their blood collected by 




Data are expressed as means ± SEM. Statistical analysis was performed using JMP and Statistica 
software. Where appropriate, two-way ANOVAs were performed using drug treatment and state 
as grouping variables. Student t-tests (2-tailed) were conducted to compare treatment effects 


















Figure 6-1  Schematic of protocol. 
Schematic of protocol to assess the effects of a novel MC4R agonist (AZD2820) on maintenance 
of reduced body weight in DIO mice. Timepoints of physiological measurements and 
pharmacological treatment are indicated by arrows. WR - weight reduction, Body Comp - Body 
Composition, Calo - Calorimetry, Sac – Sacrifice, Time 0 – mice arrived at the Columbia facility 
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Percent initial body weight post pump #1 implantation of mice fed a HFD throughout the study 
(A) and treated with MC4R agonist or vehicle and weight reduced by 20% prior to 
administration of the drug (B). Percent initial body weight in medium-WR mice compared with 
high-AL group (C) and in low-WR mice compared with medium-AL group (D). Medium and 
low dose in WR mice is sufficient to maintain them at the same percentage initial body weight as 
AL mice treated with a high and medium dose of MC4R agonist, respectively. Mean initial body 
weight (g) (SEM) is given for each group in the figure legend (A, B). Nominal doses of 
AZD2820—High: 53.4 nmol/day; medium: 10.8 nmol/day; low: 2.64 nmol/day. Each data point 
























Figure 6-3  Change in percent body weight. 
Percent body weight change (A) or regain (B) at 12 weeks of drug treatment plotted individually 
for each mouse against plasma concentration of MC4R agonist. AL (A) and WR (B) mice are 
plotted separately. Black bars are % BW change means for each group. Note, the drug 
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Figure 6-4  Body Composition in AL and WR mice throughout the study. 
Fat Mass (A, B) and lean mass (C, D) in mice maintained on HFD ad lib throughout the study 
(A, C) or weight reduced by 20% prior to drug administration (B, D) measured prior to and 12 
weeks after MC4R agonist treatment. Formerly WR mice given high nominal drug dose (53.4 
nmol/day) achieved a significantly lower body fat than the controls after an 8 week body weight 
regain period.  
Nominal doses of AZD2820 - High : 53.4 nmol/day; Medium : 10.8 nmol/day; Low : 2.64 
nmol/day. Each data point represents mean fat mass or lean (fat free mass) for each group with 
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Figure 6-5  Circulating leptin concentrations in AL and WR mice throughout the study. 
Circulating leptin concentrations (ng/ml) in mice maintained on HFD ad lib throughout the study 
(A) or weight reduced by 20% prior to drug administration (B) measured at different timepoints 
during the study. As expected from the fat mass data, circulating leptin levels are lower in high 
dose treated animals (both AL and WR) after at least 11 weeks of treatment. Regression of 
circulating leptin (ng/ml) against fat mass (g) in all mice at 4 weeks (C) and 12 weeks (D) of 
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MC4R agonist treatment. The circle denotes WR mice which have an increased plasma leptin 
concentrations relative to fat mass compared to the vehicle treated AL mice. This effect is 
independent of MC4R agonist treatment and is reversed after formerly WR mice had returned to 
AL feeding for 8 weeks (D). 
Nominal doses of AZD2820 - High : 53.4 nmol/day; Medium : 10.8 nmol/day; Low : 2.64 
nmol/day. Each data point represents mean value for each group with SEM. *P < 0.05 between 
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Figure 6-6  Circulating insulin and glucose concentrations in AL and WR mice throughout 
the study. 
Circulating insulin (from plasma; A-B) and glucose (from venous tail blood; C-D) 
concentrations in mice maintained on HFD ad lib throughout the study (A, C) or weight reduced 
by 20% prior to drug administration (B, D) measured at different timepoints during the study. 
Nominal doses of AZD2820 - High : 53.4 nmol/day; Medium : 10.8 nmol/day; Low : 2.64 
nmol/day. Each data point represents mean value for each group with SEM. *P < 0.05 between 















































Figure 6-7  Food intake after 12 weeks of drug treatment in AL and WR mice. 
24 hour food intake in mice maintained on HFD diet ad lib throughout the study or weight 
reduced by 20% prior to drug administration measured at 12-13 weeks of drug treatment during 
calorimetry assessment (TSE LabMaster system). Mean body weight is provided for each group. 
Nominal doses of AZD2820 - High : 53.4 nmol/day; Medium : 10.8 nmol/day; Low : 2.64 
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Figure 6-8  Energy expenditure and body composition at 12 weeks of drug treatment. 
Absolute total (A)  and resting (B) energy expenditure (kcal/24h) measured at 12-13 weeks of 
drug treatment and immediately prior to sacrifice by indirect calorimetry (TSE LabMaster 
system). No significant difference was found in absolute total and resting EE among treatment 
groups. Body Composition in AL mice (C) and formerly WR mice (D) at 12 weeks of drug 
treatment. Formerly WR mice treated with high dose of MC4R agonist have a significantly lower 
BW and fat mass but show the same TEE and REE. (E) Resting energy expenditure (kcal/24h) 
per unit of lean mass (g) measured at 12-13 weeks of drug treatment and immediately prior to 
sacrifice by indirect calorimetry (TSE LabMaster system). Nominal doses of AZD2820 - High : 
53.4 nmol/day; Medium : 10.8 nmol/day; Low : 2.64 nmol/day. *P < 0.05 between vehicle and 
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Chapter 7   
 
“Concluding Remarks and Future Directions”    
 
Concluding Remarks  
Obesity is a physical state resulting from an imbalance of energy intake and energy expenditure 
in which excess fat is stored in peripheral tissues, primarily in the white adipose tissue; when 
adipose tissue capacity is exceeded, fat is also stored in other tissues including the liver and 
muscle, resulting in insulin resistance in both organs. Obesity has a range of metabolic, 
mechanical and psychological consequences which negatively influence health outcomes. 
Obesity and associated metabolic diseases have increased markedly over the last 4 decades. 
Genetic factors are important contributors to body weight regulation (they have been estimated 
to account for 30-60% of risk variance for human obesity); however, human epidemiological 
studies as well as rodent data suggest that perinatal environment can have substantial effects on 
body weight in adulthood. Genetic factors can of course interact with environmental factors to 
promote obesity. Pharmacological approaches and behavioral interventions have not been 
successful in producing long term weight loss in obese individuals. 
Leptin is a critical component of the central circuit that defends against reductions in body fat. 
The CNS is informed of reduced energy stores due to weight loss by rapid reduction in the 
concentration of circulating leptin [1, 2]. Weight reduction lowers energy expenditure 15-20% 
below what would be predicted from changes in body mass and composition, and induces other 
endocrine and behavioral responses that promote restoration of previous body weight [3, 4]. 
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Administration of small doses of leptin, sufficient to restore circulating leptin to pre-weight loss 
concentrations, reverses much of the metabolic and behavioral response triggered by the weight 
reduced state [5-7]. Leptin is also an important neurotrophic factor and, as such, it promotes both 
the outgrowth of hypothalamic feeding pathways during the postnatal period [8] and 
neurogenesis during gestation [9, 10]. 
The general theme of my graduate work has been the role of leptin in body weight regulation. To 
investigate the physiological consequences of transient hyperleptinemia on the defense of body 
weight later in life, we generated a transgenic mouse model of inducible (by time and degree) 
leptin overexpression. Hyperleptinemia is a surrogate for adiposity without the “confounds” of 
the secondary effects of diet, obesity per se and its associated dysmetabolism. We showed that 
exposing mice to elevated ambient leptin during the “adolescent” period or in adulthood does not 
affect body weight or composition later in life; however, inducing hyperleptinemia during the 
pre-weaning period (without permanent consequence to subsequent body weight) causes these 
mice to gain more weight when exposed to HFD. My future goal is to identify long-term 
neurobiological consequences of transient elevations in body weight – for example, the impact of 
obesity in infancy on susceptibility to obesity in adulthood. This mouse can mimic the high 
circulating leptin seen in obese pregnant and/or nursing women.  Determining neuroanatomical 
alterations in progeny caused by perinatal exposure to high ambient leptin will help in parsing 
the proximal mechanisms for apparent effects of maternal obesity on risk of obesity in offspring.  
In Chapter 4 we found that Lepob/ob mice, weight reduced by transient caloric restriction, regain 
lost weight to the level of ad libitum fed controls; unlike wild type mice that overeat for up to a 
week after release from restriction, the Lepob/ob mice regained the lost weight without any 
apparent increase in caloric intake compared to ad libitum-fed Lepob/ob controls. These 
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observations suggest that Lepob/ob mice may sense adiposity via a leptin-independent pathway 
and regulate body weight through adjustments in energy expenditure and not food intake. 
Alternatively, congenital leptin deficiency which results in impairments of the hypothalamic 
circuitry may cause these mice to ingest a fixed number of calories regardless of metabolic 
status.  
The striking resistance to dietary weight loss reported in rare humans homozygous for 
inactivating leptin mutations is consistent with this inference [11].  The RNAseq results on 
adipose tissue of weight-reduced and ad libitum fed Lepob/ob mice identified an increase (when 
animals were calorie restricted) in Ptgrf – prostaglandin 2Fα receptor; this observation led us to 
identify significantly lower concentrations of prostaglandin 2Fα (PG2Fα) in the circulation of the 
calorie-restricted mice. PG2Fα has previously been identified as a potent anti-adipogenic factor 
in cultured preadipocytes and 3T3-L1 preadipocyte cell line [12-14]. Mice deficient in Akr1b7 
(Akr1b7-/-) enzyme which catalyzes the synthesis of PG2Fα have increased fat mass and are more 
susceptible to diet-induced obesity due to reduced circulating concentrations of PG2Fα [15]. 
Interestingly, on chow diet, the Akr1b7-/- mice gain more weight by decreasing energy 
expenditure while eating the same number of calories as WT mice [15]. We intend to further 
investigate these findings by treating weight-reduced Lepob/ob mice with an inhibitor of 
prostaglandin transporter (PGT), causing increases in circulating prostaglandin E2 [16] and 2Fα 
and determining whether these mice increase energy expenditure. The results of this study could 
add to our understanding of systems governing body weight regulation and they could potentially 
provide another target for therapeutic weight loss and/or maintenance of reduced weight. 
Identifying the causal gene(s) within each associated interval has been a major challenge in 
making use of the results of genome wide association studies (GWAS). GWAS-identified loci 
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typically harbor several/many genes that are in linkage disequilibrium (LD) surrounding the 
signal. Since GWAS are intentionally biased to find signals at >5% population frequency, the 
associated SNP is typically just a “sign post” in LD to the causative gene/variant. The 
identification of the causal gene within a locus is a critical step in translating GWAS findings 
into further biological insights.  
In a GWAS of circulating leptin concentrations adjusted for adiposity, Dr. Ruth Loos and 
colleagues at Icahn School of Medicine at Mount Sinai identified loci putatively modulating 
leptin production per unit of fat mass. Low production might predispose to obesity. The loci 
included those in/near LEP, SLC32A1, GCKR, and CCNL1 [17]. We used a mouse in vitro 
adipose tissue explant model to examine directly the role of implicated candidate genes on leptin 
synthesis and secretion. Using siRNAs, we knocked down expression of the candidate genes in 
perigonadal adipose tissue explants from mice then measured leptin expression and secretion into 
the culture media 12 hours after knockdown. Using this technique, Adipogenin (Adig), 
implicated in the SLC32A1 locus identified by this GWAS, was found to modify production of 
leptin in adipose tissue (Chapter 5) [17]. These studies provide a prototype for the functional 
deconvolution of LD regions identified by GWAS in which a specific phenotype in a cell type 
can be implicated.  
Finally, Chapter 6 addresses an important issue in obesity treatment – the unsuccessful 
maintenance of reduced weight after otherwise successful weight loss. Since leptin is capable of 
rescuing neuroendocrine and behavioral compensations associated with maintenance of reduced 
weight, we hypothesized that a downstream mediator of leptin signaling, a mimetic of αMSH – 
the physiological agonist of MC4R – could mitigate these compensations by activating the 
melanocortin circuit, thereby assisting in the  maintenance of weight loss. The treatment of diet-
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induced obese mice with this novel peptide MC4R agonist in either ad libitum fed mice to induce 
weight loss or to weight-reduced mice showed that this class of drugs can do both, promote 
weight loss and maintain reduced weight; however 5 x lower dose in a weight-reduced state of 
the same drug is comparably efficacious to the higher dose in the ad libitum state (Chapter 6) 
[18]. These results suggest that the pharmacology of the weight-reduced state differs from that of 
individual at usual body weight. Similar to the effects seen in weight-reduced individuals treated 
with low doses of leptin, MC4R agonists might be effective in the maintenance of weight loss. 
Major factors limiting approval of new anti-obesity drugs are low drug efficacy in inducing 
weight loss and unacceptable side effects (i.e. increases in blood pressure). Often the dose of the 
agent must be relatively high in order to induce substantial weight loss; this high dosing 
increases off-target effects. This study suggests that a lower dose may be sufficient to maintain 
reduced body weight versus the dose required to induce the same degree of weight loss (Chapter 
6) [18]. Mice in the weight-reduced state were more sensitive to the MC4R agonist. This may be 
true for other classes of drugs as well.  
 
Future Directions 
Good research projects are never truly complete; from that perspective, all of the manuscripts in 
this thesis represent progress reports on ongoing projects. The mouse that expresses leptin in 
response to dox treatment is being used to determine both the developmental influences of leptin 
on body weight regulation and on the type and location of neuronal projections that may be 
mediated by gestational and postnatal leptin exposure (as a surrogate for maternal adiposity).  
 233 
 
In Chapter 4 we show that the Lepob/ob mice reduce energy expenditure when restricted in weight 
and that they regain fat without increasing food intake when allowed ad libitum feeding. 
RNAseq on fat pad of calorie-restricted Lepob/ob mice and ad libitum fed controls – at maximal 
difference in body weight – identified a transcript signal in prostaglandin F2α receptor. We 
measured serum prostaglandin F2α concentrations in these mice and found that it was decreased 
(2 fold) in the weight-reduced animals. We have initiated a collaboration with Dr. Victor 
Schuster – professor of Physiology & Biophysics at Albert Einstein College of Medicine – who 
is an expert in prostaglandin signaling. We intend to investigate whether PG2Fα acts as another 
signaling molecule for the status of fat stores. The details on this follow-up project are described 
in the section below.    
The functional assay that we developed to directly test a knockdown of any gene on production 
and secretion of leptin from adipose tissue can be used by others to identify new genes involved 
in regulation of leptin synthesis (Chapter 5) [17].  
Rhythm Biopharmaceutics has developed an MC4R agonist that is currently being tested in 
human patients with monogenic mutations upstream of the MC4R pathway. Dynamic weight 
loss is physiologically different than sustaining reduced body weight. During maintenance of 
reduced weight the main purpose is to correct the physiological adaptations that are present as a 
result of decreased body weight/fat; therefore, interventions designed specifically to improve 
long-term body weight maintenance are critical. The protocol we developed to test 
pharmacological agents for efficacy in maintenance of reduced body weight can be used to 
develop new strategies in obesity treatment (Chapter 6) [18].   
In the following section I describe follow up projects that I intend to pursue.  
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Determine the physiological consequences of transient hyperleptinemia during the gestational 
period on the apparent set point for adiposity.  
Chapter 2 of this thesis describes a transgenic mouse model of inducible hyperleptinemia created 
as a tool to evaluate the effects of transient elevations of leptin during adulthood, “adolescence” 
and the postnatal period on the defense of body fat later in life (Chapter 3). We identified the 
immediate postnatal period as a critical time window during which transient exposure to elevated 
leptin, per se, increases the body weight in adult offspring when given ad libitum access to 
highly palatable food. The postnatal period has previously been described as a critical time for 
the structural development of the hypothalamus. Using Di-I crystal labeling, Simerly and 
colleagues reported that in the mouse  axonal extensions from the ARH to the PVH DMH, and 
LHA occur primarily during postnatal week 2 and that neuronal outgrowth is fully mature by 
P18 [8]. When present at sub-optimal concentrations, hormones such as leptin, insulin, and 
ghrelin are capable of inducing neuroanatomical changes within the hypothalamic feeding 
circuits (described in more detail in Chapter 3) [19-22]. Another critical period for hypothalamic 
development is gestation; hypothalamic neuronal proliferation occurs primarily during mid-
gestation in rodents [23]. LepR [9] and POMC [24] expression are detected as early as E10.5, 
whereas NPY is first expressed between E13.5-14.5 [24]. MC4R mRNA is first expressed on 
E14 and by E19 is widely expressed across the brain [25].  
In non-human primates the development of hypothalamic neural projections (in particular 
AgRP/NPY neurons originating from the ARH) is evident as early as gestational day 100 (late 
second trimester), and the density of these projections is substantially increased by day 130 and 
day 170 of gestation [26]. This is in contrast to the formation of hypothalamic projections in 
rodents which occur mostly after birth [19] indicating that the critical period for the 
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hypothalamic neuronal outgrowth differs in rodents and humans; postnatal period in rodents is 
comparable to the second half of gestation in humans. A study in human fetuses demonstrated 
that some hypothalamic nuclei such as the lateral hypothalamus differentiate as early as week 9-
10 of gestation suggesting that the hypothalamic cell proliferation is initiated during the first 
trimester in humans [27]. The first appearance of NPY positive neurons in the ARH was detected 
at 21 weeks of gestation [27]. These data suggest that proliferation and differentiation of 
hypothalamic neurons begins earlier in human gestation compared to rodents.  
Lepob/ob mice display reduced proliferation of neurons starting on E14 and decreased brain size 
and weight compared to WT mice throughout their lives [10, 28]. Administration of exogenous 
leptin to Lepob/ob on E14 increases the number of neurons, indicating a role for leptin in 
neurogenesis [10].  It is therefore conceivable that exposure to elevated leptin concentrations 
during gestation may influence developmental neurogenesis in the hypothalamus with effects on 
the formation and ultimate function of the feeding circuits. Chang et al. found that maternal HFD 
feeding during pregnancy results in increased proliferation, differentiation and migration of 
neuronal progenitors towards hypothalamic regions in the offspring, leading to higher 
proportions of putative orexigenic neurons in the PVH of neonates [29]. Offspring of HFD fed 
dams displayed increased food intake and body weight in adulthood [29]. These findings suggest 
that maternal HFD and/or obesity affect neurogenesis during gestation and may influence the 
‘wiring’ of the feeding circuits.  
It is unclear how maternal HFD/obesity affect leptin concentrations in the fetus. Over the course 
of pregnancy, leptin concentrations rise by ~65% in maternal circulation in mid to late gestation 
[30-32]. Interestingly, while obese gravida have higher circulating leptin than lean pregnant 
women throughout pregnancy, the relative increase in plasma leptin concentration from first to 
 236 
 
third trimester is markedly reduced with obesity [31]. The placenta is a site of leptin synthesis 
and there are studies supporting placental leptin as a source of leptin in fetal circulation in 
rodents and humans [33, 34]; there is also evidence of transplacental leptin transport from 
maternal to fetal circulation [35], however, the relative contribution of these two sources is 
unknown. Additionally, studies have reported leptin expression in fetal tissues, other than 
placenta, such as fetal cartilage/bone, and hair follicles [33]; our preliminary data also suggest 
that the mouse fetus may produce leptin from its own tissues.  
The leptin transgenic mouse that we generated (Chapter 2) is a suitable model to investigate 
whether gestational hyperleptinemia per se influences future body fat set point. Dox crosses to 
the fetal circulation through the placenta and elevates leptin in 2TG fetuses while 1TG fetuses do 
not increase circulating leptin (Chapter 2). Thus, we can induce transient hyperleptinemia in 2TG 
offspring in utero, and include normal leptin 1TG controls that are exposed to the identical 
intrauterine environment. Dams will be exposed to dox from conception until parturition. After 
birth, 2TG pups will be released to physiologically normal endogenous circulating leptin and 
their body weight, composition and food intake will be followed. At 10 weeks of age, mice will 
be exposed to HFD to evaluate whether gestational hyperleptinemia has influenced the 
susceptibility of mice to gain weight on a highly palatable diet. We anticipate that 
hyperleptinemia during gestation will affect hypothalamic neurogenesis and result in altered 
proportions of orexigenic to anorexigenic neurons in the hypothalamus. Additionally, we will 
evaluate axonal projections from the ARH to its hypothalamic targets, PVH, DMH, and LHA 




Determine how exposure to elevated leptin during different perinatal periods impacts 
development of hypothalamic pathways known to regulate energy balance. 
In Chapter 3 we showed that hyperleptinemia during the postnatal period results in increased 
body weight gain when mice are exposed to HFD. However, the mechanism of this apparent 
postnatal programming is unclear. We have recently initiated a collaboration with Dr. Richard 
Simerly – professor of Molecular Physiology & Biophysics at Vanderbilt University – an 
internationally recognized expert on endocrine influences on hypothalamic development. He 
previously identified a specific role of leptin in the maturation of hypothalamic circuits critical to 
the regulation of energy homeostasis (work referred to throughout this thesis) [19]. Neuronal 
projections from the ARH to the PVH, DMH, and LHA are formed during a critical postnatal 
period (P5 to P16) but, if the mouse lacks leptin, these projections are not fully formed or 
functional [19].  Brains of mice transiently exposed to hyperleptinemia during the postnatal 
period - described in Chapter 3 – will be analyzed by immunohistochemical visualization of 
axons derived from AgRP and POMC neurons in the ARH, and both the distribution and density 
of neural projections to key hypothalamic targets will be quantified. Specifically, the AgRP- and 
αMSH-immunoreactive fibers in the PVH, DMH and LHA, which derive from the ARH 
neurons, will be quantified by visualizing the brain sections with confocal microscopy. Leptin 
sensitivity will be assessed by immunostaining brains for leptin-induced pSTAT3 and c-Fos.  
Presumably, if there are neuroanatomical changes in the feeding circuits, they should precede 
any change in body weight. Therefore, we are planning to repeat this study and to analyze the 
brains of postnatally hyperleptinemic mice prior to HFD exposure and immediately after 
exposure to this diet. 
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We anticipate that hyperleptinemia during gestation and during lactation will result in a 
decreased density of projections to the PVH, DMH, and LHA from AgRP- and aMSH-
containing neurons in the ARH. Similarly, the impact of elevated leptin in isolation has not been 
evaluated previously, and may alter cell number, which would alter innervation density in certain 
hypothalamic targets. We also anticipate that mice exposed to hyperleptinemia will display 
reduced leptin sensitivity (as determined by leptin induced pSTAT3 staining) before differences 
in body weight/fat are evident; due, at least in part, to the failure of ARH projections to develop 
normally. Although at present it is difficult to predict the precise outcomes of the proposed 
experiments, they will likely provide new insight into the developmental actions of leptin and 
inform future molecular-mechanistic studies. 
Determine whether administration of prostaglandin receptor inhibitor (PGT) to weight-
reduced Lepob/ob mice alters energy expenditure  
RNAseq was completed on the subcutaneous (SCAT) and perigonadal (PGAT) adipose tissue 
depots in both ad libitum and weight-reduced Lepob/ob mice. Mice were sacrificed at the end of 
the weight stabilization phase when the difference between the ad libitum fed and weight 
reduced mice was maximal; SCAT and PGAT were collected at sacrifice for RNAseq analysis 
and serum was collected for further analysis of potential circulating factors. Analysis of RNAseq 
data revealed 94 significantly (adjusted P-value<0.05) and differentially (|log2 fold change|>1.0) 
expressed genes for the SCAT and 84 using the same criteria for the PGAT (26 genes overlapped 
between the depots).  The single most significant difference in gene expression was for Ptgfr 
(significant in both adipose depots) with an adjusted P-value for difference of 10-35 in the SCAT 
(Figure 7.1A) and 10-4 in the PGAT.  Ptgfr encodes the prostaglandin F2α receptor.  Circulating 
prostaglandin F2α was measured in serum by ELISA on these same mice.  The circulating 
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prostaglandin F2α in the weight reduced mice was twofold lower than in the ad libitum fed mice 
(p-value = 0.018, Figure 7.2B).  Dr. Victor Schuster – professor of Physiology & Biophysics at 
Albert Einstein College of Medicine – and colleagues identified the prostaglandin transporter 
(PGT) which transports extracellular prostaglandins into the cytoplasm for enzymatic 
inactivation [36].  PGT-deficient mice display elevated extracellular prostaglandin E2 and F2α. 
Dr. Shuster reports (personal communication) a preliminary phenotype related to body weight 
and energy expenditure in both the PGT knockout mice and mice treated with a PGT inhibitor 
that his group has developed. These mice eat double the calories of WT mice but expand more 
energy resulting in the net reduction of body weight (decreased fat mass and increased lean 
mass) compared to WT (personal communication). The increase in energy expenditure appears 
to be due to beiging of adipose tissue that is independent of UCP1 activation (personal 
communication with Dr. Schuster). We have initiated a collaboration with Dr. Schuster to test 
the efficacy of this agent in increasing PGF2α in the serum of in weight- reduced Lepob/ob mice. 
Our hypothesis is that prostaglandin E2 and/or F2α provide a non-leptin signal of the status of 
somatic fat stores. The proposed pharmacological elevation of these specific prostaglandins will 
provide a signal of sufficiency of stores that will increase energy expenditure.  Lepob/ob mice will 
be injected IP once daily with the PGT inhibitor or vehicle in the weight-reduced state and in the 
ad libitum fed state. Core body temperature (24 hour), body weight, body composition and daily 
food intake will be measured during drug treatment. Energy expenditure will be measured using 
indirect calorimetry; the demonstration that this drug increases the energy expenditure of the 
weight reduced Lepob/ob mice could nominate PGF2α as another signaling molecule for the status 
of fat stores and open a new area of research. We hypothesize that any increase in energy 
expenditure will be due to increased beiging of the adipose tissue.   
 240 
 
The mice that I developed as part of this thesis allow experimental alteration of leptin in ways 
that have never been technically feasible before. By breeding these mice to leptin deficient, 
Lepob/ob mice, I will be able to turn leptin on and off at any point in development, and I can do 
this with congenitally leptin deficient littermates, in identical environment, that will not be 
exposed to excess leptin. I will be able to investigate the neuronal alterations in projections and 
epigenetic changes that occur with transient hyperleptinemia, and this will allow me to answer 









Figure 7-1  SCAT RNAseq data and serum PGF2α concentration in AL and CR Lepob/ob 
mice. 
(A) Volcano plot of RNAseq data from subcutaneous adipose tissue showing adjusted p-value vs 
log of fold difference in weight reduced to ad libitum Lepob/ob mice. (B) Serum prostaglandin F2α 
concentration in ad libitum compared to weight reduced mice.  All values are means ± SEM. N = 
5 per group. Significant difference calculated with Student t-test, *p-value < 0.05.  
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